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Recent evidence suggests that increased Cortisol secretion, altered Cortisol metabolism and/or
increased tissue sensitivity to Cortisol may link insulin resistance, hypertension and obesity.
Whether these changes are important in type 2 diabetes mellitus (DM) at the time of starting
this thesis was unknown. The work encompassed in this thesis aimed to answer this question
and for the first time examined whether inhibition of local tissue metabolism of Cortisol, by
blocking 11 B-hydroxysteroid dehydrogenases type 1 and 2 (11B-HSD 1 and 2), could be a
novel therapeutic target for enhancing insulin sensitivity in patients with DM.
In the introduction to this thesis, I have described the mechanisms that are implicated in the
pathogenesis of DM and highlighted the potential relevance of Cortisol to these. I have also
discussed factors that modulate the effect of Cortisol on these mechanisms and focused on a
novel therapeutic strategy to manipulate Cortisol action. Finally I have described evidence
from human studies that demonstrate the importance of Cortisol in the pathogenesis ofmany
of the abnormalities commonly associated with DM.
In chapter 2, I describe my first study, which determined whether individuals with DM or
impaired glucose tolerance (IGT) exhibit abnormalities in Cortisol activity. An integrated
assessment of Cortisol secretion, metabolism and action was carried out in 25 un-mcdicated
lean male patients with hyperglycaemia (20 DM and 5 IGT) and 25 healthy controls
carefully matched for body mass index, age and blood pressure. This study demonstrated
that patients do exhibit abnormalities in Cortisol activity with: 1) normal Cortisol secretion
and circulating levels in the face of enhanced negative feedback sensitivity (as measured by
0.25mg of dexamethasone); 2) enhanced in vivo peripheral tissue sensitivity to
glucocorticoids (as measured by dermal blanching to beclomethasone); 3) impaired hepatic
11B-HSD1 activity and normal adipose 11B-HSD1 activity, suggesting tissue-specific
alterations in 11B-HSD1 activity; and 4) increased relative excretion of A-ring reduced
metabolites ofCortisol.
Chapter 3 describes a study that examined whether altered tissue concentration of the
glucocorticoid receptor (GR), of 116-HSD1 or of 11B-HSD2 could explain the difference in
dermal blanching seen between patients with hypergiycaemia and normal healthy controls.
Unfortunately I was unable to measure tissue 11B-HSD1 and 11B-HSD2 but tissue
concentrations of GR were found to be no different between patients with hyperglycaemia
and normal healthy subjects.
In chapter 4, I describe a study, which assessed whether inhibition of local tissue metabolism
of Cortisol, by carbenoxolone (an inhibitor of both 11B-HSD1 and 11B-HSD2) improved
insulin sensitivity. 6 patients with DM and 6 matched controls, participated in a double-
blind cross-over comparison of carbenoxolone (100 mg 8 hrly orally for 7 d) and placebo. At
the end of each phase glucose kinetics were measured in the fasting state from 07:00-07:30
h, during a 3 h euglycaemic hypennsulinaemic clamp and during a 2 h euglycaemic
hyperinsulinaemic clamp with a 4-fold increase in glucagon levels. Carbenoxolone reduced
total cholesterol in healthy subjects but had no effect on cholesterol in patients with DM.
Carbenoxolone did not affect insulin sensitivity, but it did reduce glucose production rate
during hyperglucagonaemia in patients with DM
In conclusion I have demonstrated that abnormalities in Cortisol activity are seen in patients
with DM and that drugs specifically targeted at preventing Cortisol regeneration in tissues
may enhance insulin sensitivity and lead to novel developments in the treatment of DM.
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General introduction and overview
Glucocorticoids are so named because it was recognised long ago that one of their
main actions is to increase blood glucose concentrations (Dallman et al., 1993).
These hormones (mainly Cortisol in man; corticosterone in rodents) also play a key
role in regulating salt and water metabolism, blood pressure and immune function.
Part of the mechanism causing these effects depends on opposing the actions of
insulin, i.e. inducing a state of insulin resistance. For this reason glucocorticoids
were one of the first hormones that were implicated in the development of Diabetes
Mellitus. Early studies, though, found that Cortisol secretion was normal in these
individuals steering research away from this field (Mortimore et al., 1956).
Further investigations into the pathogenesis of diabetes led researchers to realise that
there were in fact 2 forms of diabetes. One in which the onset was early, acute, more
severe and associated with insulin sensitivity (Type 1 diabetes) and the other which
was late onset, was less severe and associated with obesity and insulin resistance
(Type 2 diabetes) (Lawrence, 1951). These finding should have prompted scientists
to re-examine the role of glucocorticoid function in a population made up purely of
individuals with Type 2 Diabetes (T2DM), but it was not until the early 1990s that
interest in glucocorticoids would remerge.
Gerald Reaven's proposal that the conditions making up the "metabolic syndrome":
impaired glucose tolerance, obesity, essential hypertension and coronary artery
disease could all be linked by a common cause (Reavan, 1988) was the catalyst.
Realisation that individuals with Cushing's syndrome, an excess of Cortisol,
exhibited many of these abnormalities was the first step. Studies of groups with
hypertension, obesity and coronary artery disease followed (Walker et al., 1991)
(Andrew et al., 1998) (Walker, 1996), all of which confirmed that abnormalities in
glucocorticoid function were present. Further research in this field has led many to
believe that abnormalities in Cortisol could be the link that explains why the diseases
found in the metabolic syndrome tend to cluster together (Andrews & Walker, 1999)
(Bjorntorp et al., 1999) (Phillips et al., 1998). Whether abnormalities in
glucocorticoids are important in the pathogenesis ofT2DM remains to be elucidated.
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In this introduction I will describe the mechanisms that have been implicated in the
pathogenesis of T2DM and highlight the potential relevance of glucocorticoids. I
will then discuss factors that modulate the effect of glucocorticoids on these
mechanisms and focus on a novel therapeutic strategy to manipulate glucocorticoid
action, which may prove useful in treating subjects with T2DM and associated
diseases. Finally I will describe evidence from human studies that demonstrates that
glucocorticoids are important in the pathophysiology of many of the abnormalities
commonly associated with T2DM.
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Type 2 diabetes
Type 2 diabetes is the most common type of diabetes, accounting for 85% of cases
worldwide. It is currently undergoing a worldwide epidemic its prevalence having
tripled in the last 30 years. Recent surveys in Europe indicate a prevalence of almost
5%, in the middle-aged and older population (Amos et al., 1997). The disease
typically affects adults over the age of 40y and is strongly associated with obesity
(over 80% of patients with T2DM are obese), inactivity, family history of diabetes
and ethnic background. In the last 10 years there has been a shift towards a younger
age onset and an emerging epidemic of the disease in children, adolescents and
young adults, most notably in the USA and Japan (Nolan, 2002).
Diabetes related complications are a major cause of disability and suffering, and
incur costs of 5-10% of gross national health budgets. Diabetes remains the principal
cause of renal failure, limb amputations and blindness, and is also a major risk factor
for heart disease and stroke (Bagust et al., 2003).
Pathophysiology of Type 2 diabetes
T2DM is a chronic, progressive metabolic disorder characterised by defects in both
insulin action and insulin secretion. Although debate continues about whether
insulin resistance or impaired insulin secretion is the primary initiating event on the
road to the development of diabetes, both are clearly implicated in the development
of frank diabetes. In patients with established T2DM, basal hepatic glucose output is
increased (hepatic insulin resistance), insulin stimulated muscle glucose uptake is
markedly reduced (peripheral insulin resistance) and, despite high concentrations of
circulating insulin, the beta-cell ((3 cells) response to hyperglycaemia is inadequate
(impaired insulin secretion) (Kahn, 1994).
Insulin Secretion
Insulin is composed of 2 peptide chains, A and B, linked by a disulphide bond.
Synthesised as a larger single polypeptide, pre-proinsulin, by the beta cells in the
Islets of Langerhans it is soon cleaved to form proinsulin. This is then packaged into
17
vesicles where it remains until required. When stimulation occurs these vesicles
move to the cell surface, proinsulin is cleaved and insulin and c-peptide released.
In general insulin secretion is stimulated under circumstances of fuel excess and is
inhibited under circumstances of fuel deficiency. The major stimulation to insulin
secretion is a rise in blood glucose concentration, although certain amino acids, such
as arginine, gastrointestinal hormones, glucagon, growth hormone and activation of
the parasympathetic nervous system can also stimulate insulin secretion.
Insulin secretion is biphasic. The first phase insulin response is a rapid increase in
plasma insulin concentration to a peak concentration at 2-4 minutes. Insulin
concentration then decreases to a nadir at 10-15 minutes followed by a gradual
progressive increase to a steady state at 2-3 hours, the second phase insulin release
(Gerich, 2002). The first phase insulin response is believed to be important in
suppressing hepatic glucose output and the second phase response in stimulating
glucose uptake in muscles and adipose tissues (Del Prato et al., 2002).
Measurement
Insulin secretion "in v/vo" can be measured by a variety of techniques. Oral glucose
tolerance tests (OGTT) or mixed meals can be used to assess both phases of insulin
secretion, with insulin measured every 5 minutes for 2 hours after ingestion.
Unfortunately these tests do not provide a standard glucose stimulus as absorption
can vary and this means that they lack accuracy, specificity and are difficult to
reproduce (Ferrannini, 1998).
One-way around this is to provide an IV glucose load (IVGTT), thus standardising
the glucose stimulus (Ferrannini & Pilo, 1979). Using these techniques an accurate
measure of acute insulin release in response to a glucose load can be made. The
insulin response to this IV glucose load tends not to be biphasic and only provides
information about insulin secretion under maximal stimulation. How this relates to
the oscillatory patterns of minute to minute insulin release is not known. Recent use
of glucose clamps and deconvolution analysis has allowed dose response curves to
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be constructed and oscillatory patterns of insulin secretion throughout the day to be
examined. The finding that insulin secretion is affected by age, race, sex, physical
fitness, BMI, and prevailing glucose and insulin concentrations (Clausen et al., 1996)
(Kahn, 2003) has led many researchers to re-examine previous data and again
question the role that insulin secretion plays in the pathogenesis of T2DM.
Evidence that insulin secretion is important in the development ofdiabetes
Relative or absolute insulin deficiency is one of the characteristics which defines
diabetes (WHO Expert Committee on Diabetes Mellitus, 1980). No matter how
insulin resistant an individual is, T2DM will only occur when the pancreas fails to
secrete enough insulin. Early theories on the pathogenesis of diabetes suggested that
in the prediabetic state when glucose tolerance is normal insulin resistance is already
present, and that a compensatory increase in insulin secretion maintains normal
glucose tolerance. Progression to impaired glucose tolerance (IGT) occurs because
of worsening insulin resistance without an appropriate increase of insulin secretion.
IGT deteriorates into overt diabetes when (3-cells become exhausted after years of
greater than normal insulin secretion. Improvements in techniques used to measure
insulin secretion have challenged this view and some individuals have suggested that
abnormalities in insulin secretion occur before the development of insulin resistance
(Saad et al., 1998).
In individuals at risk of developing IGT and T2DM, abnormalities of insulin
secretion have been described. First-degree relatives of patients with T2DM have a
lower first phase insulin response to a glucose load than those without a family
history (Bogardus & Tataranni, 2002). Offspring of diabetic pregnancies also have a
lower first phase insulin response when compared to offspring of normal pregnancies
(Bogardus & Tataranni, 2002). Studies of identical twins, discordant for T2DM,
demonstrate impairment in P-cell function well before the onset of IGT or T2DM
(Cerasi & Luft, 1967) (Barnett et al., 1981) (Pyke & Taylor, 1967). In the only twin
study that simultaneously examined insulin sensitivity and insulin secretion, first
phase insulin secretion was found to be reduced at a time when insulin sensitivity
was normal (Vaag et al., 1995).
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The importance of this impaired (3-cell function in the pathogenesis of T2DM has
also been demonstrated in recent cross sectional studies. In the San Antonio Heart
Study a low incremental 30 minute insulin concentration (an indicator of first phase
insulin response) was predictive of the progression of normal glucose tolerance to
impaired glucose tolerance in a Mexican-American population (Haffner et al., 1996).
A reduced insulin secretion response was also found to be predictive of the
development of T2DM in a population made up of Pima Indians (Bogardus &
Tataranni, 2002).
Because of this evidence many researchers believe that loss of first phase insulin is
the first and most important factor in the development of T2DM. Further evidence
for this comes from research which has looked at the effect of blocking the first
phase insulin response. When somatostatin is used to block this response, glucose
tolerance deteriorates (Del Prato et al., 2002).
In 1995 Zowalich proposed different mechanisms by which abnormalities in insulin
secretion causes T2DM (Zawalich & Kelley, 1995). He proposed that the first
abnormality seen in patients destined to get T2DM is enhanced P-cell responsiveness
to glucose, a result of increases in vagal and fuel stimulation. This increase in P-cell
responsiveness leads to chronic hyperinsulinaemia, which in turn is then responsible
for changes in target tissue sensitivity to the glucose-regulatory effect of insulin
(insulin resistance). Although somewhat speculative this theory does explain why
hyperinsulinaemia is seen to predate T2DM (see below), why lowering insulin levels
restores insulin sensitivity, and why diabetes flourishes in populations where over
nutrition is apparently the major precipitating event in disease emergence (Zimmet,
1982)(Zimmet et al., 1984).
So whether it is loss of first phase insulin secretion or enhanced P-cell
responsiveness to glucose there is a large body of evidence that suggests that
abnormalities in insulin secretion are important in the pathogenesis of T2DM.
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How do glucocorticoids affect insulin secretion?
Both animal and human studies have clearly demonstrated that high plasma
concentrations of glucocorticoids can inhibit insulin secretion (Delaunay et al., 1997)
(Ling et al., 1998) (Lambillotte et al., 1997). Animals chronically exposed to high
concentrations of glucocorticoids show increased islet cell volume but a decreased
insulin response to glucose (Ogawa et al., 1992). In healthy individuals the decrease
in insulin secretion seen with dexamethasone is dose dependent, with higher doses
causing greater suppression (Matsumoto et al.. 1996).
The role that physiological concentrations of glucocorticoids play in determining
insulin secretion is less clear. In 1995 Plat et al demonstrated that a small increase in
plasma Cortisol concentrations, induced by low doses of IV hydrocortisone or low
doses of IV corticotrophin-releasing hormone (CRH), abruptly inhibited insulin
secretion without changes in glucose concentrations (Plat et al., 1996). Further
studies though are required to confirm or refute these findings.
The exact mechanism by which glucocorticoids decrease insulin secretion has yet to
be proven. They could have a direct action on glucocorticoid receptors in the
pancreas, somehow affecting the efficiency of calcium on the insulin secretory
pathway (Lambillotte et al., 1997). Alternatively the rise in glucose or free fatty
acids induced by Cortisol could have a toxic effect on the pancreas resulting in less
insulin secretion (Toschi et al., 2002) (Lupi et al., 2002).
The importance of the effect of glucocorticoids on insulin secretion is most markedly
seen in individuals who are on high doses of glucocorticoids. All of these
individuals show evidence of increased insulin resistance but only a few develop
glucose intolerance and only a handful develop frank diabetes. All those who
develop impaired glucose tolerance or diabetes show a decrease in insulin secretion,
whereas those who maintain normal glucose tolerance retain normal insulin secretion
(Wajngot et al., 1992).
21
Insulin resistance
Once insulin has been secreted, it circulates unbound to its target tissue. Here it
binds to a cell-surface receptor made up of two alpha (a) and two beta ((3) subunits.
Binding induces a conformational change in the (3 subunit, which in turn activates
tyrosine kinase, so called phosphorylation of the receptor (figure 1.1). Once
activated, tyrosine kinase, phosphorylates intracellular proteins; such as insulin
receptor substrate 1 (IRS-1) and insulin receptor substrate 2 (IRS-2). It is through
these second messengers that insulin has its effects. In broad terms insulin actions
can be divided into the regulation of long-term growth and short-term metabolism,
both of which are mediated by different intracellular second messenger signalling
pathways (Baynes et al., 1997).
Definition
The term insulin resistance' was first coined by Himsworth in 1936 (Himsworth,
1936) and has subsequently been defined as "a state in which a given concentration
of insulin produces a less than normal biological response" (Kahn, 1994). In most
circumstances insulin resistance is used to refer to the acute regulation of
carbohydrate metabolism by insulin, but it could just as easily be used to describe the
effect of insulin on growth
Measurement
Insulin action in vivo can be measured by a variety of techniques. Some of these use
mathematical models (Homeostasis Assessment Model (HOMA) and intravenous
glucose tolerance test (IVGTT)), others measure the rate of decline in glucose to a
given insulin load (insulin tolerance test (ITT)) and others measure the amount of
glucose needed to be infused to maintain glucose concentration at predetermined
levels, whilst infusing insulin at a constant rate (euglycaemic clamps and
hyperglycaemic clamps).
HOMA is a mathematical model which allows values for insulin sensitivity and (3































Figure 1.1. Mechanism of insulin action
A schematic for an archetypal insulin-sensitive cell is shown. Insulin binds to its
transmembrane receptor. Binding induces a conformational change in the P subunit,
which in turn activates tyrosine kinase. Once activated, tyrosine kinase
phosphorylates intracellular proteins such as insulin receptor substrate 1 (IRS-1) and
insulin receptor substrate 2 (IRS-2). It is through these second messengers that
insulin has its effects, activating glucose uptake and stimulating protein synthesis.
insulin concentration are known (Matthews et al., 1985). Estimates of insulin
resistance correlate well with estimates from the euglycaemic clamp (Rs = 0.88,
p<0.0001 (Matthews et al., 1985)) and are reproducible with roughly an 11% intra-
individual coefficient of variation (Emoto et al., 1999). In contrast to other methods,
HOMA gives an estimate of basal insulin resistance, whereas all other tests provide
estimates of stimulated insulin resistance. Limitations of this test are that; it assumes
that insulin and glucose are in a steady state at the time of measurements; and the
accuracy of this test is dependant on the fact that individuals being tested have a
normal insulin secretion, something not found in all patients with T2DM.
In the IVGTT a fixed glucose load is given and glucose and insulin concentrations
measured at 5 minute intervals over a 3 hour period. For each patient, estimates of
insulin resistance and (3 cell function are made using curve fitting techniques
(Bergman et al., 1979). There are, however, problems with using this technique as
for some profiles there is no unique mathematical solution. Since the model used
with this test relies on glucose disappearance rate in response to insulin, it is essential
to have adequate endogenous insulin secretion. Thus in subjects with diabetes the
test needs to be modified by giving a bolus of intravenous tolbutamide (Yang et al.,
1987) to augment 2nd phase insulin secretion or by giving a bolus of insulin, 20
minutes into the test (Finegood et al., 1990). Estimates of insulin resistance using
this technique correlate well with those from the euglycaemic hyperinsulinemic
clamp (r=0.89, p<0.001 (Bergman et al., 1987). There is a within subject coefficient
of variation of roughly 20% (Steil et al., 1986). Limitation of this test are that; it is
time consuming and expensive, as 25 blood specimens are taken over a 3 hour
period; analysis of the results requires a computer programme; and the lack of
standardisation in the methodology used for the IVGTT makes comparisons across
studies difficult (Bingley et al., 1992).
The short insulin tolerance test is a simple test in which an estimate of insulin
resistance is obtained from the rate of decline in glucose following an intravenous
bolus of insulin. Soluble insulin (0.1-0.5 U/kg) is administered intravenously and
blood samples (for insulin and glucose) are collected at 2-min intervals for 15
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minutes. The short duration of the test avoids the problem of interference from the
release of counter-regulatory hormones. The test reflects the combination of
suppression of hepatic glucose output and stimulation of peripheral glucose uptake
by insulin. Insulin sensitivity is determined by calculating the rate of decline of the
log transformed glucose concentrations estimated by linear regression. The test has
acceptable reproducibility with a mean within subject coefficient of variation 13%,
and between subject coefficient of variation of 26% (Hirst et al., 1993). Insulin
sensitivity with this test correlates well with that measured by HOMA in
normoglycaemic subjects (r= -0.61, p<0.0001), but less well in subjects with
impaired glucose tolerance (r=-0.42, p=0.05) (Phillips et al., 1994).
The euglycaemic hyperinsulinemic clamp is now regarded as the gold standard for
measurement of insulin sensitivity, (Ferrannini & Mari, 1998). In this insulin is
infused at a constant speed to maintain a given insulin concentration such as 80mu/l,
whilst glucose is infused at a varied rate to maintain arterial glucose at 5.0mmol/L.
The amount of glucose required to maintain this concentration is a measure of insulin
sensitivity. The use of radio labelled glucose with this technique allows
measurement of the sensitivity of the liver to the inhibitory effect of insulin
(switching off of glucose output) and the sensitivity of muscles and adipose tissues to
the stimulatory effect of insulin (uptake of glucose into these cells).
Merits of the insulin clamp are that its estimates are free of assumptions, are derived
under conditions of steady state, and are reproducible with roughly a 10% intra-
individual coefficient of variation (Ferrannini & Mari, 1998). One limitation of this
clamp is that it only looks at the effect of insulin on glucose at one glucose
concentration. Full dose response curves for in vivo insulin-stimulated glucose
uptake have been constructed by performing multiple euglycaemic or
hyperglycaemic clamps on one individual, but this laborious approach is only
feasible in small number of subjects (Rizza et al., 1981). An additional difficulty
with these clamps is that insulin sensitivity estimated during insulin administration
may not bear a close relationship to that seen in the fasting state where hepatic
glucose output and non-insulin-dependent glucose utilization dominate glucose
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homeostatis. Despite these limitations the use of the euglycaemic hyperinsulinemic
clamp has become prevalent enough to generate databases that can be used to look at
the importance of insulin resistance in the pathogenesis of diabetes.
Evidence that insulin resistance is important in the development ofdiabetes.
There is a large body of evidence that implicates insulin resistance in the
pathogenesis of T2DM. The majority of individuals with T2DM are resistant to the
action of insulin. This was exemplified in a recent study, which measured insulin
sensitivity in a large, tri-ethnic (non-Hispanic whites, Hispanics and African-
Americans) cohort of subjects (Haffner et al., 1997) with T2DM. The incidence of
insulin resistance was high (83%-96%) in lean as well as obese individuals,
regardless of ethnicity.
One way to examine the pathogenesis of T2DM is to study those who are at risk of
developing the disease. Individuals with impaired glucose tolerance (IGT) have a ten
fold increased risk of developing T2DM when compared to the normal population
and have conversion rates estimated between 2-12% per year, depending on the
population studied (Ferrannini, 1998). Case control studies have shown that
individuals with IGT have a similar degree of insulin resistance to that seen in
subjects with T2DM (Bogardus et al., 1984). Furthermore this insulin resistance is
independent of obesity (Reavan et al., 1989). Prospective studies in these individuals
demonstrate that high fasting insulin concentrations and high 2-hour insulin
concentrations after a fixed oral glucose load predict the development of T2DM
(Saad et al., 1988).
Having a first degree relative who suffers with T2DM carries a 2-3 fold increased
risk of developing T2DM compared to the normal population (Nolan, 2002). These
individuals prior to the development of IGT or T2DM demonstrate higher fasting
insulin concentration and are more insulin resistant than individuals without a family
history. Interestingly the insulin resistance seen in this population is independent of
the degree of obesity (Ishikawa et al., 1998). Prospective studies in these individuals
also show that high fasting insulin concentrations and high 2 hour insulin
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concentration after a fixed oral glucose load predict the development of IGT and
T2DM (Lillioja et al., 1993) (Haffner et al., 1996).
Another way to examine the pathogenesis of T2DM is to look at identical twins.
Normally the concordance of T2DM in identical twins is between 90-100% (Nolan,
2002). Thus examination of twins non-concordant for T2DM can give us some idea
as to what abnormalities precede the development of this disease. Studies reveal that
insulin resistance is present from an early age and that the primary abnormality is
with insulin stimulated glucose uptake into muscles (peripheral insulin resistance)
perhaps caused by a decrease in glycogen synthesis (Gulli et al., 1992).
The final evidence that implicates insulin resistance in the pathogenesis of T2DM
comes from two large randomised controlled trials that have shown that it is possible
to interrupt the progression from IGT to T2DM by lifestyle interventions
(Tuomilehto et al., 2001) (Knowler et al., 2002). In the Diabetes Prevention
Programme 3,234 individuals with IGT were randomised to diet, exercise or
metformin. The risk of developing diabetes was reduced by 58% in the lifestyle
intervention group, members ofwhich maintained daily physical activity (walking or
moderate exercise) for 30 minutes per day and lost 5-7% of their body weight. In the
group treated with metformin, an insulin sensitising agent, the risk of diabetes was
reduced by 31% (Tuomilehto et al., 2001).
In the Finnish Diabetes Prevention Study progression from IGT to T2DM was
reduced by a similar degree (58%). Here diet was modified by a reduction in
saturated fat and moderate exercise was recommended for 30 minutes per day
(Knowler et al., 2002). Common to both of these studies, is a definitive lifestyle
intervention resulting in a reduction in acquired insulin resistance, which in turn
leads to a reduced incidence ofT2DM in a population at very high risk of developing
this disease.
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How do glucocorticoids cause insulin resistance ?
Bierry was the first person to recognise that glucocorticoids were important in
glucose metabolism when he demonstrated that adrenalectomised animals became
hypoglycaemic (Bierry & Malloizel, 1908). Later when insulin therapy became
available for the treatment of diabetes mellitus, a Spanish physician reported that
diabetic patients who developed adrenal insufficiency (lack of glucocorticoids) had a
reduced need for exogenous insulin, indicating a state of insulin sensitivity (Maranon
1925). Recognition that excessive circulating concentrations of glucocorticoids,
whether induced pharmacologically or due to endogenous production, results in
insulin resistance confirmed that glucocorticoids are important in determining the
action of insulin, i.e. determining the degree of insulin resistance.
It is now recognised that even within the physiological range that glucocorticoids can
induce a state of insulin resistance which is seen both in hepatic and extrahepatic
tissues. In the liver glucocorticoids increase production of glucose by stimulating the
formation of glucose (gluconeogenesis) and by encouraging the breakdown of
glycogen (glycolysis) (Rizza et al., 1982). In muscles and adipose tissue
glucocorticoids impair both insulin-stimulated glucose uptake and non-insulin
stimulated glucose uptake, mainly by reducing glycogen synthesis {Holmang &
Bjorntorp, 1992). But how do glucocorticoids induce this state of insulin resistance?
In simplistic terms interference with insulin action (causing insulin resistance) by
glucocorticoids can either be generalised affecting all cells and tissues in a similar
manner or cell specific, affecting tissues in different ways. Broadly, interference in
insulin receptor binding, receptor phosphorylation or second messengers would
cause generalised insulin resistance, whereas interference with transporter proteins,
enzymes and metabolic pathways would lead to insulin resistance that is tissue
specific.
Generalised abnormalities in target organ responses to insulin
In patients with severe insulin resistance, more than 50 mutations of the insulin
receptor (Baynes et al., 1997) and 3 mutations of the insulin receptor substrate 1
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protein (Yoshimura et al., 1997) have been characterised. However, these mutations
are rare and do not explain insulin resistance in the vast majority of patients with
T2DM.
Numerous studies have looked at the effect of glucocorticoids on insulin receptor
binding but no consensus has emerged. So far, human studies have found that
glucocorticoids can decrease insulin receptor binding affinity without decreasing
insulin receptor numbers (Kahn et al., 1978) (de Pirro et al., 1980) can decrease
receptor number and receptor affinity (Beck-Nielsen et al., 1980) have no effect on
affinity or number (Pagano et al., 1983) or can increase receptor number without
affecting affinity (Rizza et al., 1982). Where in vivo and in vitro studies have been
carried out simultaneously, they have not been in agreement (de Pirro et al., 1980)
(Fantus et ai., 1981). It seems reasonable to conclude that the small changes in
insulin receptor number or binding affinity would not be sufficient to explain the
degree of insulin resistance seen with glucocorticoids. The discrepancies between in
vitro and in vivo observations probably reflect difficulties in controlling for indirect,
and potentially compensatory, effects of glucocorticoids. For example, very few
experiments have controlled for the hyperinsulinaemia induced by glucocorticoids.
When compensatory hyperinsulinaemia was prevented by streptozotocin treatment in
rats, glucocorticoid induced changes in insulin receptor number, IRS-1 and
phosphorylation were abolished (Giorgino et al., 1993).
Tissue-specific determinants of insulin response
The effect of activation of the insulin receptor differs between tissues. In peripheral
tissues, such as fat and skeletal muscle, it depends primarily on altered activity of
glucose transporters whereas in the liver it depends on increasing the activity of
enzymes controlling glycolysis and gluconeogenesis.
Determinants of peripheral glucose uptake
The first determinant of insulin-dependent peripheral glucose uptake is the
availability on the cell membrane of the GLUT 4 transporter, which is expressed
mainly in skeletal muscle and increased by insulin. To date, no mutations in GLUT
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4 transporters have been reported in patients with insulin resistance (O'Rahilly et al.,
1992). The expression of GLUT 4 is increased by glucocorticoids in both skeletal
and adipose tissue, but translocation of this transporter to the cell surface in response
to insulin and other stimuli (e.g. hypoxia) is inhibited in the presence of
glucocorticoids (Oda et al., 1995) (Coderre et al., 1996) (Owen & Cahill, 1973)
(Weinstein et al., 1995) (Dimitriadis et al., 1997).
The rate of glucose uptake also depends on the gradient of glucose concentration
across the cell membrane. This is influenced both by local delivery of glucose,
determined in euglycaemic conditions by blood flow, and by the rate of removal of
glucose by phosphorylation or oxidation inside the cell (Figure 1.2). Within the
target cell, glucose oxidation is influenced by competing substrates including non-
esterified free fatty acids. Randle proposed that free fatty acids might induce insulin
resistance by reducing glucose oxidation inside the cell (Randle et al., 1965). This
phenomenon is seen during acute administration (Boden, 1997). Furthermore free
fatty acids are increased in some subjects with T2DM, especially those who are
obese. Acipimox and nicotinic acid, which lower free fatty acid concentrations, also
increase insulin sensitivity (Petrie & Donnelly, 1994). Chronic administration of free
fatty acids however does not induce insulin resistance (Boden et al., 1995), and free
fatty acids may simply be elevated in insulin resistant subjects due to impaired
insulin-dependent down-regulation of lipolysis. These findings suggest that elevated
free fatty acids could both result from, and contribute to, impaired insulin-dependent
glucose uptake.
Increased lipolysis may be important in glucocorticoid induced insulin resistance,
since this is reversed by inhibition of lipolysis (Ekstrand et al., 1992) or lipid
oxidation (Guillaume-Gentil et al., 1993) (figure 1.2). However, cause and effect are
difficult to elucidate because free fatty acids have been reported to influence
glucocorticoid receptor binding (Haourigui et al., 1994) (Vallette et al., 1991).
Increased lipolysis induced by glucocorticoids may be mediated indirectly, by up-
regulation of phenylethanolamine N-methyltransferance (Kennedy et al., 1993), an




Figure 1.2. Effects of insulin and glucocorticoids on peripheral glucose uptake.
A schematic for an archetypal insulin-sensitive cell is shown. In adipocytes,
lipogenic pathways predominate whereas in skeletal muscle either oxidative
metabolism (of pyruvate or free fatty acids) or glycogen synthesis predominates.
GLUT 4 is expressed principally in skeletal muscle and lipoprotein lipase principally
in adipose tissue. Actions of glucocorticoids (blue arrows) and insulin (red arrows)
are shown either as positive (arrow up) or negative (arrow down) effects. The major
effect of glucocorticoids may be to reduce insulin-mediated vasodilatation, reduce
translocation ofGLUT 4 to the cell surface and enhance local synthesis of adrenaline
(see text) thereby increasing free fatty acid competition with pyruvate for
mitochondrial oxidative metabolism.
Inhibition of this enzyme ameliorates glucocorticoid induced insulin resistance
(Kennedy et al., 1993). Alternatively, effects on lipolysis may be mediated via up-
regulation of peroxisome-proliferator-activated y receptors, for which the insulin-
sensitising thiazolidinediones are exogenous ligands. Finally, glucocorticoids may
increase circulating free fatty acids by inhibiting lipoprotein lipase (figure 1.2) (Ong
eta!., 1992).
Baron and others have demonstrated that insulin induces endothelium-dependent
vasodilatation, probably mediated by increased nitric oxide synthesis or action
(Baron et al., 1995). They have suggested that this action contributes to enhanced
glucose uptake in response to insulin and other vasodilator stimuli, particularly in
skeletal muscle. Furthermore their model suggests that the impaired endothelium-
dependent vasodilatation seen in subjects with the features of the metabolic
syndrome (hypercholesterolaemia (Leung et al., 1993), hypertension (Panza et al.,
1993) or diabetes mellitus) could both result from, and contribute to, impaired insulin
action in skeletal muscle. However, others have found that increased blood flow and
glucose uptake during hyperinsulinaemia are dissociated in man (Raitakari et al.,
1996).
Glucocorticoids may also influence this determinant of insulin sensitivity. Walker et
al have shown that glucocorticoids impair endothelium-dependent vasodilatation in
humans in vivo (Walker et a!., 1995) and therefore, if this is an important mechanism
dictating glucose delivery, this may also be a site where insulin action is
counterbalanced by glucocorticoids.
Determinates ofhepatic glucose release.
The pathways determining the balance between glycogen synthesis and glucose
oxidation versus glycogen breakdown (glycogenolysis) and glucose formation
(gluconeogenesis) are summarised in Figure 1.3. Abnormalities in hepatic glucose
release are most likely to be manifest as increased fasting plasma glucose. Until
recently it has been more difficult to measure hepatic than peripheral glucose
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Figure 1.3. Effects of insulin and glucocorticoids on hepatic glucose metabolism
The principal metabolic fates of glucose in the liver are shown. Actions of
glucocorticoids (blue arrows) and insulin (red arrows) are shown either as positive
(arrow up) or negative (arrow down) effects. In some respects, insulin and
glucocorticoids oppose each other's actions, particularly on gluconeogenesis
(PEPCK) and release of glucose from glucose-6-phophate. In other respects,
however, insulin and glucocorticoids do not oppose each other, especially in
promoting oxidative glycolysis and increasing turnover between glucose 6-phosphate
and glycogen.
remained obscure. One element of insulin signalling which may be specific to the
liver, and which has not been accounted for in previous human studies, is the
importance of insulin pulsatility (Polonsky et al., 1998). Like other peptide
receptors, the insulin receptor responds to specific patterns of change in insulin
concentration as well as to the absolute level. Loss of the pulsatile pattern of insulin
release may explain the hepatic insulin resistance that occurs prior to the
development of T2DM. As has been shown in the earlier section, glucocorticoids
interfere with pancreatic insulin secretion, but effects on pulsatility have not been
explored.
Contrasting effects of insulin and glucocorticoids on the liver are well characterised
in animal models (see figure 1.3) (Dallman et al., 1993). A key effect appears to be
the counter-regulation by insulin and glucocorticoids of the rate-limiting enzyme in
gluconeogenesis, phosphoenolpyruvate carboxykinase (PEP-CK) (Hanson & Reshef,
1997). However, there is a conflicting literature concerning the effects of
glucocorticoids on hepatic glucose metabolism in man. Some groups have found
gluconeogenesis to be increased (Rooney et al., 1994) (Pagano et al.. 1983) whilst
others have not noted any affects following glucocorticoid administration (Malerbi et
al., 1988) (Wajngot et al., 1990). These differences may reflect the difficulties of
measurement in man, rather than any true discrepancy between species. They could
be accounted for by increased glucose/glucose 6-phosphate cycling, which
confounds many of the tracer measurements of hepatic glucose output.
Factors which modulate the effect of glucocorticoids on insulin sensitivity
Having described the numerous potential sites of action of glucocorticoids on insulin
secretion and sensitivity, I will now address the importance of altered glucocorticoid
action in insulin resistance. This requires an understanding of the factors which
modulate glucocorticoid action, which are shown in figure 1.4.
Plasma Cortisol concentrations
An important determinant of glucocorticoid action is the circulating concentration of
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Figure 1.4. Factors determining glucocorticoid action
Schematic indicates the hypothalamic-pituitary-adrenal axis controlling secretion of
both glucocorticoids (Cortisol) and inactive cortisone. These steroids circulate in
similar free concentrations although free Cortisol is in equilibrium with a pool of
Cortisol bound to CBG and albumin. Also shown is a schematic target cell, in which
interconversion of Cortisol and cortisone by 11 P-HSDs dictates access of
glucocorticoid to receptors (R) and subsequent regulation of target genes, including
those responsible for negative feedback.
cortex, controlled principally by ACTH, and by the metabolic clearance rate of
Cortisol. Cortisol circulates in plasma in three states; 5-10% circulates unbound and
is "free" to cross cell membranes and interact with receptors; 70-75% is bound to
Cortisol binding globulin (CBG); and 15-20% is bound to albumin. CBG and
albumin therefore buffer the free Cortisol concentration, but these are saturated
within the high physiological range so that there are large excursions in free plasma
Cortisol concentrations between peaks (in the morning in man and during stress) and
troughs (at night in man).
Tissue sensitivity to Cortisol
In addition to the influence of changes in circulating Cortisol levels, the last decade
has seen the recognition of the importance of tissue-specific variations in the
mechanisms dictating target organ sensitivity to glucocorticoids. Cortisol can
activate either glucocorticoid (type 2 corticosteroid) or mineralocorticoid (type 1
corticosteroid) receptors, and indeed has higher affinity for the latter (Arriza et al.,
1987). Glucocorticoid receptors are more widely distributed and act as high
capacity, low affinity receptors, which are occupied mostly during the circadian peak
of plasma Cortisol levels (in the morning in man). By contrast, mineralocorticoid
receptors have a more restricted localisation. In some sites, e.g. in hippocampus and
hypothalamus, they act as low capacity, high affinity receptors which are occupied
during the nocturnal trough of Cortisol secretion in man and may be involved in
negative feedback control of the HPA axis (Sheppard & Funder, 1987).
In other sites, e.g. the distal nephron, sweat glands and colon, they do not bind
Cortisol and act as receptors for the much lower plasma concentrations of
aldosterone, thereby regulating salt balance (Krozowski & Funder, 1983).
For some time, it was a paradox that mineralocorticoid receptors could bind Cortisol
in some sites but not in others. This paradox was explained by the activity in
aldosterone target sites of an enzyme, 11 P-hydroxysteroid dehydrogenase type 2
(11P-HSD2), which inactivates Cortisol by converting it to the metabolite cortisone.
When this mechanism is defective, as in a rare congenital syndrome of 11P-HSD2
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mutations (Mune et al., 1995), or after administration of the 11P-HSD inhibitor
liquorice (Stewart et al., 1987), Cortisol gains inappropriate access to
mineralocorticoid receptors and induces salt retention, hypokalaemia, and
hypertension (Edwards et al., 1988) (Funder et al., 1988).
This model of enzyme-mediated regulation of ligand access to intracellular receptors
is not unique to mineralocorticoid receptors. For example, thyroxine is also activated
in target tissues to triiodothyronine by 5'-monodeiodinases, testosterone is activated
by 5a-reductase to dihydrotestosterone, and similar mechanisms influence activation
of vitamin D and retinoid receptors (Stewart & Sheppard, 1992). Recent evidence
has suggested that the access of Cortisol to glucocorticoid receptors is also regulated
by an enzyme, and that this is relevant to the effects of Cortisol on insulin sensitivity.
Modulation ofinsulin sensitivity by 11/3-HSD type I
Before the cloning of 11P-HSD2 (Albiston et al., 1994) (Agarwal et al., 1994), which
catalyses the inactivation of Cortisol to cortisone, a different isozyme 11(3-HSD type
1 (lip-HSDl) had been cloned (Agarwal et al., 1989). This catalyses the same
dehydrogenase reaction in solution in vitro, but is now recognised to function
exclusively as a reductase, reactivating cortisone to Cortisol, in whole cells in culture
(Low et al., 1994) (Bujalska et ai., 1997), in perfused organs (Jamieson et al., 1995),
and in vivo in man (Walker et al., 1992). 1 1P-HSD1 is widely distributed throughout
the body and is found in the liver, in adipose tissue, and in skeletal muscle. It has
been hypothesized that its function in liver is to ensure adequate activation of low
affinity glucocorticoid receptors, by reactivating cortisone into Cortisol (Figure 1.5).
The following evidence supports this hypothesis:
i. Circulating levels of cortisone in man are ~50 nM, and are not protein bound or
subject to circadian variation (Walker et al., 1992). This compares with free
plasma Cortisol concentrations of 50-100 nM in the morning and ~10 nM in the
evening. There is therefore an ample supply of substrate for lip-HSDl to
reactivate to Cortisol.
33
Figure 1.5. Contrasting influence of llp-HSDs on Cortisol sensitivity in the liver
and kidney
Predominant conversion of Cortisol into cortisone by the dehydrogenase 11P-HSD2
in the kidney results in protection of the local mineralocorticoid receptors (MR).
Predominant conversion of cortisone into Cortisol by the reductase lip-HSDl in the
liver results in enhanced activation of glucocorticoid receptors.
The ratio of cortisol/cortisone in the human hepatic vein is 5-fold higher than that
in arterial plasma (Walker et al., 1992), confirming that 11(3-HSD1 functions as a
reductase in the human liver. Furthermore, administration of cortisone by mouth,
which is delivered to the liver by the portal circulation, results in high circulating
Cortisol concentrations but negligible circulating cortisone concentrations (Stewart
et al., 1990).
. Administration of the liquorice derivative, carbenoxolone, inhibits the conversion
of cortisone to Cortisol in man (Stewart et al., 1990) and also inhibits hepatic 11P-
HSD1 activity in isolated perfused rat liver (Jamieson et al., 1995).
Carbenoxolone also results in enhanced whole body insulin sensitivity measured
by the euglycaemic hyperinsulinaemic clamp technique but does not alter
peripheral insulin sensitivity measured by forearm glucose uptake (Walker, et al.,
1995). This suggests that inhibition of hepatic 11P-HSD1 in man results in lower
intrahepatic Cortisol concentrations which in turn is associated with enhanced
insulin-dependent down-regulation of hepatic glucose output.
. In rats, oestrogen represses the expression of lip-HSDl in the liver (Low et al.,
1994). In adrenalectomised rats, oestrogen induces a rise in the gluconeogenic
enzyme PEP-CK but in rats with intact glucocorticoid secretion oestrogen
suppresses PEP-CK (Jamieson et al., 1998), consistent with enhanced insulin
sensitivity due to lower intra-hepatic insulin sensitivity.
Transgenic deletion of the lip-HSDl gene in mice results in inability to convert
11-dehydrocorticosterone into corticosterone (the equivalent of cortisone and
Cortisol, respectively, in man) and, despite elevated plasma corticosterone
concentrations, is associated with impaired induction of hepatic gluconeogenic
enzymes during starvation (Kotelevtsev et al., 1997). Furthermore these animals
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show normal hepatic lipid synthesis but an increase in lipid catabolism, resulting
in elevated HDL-cholesterol and reduced total cholesterol (Morton et al., 2001).
vi. Selective inhibition of lip-HSDl in hyperglycaemic mice, lowers hepatic PEP-
CK and glucose-6-phosphatase mRNA, resulting in decreased plasma glucose and
insulin concentrations (Alberts et al., 2002).
11P-HSD1 also influences insulin sensitivity in peripheral tissues such as skeletal
muscle and fat. Mice with transgenic over-expression of lip-HSDl selectively in
adipose tissue under the aP2 promoter develop central obesity, insulin resistance, and
hyperglycaemia (Masuzaki et al., 2001). Thus specific inhibitors of lip-HSDl
might provide a useful therapeutic strategy to enhance insulin sensitivity in the liver
and adipose tissues in many different syndromes.
Evidence that glucocorticoid activity is increased in subjects with insulin
resistance
From the above it is clear that excessive activity of glucocorticoids, whether by
increased circulating levels of Cortisol or increased tissue sensitivity to Cortisol, is a
plausible contributor to both insulin resistance and impaired insulin secretion and
may thus be important in the pathogenesis of T2DM. This could also explain why
hypertension, central obesity, dyslipidaemia, and endothelial dysfunction tend to
occur in patients with T2DM.
In addition, glucocorticoid excess in utero results in lower birthweight offspring
which subsequently exhibit insulin resistance and hypertension (Benediktsson et al.,
1993) (Lindsay et al., 1996), so that glucocorticoid excess provides a potential
mechanism to explain the association of low birthweight with T2DM and other
features of the metabolic syndrome (Barker et al., 1989) (Phillips et al., 1994).
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A series of recent studies have examined the relationship between aspects of Cortisol
secretion and tissue action in these diseases.
Plasma Cortisol concentrations: activation of the hypothalamic-pituitary-ailrenal
axis
Phillips et al have shown that elevated 0900 h plasma Cortisol occurs in adult men
who were a lower birthweight and is associated with relative hypertension, insulin
resistance, glucose intolerance, and hypertriglyceridaemia (Phillips et al., 1998).
Similar results have been obtained in other cohorts (Stolk et al., 1996) (Filipovsky et
al., 1996). More recent data confirms that these men have evidence of chronic
activation of the hypothalamic-pituitary-adrenal (HPA) axis (Reynolds et al., 1998).
The rate of Cortisol secretion is also increased in young men with a familial
predistribution to essential hypertension but not in men with a similar elevation of
blood pressure whose parents had low blood pressure (Walker et al., 1998). This
suggests that elevated Cortisol is an early and perhaps inherited feature of essential
hypertension.
Primary activation of the HPA axis may not be responsible for increased Cortisol
secretion in all circumstances characterised by insulin resistance. The insulin
resistance which is associated with obesity is in many ways distinct from insulin
resistance in lean subjects, not least because it can usually be reversed by weight
loss. Abnormalities of glucocorticoids are also different in lean and obese
individuals. The higher plasma Cortisol observed in the studies described above
appears to co-segregate with insulin resistance but not with obesity. Indeed, plasma
Cortisol is lower in obese subjects (Ljung et al., 1996) perhaps due to enhanced
metabolic clearance of Cortisol by the enzyme 5a-reductase, which is expressed in
liver and fat (Andrew et al., 1998). The tendency of this enzyme to lower plasma
Cortisol may result in a compensatory increase in CRH, ACTH and Cortisol secretion,
which may explain the increased Cortisol secretion seen in obesity (Marin et al.,
1992) (Pasquali et al., 1993). The same effect may explain the increased drive to
adrenal steroidogenesis in the insulin-resistant polycystic ovarian syndrome (Stewart
et al., 1990). An alternative mechanism for this increased secretion of Cortisol could
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be decreased feedback sensitivity to Cortisol, which has recently been described by
Jessop et al. (Jessop et al., 2001). This again contrasts with changes seen in the HPA
of lean insulin resistant men, who show enhanced feedback sensitivity (Reynolds et
al., 2001) and inappropriate central drive, as exhibited by impaired habituation of
Cortisol in response to repeated sampling (Reynolds et al., 2001).
Tissue sensitivity to Cortisol
Assessment ofglucocorticoid receptor sensitivity in man is difficult. Dexamethasone
suppression tests assess central negative feedback suppression of ACTH and Cortisol
secretion. Although the response to dexamethasone is variably reported as increased
or impaired in obesity (Hautanen & Adlercreutz, 1993) (Rosmond et al., 1998), it has
not been reported to be abnormal in essential hypertension or lean insulin-resistant
subjects.
An alternative test of peripheral glucocorticoid receptor sensitivity in vivo involves
measuring the intensity of dermal blanching following topical administration of
synthetic glucocorticoids. This response is increased in patients with essential
hypertension, in young adults with a familial predisposition to hypertension (Walker
et al., 1996) and in men with relative glucose intolerance and insulin resistance
(Walker et al., 1998). Furthermore, the skin response is increased in healthy subjects
who carry a polymorphism of the glucocorticoid receptor gene (Panarelli et al., 1998)
which is more common in those with a familial predisposition to hypertension (Watt
et al., 1992) and is associated with greater hyperinsulinaemia in obese subjects
(Weaver et al., 1992).
Glucocorticoid receptor function can also be measured ex vivo in leucocytes.
Although these measurements do not relate to the polymorphism associated with
increased dermal sensitivity (Panarelli et al., 1998), glucocorticoid receptors have a
higher affinity for dexamethasone in leucocytes from subjects predisposed to
hypertension (Walker et al., 1998). On the other hand, in established essential
hypertension, glucocorticoid receptor binding may be impaired (Mulatero et al.,
1997).
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These data suggest that glucocorticoid receptor sensitivity may be increased in the
metabolic syndrome in peripheral tissues, but not in the central tissues responsible
for negative feedback. This inference has remarkable parallels in animal models of
the metabolic syndrome. In rats exposed to dexamethasone in utero who are born
small and develop insulin resistance and hypertension as adults (Benediktsson et al.,
1993) (Lindsay et al., 1996), glucocorticoid receptor expression is increased in their
liver in association with up-regulation of the gluconeogenic enzyme PEP-CK
(Nyirenda et al., 1998). However central glucocorticoid receptor expression is down
regulated, explaining why these animals are relatively hypercorticosteronaemic
(Levitt et al., 1996). Similarly, men with insulin resistance have now been shown to
have normal suppression of plasma Cortisol to dexamethasone, but increased
expression of the GR in muscle (Reynolds et al., 2002) (Whorwood et al., 2002).
11(^-hydroxysteroid dehydrogenases
Cortisol metabolism by llp-HSDs is also altered in subjects with insulin resistance,
although these data are less consistent than the information concerning the
glucocorticoid receptor. Insulin is a major inhibitor of lip-HSDl expression
(Jamieson et al., 1995) (Hammami & Siiteri, 1991), so that it would not be surprising
if insulin resistance were associated with differences in the activity of this isozyme.
Patients with essential hypertension demonstrate a higher ratio of the metabolites of
Cortisol to those of cortisone and impaired conversion of Cortisol to cortisone
(Walker et al, 1998) (Walker et al., 1993) (Soro et al., 1995). However, in patients
with polycystic ovarian syndrome, the reverse has been observed in some studies
(Rodin et al., 1994).
In the obese Zucker rat, a model for human obesity, abnormalities in Cortisol
metabolism have been found. These animals have differences in the urinary
metabolites of corticosterone (rat equivalent of Cortisol) that are consistent with
overall balance of whole body 1 lp-HSDs towards inactive 11-dehydrocorticosterone
(rat equivalent of cortisone) (Livingstone et al., 2000). They also show tissue
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specific abnormalities in llp-HSDl, with decreased activity in the liver, normal
activity in skeletal muscle and subcutaneous adipose tissue, and increased activity in
the omental fat (Livingstone et al., 2000). Similar findings have been found in obese
humans with overall 1 lP-HSDs activity favouring conversion of Cortisol to cortisone
(Stewart et al., 1999) (Rask et al., 2002), impaired conversion of cortisone to Cortisol
in the liver and increased re-activation of cortisone to Cortisol in omental fat (Rask et
al., 2002). Whether similar abnormalities will be found in patients with T2DM
remains to be elucidated.
Oral treatment options for patients with type 2 diabetes
The UKPDS study demonstrated that tight glycaemic control can prevent and delay
the progression of complications of diabetes (The UKPDS Study Group (33), 1998)
(The UKPDS Study Group (34), 1998). In this study the intensive control group
aimed to achieve an HbAlc of 7% or less, equivalent to a fasting plasma glucose
level of 7.8mmol/l. Regardless of initial response to and mode of treatment,
glycaemic control gradually worsened over time. After 3 years only 50% of patients
could maintain these targets on monotherapy and this figure fell to 25% at 9 years
(Turner et al., 1999). Thus the majority of patients required multiple therapies in an
effort to maintain intensive control over time. In many cases this ultimately led to
the introduction of insulin. Current options for the tablet of treatment of type 2
diabetes come from three main groups. These work by:
1) Increasing insulin release with sulphonylureas and meglitinides
2) Increasing insulin responsiveness with a biguanide or thiazolidinediones
3) Modification of intestinal absorption of carbohydrate with an alpha -
glucosidase inhibitor, or absorption of fat with a lipase inhibitor.
Drugs that increase insulin release.
Sulphonylureas stimulate insulin secretion by increasing response of the pancreatic
P-cells to both glucose and non glucose secretagogues (e.g. amino acids). Initially
they lower blood glucose concentration by 20%, or decrease HbAlc by up to 2%.
The commonest side effect is weight gain which can initiate a vicious circle of
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increasing insulin resistance leading to escalation in drug dose and eventually to a
relative insulin deficiency. There is some data to suggest that cardiovascular
outcome may be worsened in patients taking sulphonylureas (Rytter et al., 1985)
(The Digami Study Group, 1997) although further research to confirm or refute this
is required.
The meglitinides act in a similar manner to sulphonylureas but have a shorter
duration of action. They produce a similar improvement in glycaemic control but are
more expensive and have no therapeutic advantages over the older sulphonylureas
(Hollander et al., 2001). Long term safety data is not yet available.
Drugs that increase insulin responsiveness
Metformin, a biguanide, improves insulin action by an unknown mechanism. The
UKPDS noted that metformin not only improved glycaemic control but also reduced
cardiovascular risk in obese patients. This study also found that metformin was
associated with the least weight gain when compared to other modes of treatment
(The UKPDS Study Group, 1998). Unfortunately many individuals are unable to
tolerate metformin or have contraindications to its use.
Thiazolidinediones are the most recent class of drug to be used in type 2 diabetes.
They increase insulin sensitivity by acting on muscle and liver to improve glucose
uptake and limit glucose production. Although they are known to bind to and
activate the transcription factor peroxisome proliferators-activated receptor-gamma,
their exact mode of action is still to be elucidated. Unfortunately these drugs have
not performed as well as had been anticipated, and although they improve glycaemic
control to a small degree (HbAlc improved by <1%), as yet they are not licensed for
monotherapy and, unlike other anti-hyperglycaemic agents, they cannot be used with
insulin. An additional side effect is that on average individuals gain 4kg in weight
with this therapy (Gale, 2001).
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Drugs that modify absorption ofcarbohydrate orfat
Alpha-glucosidase inhibitors prevent the conversion of carbohydrates into
monosaccharides in the upper G-I system thus decreasing the absorption of glucose.
This increases glucose load in the colon resulting in unwanted gastrointestinal side
effects. In those able to tolerate these side effects, only 20%, it can improve HbAlc
by up to 0.9% (Catalan et al., 2001).
Orlistat, a lipase inhibitor, reduces the absorption of ingested fat by 30%. In doing
so it can lead to an average weight loss of 4kg. This drug has no direct effect on
glycaemic control and thus tends to a useful adjunct in the treatment of overweight
patients with diabetes. Unfortunately it also has significant gastrointestinal side
effects (Miles et al., 2002).
This section demonstrates that present tablet treatment of diabetes is far from ideal.
Drug choice is limited, side effects are common, and these drugs only seem to delay
an inevitable worsening of diabetes control. Even more disappointing is the fact that
no truly effective new class of agent has been found in the last forty years. Research
into new therapeutic targets for type 2 diabetes is desperately needed to avoid these
individuals ending up on insulin as this in the long term leads to weight gain and
further worsening of insulin resistance.
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Conclusions
In this introduction I have illustrated the plausibility of a hypothesis that enhanced
activity of Cortisol contributes to insulin resistance, that it also may impair insulin
secretion and thus that may have a significant role to play in the pathogenesis of
T2DM. I have also presented evidence to suggest that manipulation of Cortisol
action may provide a novel therapeutic target to enhance insulin sensitivity and
increase insulin secretion. Further work is required to address whether alterations in
Cortisol secretion and sensitivity are seen in patients with T2DM and to confirm or
refute whether manipulation of Cortisol action can help in the treatment of this
disease.
In this thesis my aims are to determine whether abnormalities in Cortisol secretion,
metabolism or sensitivity are present in patients with T2DM. I also aim to assess
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In the previous chapter I explained that enhanced activity of Cortisol could be
important in the insulin resistance and impaired insulin secretion that is seen in Type
2 Diabetes (T2DM). Interestingly there is a long history in this area. In the early
1940s at autopsies adrenocortical adenomas, non-malignant tumours of the adrenal
gland, were reported to be found 16 times more often in patients with diabetes than
in individuals without (Russi et al., 1945). Similarly in the mid 1950s patients with
diabetes who developed complications were found to have a higher incidence of
adrenocortical adenomas and heavier adrenal glands than those who did not (Becker
et al., 1954). Whether these pathological abnormalities translate to increased Cortisol
secretion, metabolism or sensitivity in patients with T2DM is less clear.
Table 2.1 summaries the recent studies that have looked at Cortisol activity in
patients with diabetes. The majority of these studies have tended to focus on
individuals with type 1 diabetes. These have shown increased plasma and urinary
free Cortisol levels among patients with poor glycaemic control and/or diabetic
complications (Couch, 1992 ) (Dullaart et al., 1995) (Roy et al., 1993) (Dacou-
Voutetakis et al., 1998), but these abnormalities were less marked in well-controlled
patients without complications (Couch, 1992) (Asfeldt, 1972) (see table 2.1 A). A
number of older studies looking at patients with both type 1 and type 2 diabetes
found less consistent abnormalities (Mortimore et al., 1956) (Kaye et al., 1992)
(Hudson et al., 1984) (Huther & Scholz, 1970) (Cameron et al., 1987), but again
showed higher plasma Cortisol concentrations in those with complications (Lentle &
Thomas, 1964) (Tsigos et al., 1993) (table 2.IB). Few studies have included only
patients with type 2 diabetes and these did not show altered secretion or circulating
levels of Cortisol (Serio et al., 1968) (Kerstens et al., 2000). However, obesity
(Andrew et al., 1998), gender (Finken et al., 1999) and blood pressure (Walker et al.,
1995) affect Cortisol secretion and metabolism; these factors were not controlled for
in previous studies of patients with diabetes. Moreover, no previous studies have
examined tissue responses to glucocorticoids in patients with diabetes, or attempted
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Aim
The aim of this study was to examine Cortisol secretion, metabolism and sensitivity
in nonobese, normotensive, diet-controlled male patients with T2DM or impaired
glucose tolerance. The reason for choosing this population was to ensure that
measures would not be confounded by those factors known to affect Cortisol activity,
namely: gender, obesity, blood pressure, poor glycaemic control and diabetic
complications (Andrew et al., 1998) (Walker et al,. 1995) (Couch, 1992).
Subjects and Methods
Participants
Twenty five men with T2DM or impaired glucose tolerance (as defined by WHO
criteria) were recruited from the diabetes clinics at the Western General Hospital,
Edinburgh, UK and 25 normal healthy controls recruited by advertisement. All
patients were controlled by diet alone, without oral hypoglycaemic agents or insulin
and were free of clinical or biochemical evidence of retinopathy, nephropathy and
neuropathy at their last annual review.
Exclusion criteria included:
□ Therapy for any other medical conditions - medication may have interfered
with measurement being made.
□ Major psychiatric disorder - depression is known to affect Cortisol activity
(Asfeldt, 1969).
□ Weight loss >5 kg in the previous 3 months - weight loss of this degree
tends to indicate poor glycaemic control.
□ Blood pressure >160/90 mmHg - individuals with hypertension have been
shown to have abnormalities in Cortisol activity (Walker et al., 1996)
(Walker et al., 1996) (Walker et al.. 1998).
□ Body mass index >32 kg/m2 - individuals with obesity have been shown to
have abnormalities in Cortisol activity (Andrew et al., 1998).
□ Glucocorticoid therapy by any route in the previous 3 months - will affect
measures of Cortisol activity being made.
□ Abnormal renal or thyroid function on biochemical screening - will affect
measures of Cortisol activity being made (Zumoflf et al., 1983).
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Control subjects were matched for sex, weight, height, body mass index and blood
pressure. Local ethical committee approval and written informed consent were
obtained.
Recruitment
Participants were initially contacted by phone and asked it they would like further
information about the trial. Those who did were sent written information. After a
cooling off period of 2 weeks, they were invited to participate in the trial and a first
appointment was arranged for those who were interested.
Protocol (seefigure 2.1)
The participants met with the researcher on 5 occasions.
Visit 1 - Baseline measurements - duration 30 minutes
Participants attended on one morning non-fasted. Once formal consent for the trial
had been obtained, the researcher performed baseline measurements and blood tests.
A brief medical history and examination was made and measurements of sitting
blood pressure (using a Takeda UA-751 sphygmomanometer), height and weight
were taken. Blood was obtained for full blood count, urea and electrolytes, HbAiC,
liver function tests, and thyroid function tests.
At the end of this visit a timetable for subsequent visits was agreed and recorded on a
timetable sheet. A bottle and instructions were provided and the participants asked
to collect their urine for a 24 hour period before the next visit. This 24-hour urine
specimen sample was used to measure total Cortisol metabolites (see below).
Visit 2 - Application ofskin test - duration 15 minutes
Participants attended on one afternoon for application of the skin test. Solutions of
beclomethasone dipropianate (Sigma Chemical Co.) were prepared in ethanol/water
(95:5 vol/vol) at concentrations of 0, 1, 5, 10, 100, or 1000pg/ml (Noon et al., 1996).











Participant contacted by phone, further information sent if interested.
Second contact
Participants contacted by phone, if interested first appointment
arranged.
Visit 1 (30 minutes)
Formal consent, history and examination and baseline measurements
(blood pressure height and weight and blood specimen)
24 hour urine collection carried out between visit 1 and visit 2
Visit 2 (15 minutes)
Skin test applied and urine collected.
Bandage left on for 17-18 hours, removed an hour before next
appointment
Visit 3 (40 minutes)
Reading of skin test and skin biopsy if patient agreeable.
Participant asked to remain nil by mouthfrom 23:00h the night before
until 08:3Oh the next morning
Visit 4(15 minutes)
Fasting blood for Cortisol, Cortisol binding globulin, glucose, and
insulin.
Participant asked to take 250pg dexamethasone by mouth at 23:00 h
andfasted until attending the following morning at 08:30 h
Visit 5 (2 hours and 30 minutes)
Fasting blood for Cortisol, then cortisone test.
Figure 2.1. Timetable for study.
with these codes not being revealed until the end of the study. This meant that both
the participant and researcher were blinded to the strength of solution being applied.
Between 16:00 and 17:00 h, 50pl of each solution was applied in random order into 6
circles of 20mm diameter on the volar surface of the non-dominant forearm, each site
receiving a different solution. After the ethanol had evaporated, all sites were
occluded with Saran wrap (Dow), which was removed at 08:00 h the following
morning (see figure 2.2).
At the end of this visit the 24-hour urine was collected and instructions about what to
do with the bandaging were supplied. The total volume of urine was measured and
four 50 ml aliquots were stored in a -20°C freezer until analysis (see below).
Visit 3 - reading ofskin test and skin biopsy - duration 40 minutes
Having removed the bandaging at 08:00 h each participant attended at 09:00 h for
reading of the skin test. The degree of blanching was read by using a reflectance
spectrophotometer (Erythemameter, Diastron Ltd). This device measures the ratio of
red/green light reflected from the skin surface, called the erythema index (Noon et
al., 1996). Because red reflects oxyhaemoglobin concentration and green reflects
melanin concentrations, the erythema index corrects for variations in skin colour
between individuals. The erythema index for each test site was divided by the
erythema index for the site treated with ethanol/water alone to produce a blanching
index. The blanching index corrects for the non-specific variations in skin colour
that occur in different environments in the same individuals. A lower blanching
index indicates more intense blanching and thus a greater sensitivity to
glucocorticoids (see figure 2.2).
After reading of the skin tests, participants were asked if they would be willing to
undergo a gluteal skin biopsy. Those who consented had a biopsy of skin and
subcutaneous fat (2cm x 1cm x 1cm) taken from the gluteal region under local
anaesthesia (2% lignocaine hydrochloride; Astra, Herts, U.K.). The biopsy was




Figure 2.2. Application and reading of skin test.
a) Application:- Solutions of beclomethasone dipropianate were prepared in
ethanol/water (95:5 vol/vol) at concentrations of 0, 1, 5, 10, 100, or 1000p.g/ml and were
labelled A-F by an independent observer. Between 16:00 and 17:00 h 50pl of each solution
was applied in random order into 6 circles of 20mm diameter on the volar surface of the non-
dominant forearm. After the ethanol had evaporated, all sites were occluded with Saran
wrap and left covered until 08:00 h the next day.
b) Reading:- Having removed the bandaging an hour early the degree of blanching was
read at 09:00h using a reflectance spectrophotometer. The more intense and widespread the
blanching, the greater the sensitivity to glucocorticoids.
measurement of in vitro adipose 11(3-HSD 1 activity (see below), 1/3 being
embedded in paraffin for future measurement ofglucocorticoid receptor mRNA by in
situ hybridisation (see chapter 3) and 1/3 immersed immediately in cold (4 °C)
physiological salt solution (PSS) for later dissection of resistance arteries, which
were studied by wire myography (performed by Dr P.W.F. Hadoke see (Mcintyre et
al., 2001)).
Visit 4 - Fasting blood test and removal ofstitches - duration 15 minutes
Participants attended at 08:30 h having fasted from 23:00 h the previous evening.
They lay supine, an intravenous cannula was inserted into the antecubital fossa and
blood was taken 30 minutes later for Cortisol, Cortisol binding globulin (CBG),
cholesterol, triglycerides, glucose and insulin. At the end of this visit participants
were provided with 0.25mg of dexamethasone and instructions for the next visit. If
subjects had had a fat biopsy at the previous visit stitches were removed.
Visit 5 - Dexamethasone suppression test and cortisone test - duration 150 minutes
Participants took 250pg dexamethasone (Decadron; Merck Sharpe & Dohme) by
mouth at 23:00 h and fasted until attending the following morning at 08:30 h. An
intravenous cannula was sited and 30 minutes later blood was taken for Cortisol
estimation. Participants then took 25 mg cortisone acetate (Cortisyl; Hoechst Marion
Roussel) by mouth and blood was taken for Cortisol every 15 minutes for 2 hours.
The difference between the 09:00 h Cortisol concentration taken at visit four and that
taken at visit five provided a measure of the degree ofHPA axis suppression induced
by 0.25mg of dexamethasone. The increase in plasma Cortisol after the ingestion of
cortisone acetate enabled us to look at the hepatic activity of 11(3-HSD 1.
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In Vitro adipose 11 /VILSI) 1 activity
Seventeen subjects (5 DM and 12 Controls) consented to return for a 500mg
subcutaneous fat biopsy to be taken from the gluteal region under local anaesthesia.
Subcutaneous fat was frozen immediately at -70C. After thawing, it was
homogenised in Krebs buffer at pH 7.4 and 750pg/ml protein was incubated at 37 °C
with NADP (2mM) and l,2,6,7-3H4-cortisol (100 nM) for 30 hours. Samples were
taken at 3, 6, 20 and 30 hours for separation of Cortisol and cortisone by HPLC with
on-line liquid scintillation detection (Rask et al,. 2001). llp-HSDl activity was
measured in the dehydrogenase direction (i.e. Cortisol to cortisone) rather than the
reductase direction (cortisone to Cortisol). This was because dehydrogenase activity
is more stable than reductase activity in vitro, and because dehydrogenase is the
preferred reaction when the enzyme is liberated from its intracellular environment
(Seckl & Walker, 2001). Under these conditions, the conversion of Cortisol to
cortisone is proportionate to the total protein added, and therefore reflects llp-HSD
1 protein concentrations in the biopsy sample. I performed the biopsies and the
experiments for the in vitro assessment of 11P-HSD1 activity were kindly completed
by Dr Dawn EW Livingstone.
Laboratory analyses
Plasma and urine samples were stored at -80°C and -20°C, respectively.
Radioimmunoassays were used to measure plasma Cortisol (McConway & Chapman,
1986), dexamethasone (Cozart Bioscience) and corticosteroid binding globulin
(Medgenix diagnostics). Insulin was measured by enzyme immunoassay
(Eurogenetics Tasah corporations UK Ltd). Glucose was measured by an enzymatic
technique (Cabas Mira Plus, Roche). Ion exchange high performance liquid
chromatography was used to measure the HbAic (Variant 11, Biorad).
Cortisol and its metabolites were measured in urine by electron impact gas
chromatography/mass spectrometry following Sep-pak CI8 extraction, hydrolysis
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with [^-glucuronidase, and formation of the methoxime-trimethylsilyl derivatives
(Best & Walker, 1997). Epi-cortisol and epi-tetrahydrocortisol were used as internal
standards. Intra-assay coefficients of variation were <10% for unconjugated steroid
and <20% for total steroids. The limit of detection was 20r)g/sample and peaks were
quantified when they exceeded 3 times the background signals. Total Cortisol
metabolite excretion was calculated as tetrahydrocortisols (THFs) +
tetrahydrocortisone (THE) + cortols + cortolones (Zumoff et al., 1974). Relative
metabolism by 5a and 5(3-reductases were inferred from the 5|3-THF/5a-THF ratio.
A-ring reduction of Cortisol was inferred from the ratios of TFIFs/cortisol (Ulick et
al., 1992) and 5P-reductase activity from the ratio of THE/cortisone. Whole-body
equilibrium between Cortisol and cortisone, determined by the balance of tissue-
specific activities of 11 (3-reductase and 11 P-dehydrogenase activities, was inferred
from the ratio of THFs/THE. Renal 11 P-dehydrogenase activity was inferred from
the urinary free cortisol/cortisone ratio (Best & Walker, 1997) (Faiman &
Moorhouse, 1967).
I carried out the measurements for Cortisol and CBG. Measurements of insulin,
glucose, urea and electrolytes, HbAiC, liver function tests, thyroid function tests,
cholesterol and triglycerides were carried out by the local biochemistry laboratory
under the supervision ofMrs Susan Walker. Measurement of dexamethasone and the
urinary Cortisol and its metabolites were performed by Ms Jill Campbell and Dr Ruth
Andrew.
Statistics
Data are expressed as means ± SE. All groups were compared by Student's t test
apart from the urine data, which were compared by Mann Whitney U test, as these
data were not normally distributed. Profiles of Cortisol and dermal vasoconstriction




Characteristics of participants are shown in Table 2.2. The groups were well
matched for anthropometric, clinical and biochemical variables except that patients
with diabetes (DM) had higher fasting plasma glucose, HbAic, and triglycerides than
controls. Cortisol binding globulin and albumin did not differ between the groups so
only total plasma Cortisol was used in further analysis.
Hypothalamic-pituitary-adrenal axis activity
Fasting morning plasma Cortisol (Table 2.2) and total urinary Cortisol metabolite
excretion rate (Table 2.3) were not different between groups. However, the morning
after 250 pg oral dexamethasone, plasma Cortisols were lower in patients with
diabetes (Table 2.1 and figure 2.3). This could not be attributed to differences in
dexamethasone concentrations (Table 2.1).
Cortisol metabolism
Although total Cortisol metabolite excretion was not different between groups, there
were changes in relative metabolite excretion (Table 2.2). DM patients excreted less
unmetabolised Cortisol (p<0.03) and cortisone (p=0.07) and tended to excrete more
as 5P-THF (p=0.07). As a result, ratios reflecting 5P-reduction of Cortisol (5P-
THF/cortisol, p<0.001) and cortisone (THE/cortisone, p<0.005) were increased in
DM patients, and there was a trend for increased 5a-reduction of Cortisol (5a-
THF/cortisol). Absolute excretion of other metabolites, and ratios reflecting 11P-
HSD2 (cortisol/cortisone) and overall 1 ip-HSDs (TFLFs/THE) were not different.
Hepatic lip-HSD 1 activity, measured as conversion of orally administered
cortisone to Cortisol, was impaired in the DM group (Figure 2.4; area under curve








Age (yr) 59 ±2 58 ±2 0.59
Body mass index (kg/m2) 27.2 ±0.5 27.610.6 0.56
Systolic blood pressure (mmHg) 130 ±3 131 ±2 0.66
Diastolic blood pressure (mmHg) 78 + 2 78 1 1 0.78
Plasma creatinine (pM) 89.2 + 2.6 89.8 ±2.7 0.87
HbA,c (%) 6.010.1 6.910.2 <0.0001
Fasting plasma glucose (mM) 5.7 ±0.2 8.210.6 <0.0002
Fasting plasma insulin (mU/L) 19.614.2 21.413.0 0.74
Plasma triglycerides (mM) 2.1 ±0.2 3.5 ±0.6 <0.05
Total plasma cholesterol (mM) 5.610.2 5.610.2 0.92
Plasma Albumin (g/L) 4210.5 4210.8 0.50
09:00 h plasma Cortisol (nM) 420 1 30 428 1 24 0.85
09:00 h plasma Cortisol post-
dexamethasone 250 pg (nM)
238 ±20 1721 16 <0.01
Plasma Cortisol binding globulin
(pg/ml)
31.91 1.4 28.8 1 1.7 0.16
Plasma dexamethasone post-
dexamethasone 250 pg (ng/ml)
0.4010.11 0.41 ±0.05 0.92
Table 2.2. Clinical Characteristics and biochemistry









Cortisol 100 + 6 84 ±9 0.03
Cortisone 112 ± 14 75 ±6 0.07
5a-tetrahydrocortisol (5a-THF) 1197+ 153 1196 ± 104 0.66
5p-tetrahydrocortisol (5P-THF) 1036 ±95 1264 ±90 0.07
Tetrahydrocortisone(THE) 2218 + 685 1433 ± 105 0.13
Total Cortisol metabolites* 7691+1336 7535 ± 1514 0.80
(5a-THF + 5p-THF)/THE 1.94 ±0. 19 1.80 ± 0.11 0.47
5p-THF/5a-THF 1.06 ±0.11 1.19 ± 0.11 0.29
Cortisol/cortisone 1.09 ±0.08 1.13 ±0.05 0.97
5p-THF/cortisol 11.0 ± 1.0 16.4 ± 1.0 0.001
5a-THF/cortisol 12.6 + 1.6 16.5 ± 1.6 0.07
THE/cortisone 15.8 + 2.2 20.4+ 1.2 0.005
Table 2.3. Urinary Cortisol Metabolites
Results for each steroid are p.g/day; other results are ratios; Mean + SE
Total Cortisol metabolites = 5a-THF + 5(3-THF + THE + cortols + cortolones
NS
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Figure 2.3. HPA axis sensitivity
Plasma Cortisol concentrations were measured at 09:00h on two occasions. Once
before and once after an oral dose of 250 pg of dexamethasone at 23:00 h. Data are
mean ± SE for controls (blue, n=25) and DM patients (Red, n=25). Comparisons by
student's t tests between the two groups revealed no significant differences at
baseline but after dexamethasone the DM group had significantly lower plasma
Cortisol than the control group.
***
Figure 2.4. In vivo hepatic lip-HSD 1 activity: conversion of oral cortisone to
plasma Cortisol
Subjects received oral dexamethasone 250 pg at 23:00 h the previous evening and 25
mg oral cortisone at 09:00 h (time 0; arrowed). Data are mean ± SE for controls
(open symbols, n=25) and DM patients (filled symbols, n=25). By repeated measures
two-way ANOVA, plasma Cortisol was lower in diabetics (p<0.005). Asterisks show
post-hoc comparisons at each time point by least squares difference tests: * p<0.02;
** p<0.01; *** pO.OOOl.
taken to reach maximum plasma Cortisol (111 ±3 min vs 100 + 4 min, p<0.05). By
simple regression, there was no relationship between hepatic lip-HSDl and any
individual urinary Cortisol metabolite or ratio. Adipose in vitro lip-HSD 1 activity
was no different between the two groups (Figure 2.5 area under the curve 119+21 %
controls vs 128+56 % DM, p=0.8).
Peripheral tissue sensitivity to glucocorticoids
Dermal vasoconstriction to topical beclomethasone dipropionate was more intense in
the DM than the control group (Figure 2.6).
Discussion
This study demonstrates that non-obese normotensive men with hyperglycaemia
exhibit abnormalities in Cortisol activity. The differences in Cortisol metabolism and
tissue sensitivity were more striking than any differences in HPA axis function.
Specifically, these patients with T2DM or impaired glucose tolerance show:
1) Normal Cortisol secretion and circulating levels in the face of enhanced
negative feedback sensitivity (as measured with dexamethasone).
2) Enhanced in vivo peripheral tissue sensitivity to glucocorticoids (as measured
by dermal blanching).
3) Impaired hepatic lip-HSD 1 activity but normal adipose 11P-HSD 1
activity, suggesting tissue-specific alterations in lip-HSD 1 activity.
4) Increased relative excretion of A-ring reduced metabolites ofCortisol.
These findings suggest that isolated hyperglycaemia is associated with some, but not
all, of the changes in Cortisol metabolism and action which have been observed in
subjects with other features of the Metabolic Syndrome such as hypertension and
obesity.
Table 2.1 summaries the recent studies that have looked at Cortisol activity in















3 6 20 30
Incubation time (h)
Figure 2.5. In vitro lip-HSD 1 activity in subcutaneous fat biopsy.
Data are mean ± SE for % conversion of Cortisol to cortisone at fixed protein
concentrations for control subjects (open symbol, n=12) and DM patients (filled
symbols, n=5). By repeated measures two-way ANOVA there was no difference
between the two groups (p=0.8).
Figure 2.6. Dermal vasoconstriction following topical beclomethasone
dipropionate
Blanching index was recorded following overnight topical application of
beclomethasone dipropionate. A lower index indicates more intense blanching. Data
are mean ± SE for controls (open symbols, n=25) and diabetics (filled symbols,
n=25). By repeated measures two-way ANOVA, blanching was greater in diabetics
(p=0.05). Asterisks show post-hoc comparisons at each dose by least squares
difference tests: ** p<0.01.
type 1 diabetes or mixed patient populations with few studies including only patients
with type 2 diabetes. None of these studies have controlled for factors known to
affect Cortisol activity, namely: gender, obesity, blood pressure, poor glycaemic
control and complications of diabetes (Andrew et al., 1998) (Walker et al., 1995)
(Couch, 1992), making interpretation difficult. Studies in patients with type 1
diabetes show increased plasma and urinary free Cortisol levels among patients with
poor glycaemic control and/or complications of diabetes (Couch, 1992) (Dullaart et
al., 1995) (Roy et al., 1993) (Dacou-Voutetakis et al., 1998), but these abnormalities
were less marked in well-controlled uncomplicated patients (Couch, 1992) (Asfeldt
1972). Studies looking at patients with both type 1 and type 2 diabetes found less
consistent abnormalities (Mortimore et al., 1956) (Kaye et al., 1992) (Hudson et al.,
1984) (Huther & Scholz, 1970) (Cameron et ai., 1987) but again showed higher
plasma Cortisol concentrations in those with complications (Lentle & Thomas, 1964)
(Tsigos et al., 1993). Studies in patients with type 2 diabetes have not demonstrated
any abnormalities in secretion or circulating levels of Cortisol (Serio et al., 1968 )
(Kerstens et al., 2000). No studies to date have examined tissue responses to
glucocorticoids in patients with diabetes, or attempted to dissect tissue-specific
changes in Cortisol metabolism.
The strength of the current study is the careful matching of controls and patients with
type 2 diabetes or impaired glucose tolerance, the focus on men only, and the
exclusion of patients with obesity, hypertension, and diabetes complications. The
aim was to isolate the influence of abnormal insulin action and hyperglycaemia from
these confounding effects. This was achieved in so far as the only detected
differences in baseline characteristics between patients and controls were in fasting
plasma glucose, HbAic, and triglyceride levels. Fasting insulin levels were not
different between groups, consistent with a relative insulin deficiency in the
hyperglycaemic patients. In order to achieve this close matching of affected and
unaffected groups, it was necessary to select patients with extremely good glycaemic
control. As a result, the current study may underestimate effects of hyperglycaemia
per se, but nonetheless will detect differences intrinsic to patients with pancreatic P-
cell dysfunction.
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Other studies have used conventional techniques to assess Cortisol secretion, i.e.
plasma Cortisol concentrations and urinary free Cortisol, which are relatively
insensitive. Cortisol is secreted in a pulsatile manner throughout the day with higher
amplitude and greater frequency in the morning than the evening so that plasma
Cortisol provides only a brief snap shot of the diurnal pattern. Urinary free Cortisol is
a small fraction (<5%) of total Cortisol metabolite excretion, determined principally
by free plasma Cortisol clearance. The sum of the urinary metabolites of Cortisol in
24h urine, as used in this study, provides a better assessment of 24h secretion of
Cortisol (Zumoff et al., 1974) although it is still not able to detect changes in diurnal
variation of Cortisol secretion. Using this method the current study showed that
Cortisol secretion over 24h is normal in lean patients with type 2 diabetes or impaired
glucose tolerance.
The rate of Cortisol secretion is controlled by central 'drive' to the HPA axis and by
negative feedback suppression by glucocorticoids (see figure 2.7). Dexamethasone
suppression of plasma Cortisol is the conventional test to examine negative feedback.
Previous studies in patients with diabetes have used 1 mg of dexamethasone (Hudson
et al., 1984) (Kaye et al., 1992) (Lentle & Thomas, 1964) (Cameron et al., 1984) (see
table 2.1) , as is used in clinical practice to detect Cushing's syndrome, and found
that in most cases suppression was normal. Interpretation of this test is qualitative
rather than quantitative, since the vast majority of controls and patients suppress to
below the detection limit for plasma Cortisol. In this study we used 250 pg of
dexamethasone as an approximate ED50 dose in order to quantify more subtle
variations in suppression within the 'non-Cushing's' range (Reynolds et al. 2001)
(Walker et al., 1996). Using this very low dose test, we have shown that patients
with type 2 diabetes have greater sensitivity of the HPA axis to negative feedback.
This could not be accounted for by differences in dexamethasone concentrations.
Although recent data suggest differences in the feedback response to synthetic and
endogenous glucocorticoids in man (Jessop et al., 2001), the finding of normal 24h
secretion in the face of this enhanced feedback sensitivity suggests that another




















Figure 2.7. Factors influencing Cortisol secretion.
Schematic indicating the factors which control Cortisol secretion. Cortisol secretion
is primarily under the control of the hypothalamic-pituitary-adrenal axis by way of
CRH and ACTH. Increasing Cortisol concentrations tend to turn off this drive
(negative feedback) whereas physical and psychological stress and other hormones
can stimulate this drive.
Increased metabolism of Cortisol or inappropriate central drive to the HPA axis
(figure 2.7) could be the factor driving this Cortisol secretion. Studies in obese
individuals also show increased Cortisol secretion in spite of normal or increased
feedback sensitivity (Ljung et al., 1996). Here, increased metabolic clearance of
Cortisol (Strain et al., 1982), principally by 5a-reductase (Fraser et al., 1999)
(Andrew et al.,. 1998) but with increased 5(3-reduced metabolites also (Rask et al.,
2001), may be a driving force for the increase in Cortisol secretion. In this study, we
found an increase in the relative excretion of 5a- and, most strikingly, 5p-reduced
Cortisol metabolites in the absence of obesity in the hyperglycaemic group.
Notably, it has been shown that insulin therapy reduces excretion of 5a-reduced
Cortisol metabolites (Kerstens et al., 2000). This suggests that peripheral clearance
of Cortisol is enhanced by mechanisms directly associated with relative insulin
deficiency and hyperglycaemia. An alternative explanation is that inappropriate
central drive to the HPA, rather than enhanced Cortisol clearance, is maintaining
Cortisol secretion in the face of enhanced feedback in these individuals. This is
consistent with the observation that habituation of Cortisol in response to repeated
sampling is impaired in hyperglycaemic men (Reynolds et al., 2001).
The finding of normal Cortisol secretion and circulating Cortisol levels in
hypergiycaemic patients suggests that if Cortisol is to play a role in the pathogenesis
of type 2 diabetes, it will be determined by variations in the amount of Cortisol made
available to peripheral tissue One important determinant of tissue response to Cortisol
is the extent of metabolism of Cortisol within the target tissues by 11(3-
hydroxysteroid dehydrogenases (1 l(3-HSDs) (see introduction). Two enzymes exist:
11P-HSD 1 which reactivates cortisone to Cortisol and serves to maintain adequate
exposure of glucocorticoid receptors to Cortisol (Seckl & Walker, 2001); and 11P-
HSD 2 which converts Cortisol to cortisone and prevents Cortisol from gaining
inappropriate access to mineralocorticoid receptors. Overall, activities of these
enzymes can be inferred from the balance of Cortisol and cortisone metabolites in
urine. These have been measured in previous studies in patients with type 1 diabetes
(Dullaart et al., 1995), in whom the ratio of cortisol/cortisone metabolites was lower
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than in controls, and type 2 diabetes (Kerstens et al,. 2000), in which there was no
difference between relatively obese patients and controls. In this study no
differences in overall lip-HSD activity were found between the controls and
individuals with impaired glucose tolerance. However, these urinary ratios are
insensitive to tissue-specific changes in lip-HSD 1 activity (Mortimore et al., 1956).
In obese humans 11(3-HSD 1 is decreased in liver (Stewart et al., 1999) but increased
in adipose tissue (Rask et al., 2003) (Paulmyer-Lacroix et al., 2002) (Rask et al.,
2001). Here, in non-obese hyperglycaemic men, hepatic first pass conversion of
cortisone to Cortisol was impaired, albeit to a lesser extent than in obese subjects
(Rask et al., 2001) (Stewart et al., 1999). However, lip-HSD 1 activity in gluteal
adipose tissue was normal. This could reflect true differences between non-obese
hyperglycaemic men and obese men or could be explained by the fact that the
biopsies were taken in different regions - those in this study were taken from the
gluteal region compared to peri-umbilical biopsies in other studies (Rask et al,,
2001). A further confounding factor may relate to the fact that relatively few
subjects (17 of the original 50) consented for a biopsy. Nonetheless, there is no trend
to suggest that anything approaching the 3-fold differences observed in obesity occur
in lean hyperglycaemic subjects.
The mechanism for tissue-specific dysregulation of 11P-HSD 1 in obesity is
unknown (Livingstone et al., 1999) (Tomlinson et al., 2001), but these data hint that
hepatic dysregulation is related to insulin action while adipose dysregulation is
determined by some other factor associated with obesity, or indeed may be a primary
mechanism in obesity (Bujalska et al., 1997) (Masuzaki et al. 2001). One possible
mechanism for this tissue specific change in lip-HSD 1 activity is differences in
local concentrations of Insulin like growth factors (IGFs). Adminsitraion of GH has
been shown to be a potent inhibitor of lip-HSD 1 activity and even when given in
small concentrations can inhibit the conversion of cortisone to Cortisol (Toogood et
al., 2000). Furthermore changes in local IGF-1 concentrations, free IGF-1 and its
binding proteins have been demonstrated in patients with T2DM (Krsek et al., 2003).
Thus it is is conceivable that tissue specific changes in 11P-HSD 1 activity could be
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explained by alteration in local tissue concentration of GH. Further research is
needed to confirm or refute this.
We tested whether variations in A-ring reductase activities might explain variation in
hepatic 11P-HSD1 but did not find any correlations. It is intriguing to speculate that
down-regulation of lip-HSD 1 is a compensatory mechanism to protect the liver
from glucocorticoid excess in obesity and hyperglycaemia; it may be that the lack of
simultaneous increase in adipose lip-HSD 1 explains why the group of patients
studied here are members of an unusual cohort with impaired glucose tolerance but
without obesity. Importantly, inhibition of lip-HSD 1 has been proposed as a
therapy to improve metabolic control in diabetes and obesity (Walker et al., 1994)
(Bujalska et al., 1997); these data suggest that sufficient 11P-HSD 1 activity exists in
patients with type 2 diabetes to make this strategy worthwhile, although it remains to
be seen whether inhibition in liver and/or adipose tissue will be most influential (see
chapter 4).
Another factor that is important in determining the tissue response to Cortisol is the
expression and activity of glucocorticoid receptors, which is difficult to measure in
vivo in man (see chapter 3). Studies comparing sensitivity to synthetic
glucocorticoid receptor agonists in different sites suggest that there can be tissue-
specific differences. For example, although sensitivity in skin correlates with that in
lung (Brown et al., 1991) it may not correlate with that in leukocytes (Panarelli et al.,
1998) or in the HPA axis (Ebrecht.M et al., 2000). In this study we show that dermal
vascular sensitivity to beclomethasone dipropionate is increased in patients with
glucose intolerance. Similar findings have been described in hypertensive and
insulin resistant men (Walker et al., 1998) (Walker et al., 1996). This provides
circumstantial evidence that glucocorticoid receptors are more readily activated in
dermal vessels, although there may be confounding factors influencing the dermal
blanching response. Up-regulation of glucocorticoid receptor expression has been
implicated in the pathophysiology of insulin resistance in animal models (Nyirenda
et al., 1998). Moreover, glucocorticoid receptor mRNA levels in skeletal muscle are
elevated in men with insulin resistance (Reynolds et al., 2002) (Whorwood et al.,
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2002). These observations suggest that therapeutic strategies to alter glucocorticoid
action in key insulin-sensitive target tissues are likely to be especially beneficial in
hyperglycaemic patients.
Conclusion
In summary, I have demonstrated that patients with type 2 diabetes or glucose
intolerance exhibit abnormalities in Cortisol action in the absence of hypertension or
obesity. These findings add further weight to the hypothesis that abnormalities in
Cortisol action may be important in the pathogenesis ofT2DM and may explain why
abnormalities such as hypertension, obesity and coronary heart disease occur
together more commonly than you would expect by chance.
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Chapter 3




In the previous chapter I demonstrated that dermal vascular sensitivity to
beclomethasone dipropionate is increased in patients with T2DM or glucose
intolerance. This could be explained by increased access of hormones to the
intracellular glucocorticoid receptors (GR), increased GR number, affinity or
signalling, or altered sensitivity of the dermal blood vessels to the products of the
glucocorticoid target genes. Which of these is the most important in this response is
not known.
Increased dermal vascular sensitivity to glucocorticoids has also been described in
hypertensive and insulin resistant men (Walker et ah, 1998) (Walker et al., 1996).
This increased blanching response in patients with hypertension could perhaps be
explained by an increase in GR affinity, as GR affinity is greatest in individuals with
the highest risk of developing hypertension and lowest in those at the least risk (Watt
et ah, 1992). In insulin resistant men, this response may be explained by an increase
in GR numbers, as their muscles show increased expression of GR (Whorwood et ah,
2002) (Reynolds et ah, 2002).
In patients with T2DM increased access of hormones to the intracellular GR is
unlikely to explain the increased dermal response to glucocorticoids, as overall
activity of lip-HSD 1 and 11 P-HSD 2 are normal (Andrews et ah, 2002) and
beclomethasone dipropionate is thought not to be metabolised by the lip HSDs
(Walker, 1996). Altered sensitivity of the dermal blood vessels to the products of the
glucocorticoid target genes also seems unlikely to explain this response, as in vitro
studies of subcutaneous vessels show few differences in vasodilation or
vasoconstrictive responses between healthy control subjects and patients with T2DM
(Andrews, 1999). It thus seems likely that this increased dermal response to
glucocorticoid which we have seen in patients with T2DM will be explained by
either an increased expression or increased affinity of the GR.
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Aims
The aims of this study were to investigate the distribution and concentration ofGR in
human skin in patients with T2DM and healthy controls. I also aimed to correlate
this with the blanching response previously seen (chapter 2).
Subjects and Methods
Participants
All participants who took part in the study described in chapter 2, were asked at visit
3 of the study whether they would be willing to undergo a gluteal skin biopsy. These
patients were controlled by diet alone, without oral hypoglycaemic agents or insulin
and were free of clinical or biochemical evidence of retinopathy, nephropathy and
neuropathy at their last annual review. Those who consented had a biopsy of skin and
subcutaneous fat (2cm x 1cm x 1cm) taken from the gluteal region under local
anaesthesia (2% lignocaine hydrochloride; Astra, Herts, U.K.). Twenty one subjects
(10 DM and 11 controls) consented to the skin biopsy. The biopsy was immediately
divided into 3 with 1/3 being frozen immediately at -70 °C for measurement of in
vitro adipose 11(3-HSD 1 activity (see chapter 2), 1/3 being embedded in paraffin for
measurement of glucocorticoid receptor mRNA by in situ hybridisation (see below)
and 1/3 immersed immediately in cold (4 °C) physiological salt solution (PSS) for
later dissection of resistance arteries which were studied by wire myography
(performed by Dr P.W.F. Hadoke see (Mcintyre et al., 2001)).
Riboprobes
Human cDNA clone for GR (Seckl et al., 1991) was linearised using the appropriate
restriction enzyme. Antisense and sense complementary RNA probes were
synthesised from the resultant templates using the appropriate RNA polymerases.
Probes were purified on NICK columns (Pharmacia Biotech, Uppsala, Sweden) and
checked for size and purity on denaturing polyacrylamide gels.
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In Situ Hybridization
The biopsy was embedded in paraffin and horizontal sections (5 pm thick) were cut
using a microtome (Leitz GmBH Wetzlar, Germany) and sections placed on 3-
aminopropyltriethoxysilane (APES 2%; Sigma, St Louis, MO)-coated slides.
Sections were deparaffinised by immersion in Histoclear (2 X 10 mis; Fisher
Scientific, Loughborough, Leicestershire, UK).
Histoclear was removed by washing in ethanol (100% x 2 minutes; Merck, Poole,
UK). Sections were rehydrated by immersion in graded alcohols (100%, 100%, 95%,
85%, 70%, 50%, 30% ethanol). Ethanol was removed by washing in sodium
chloride (0.9%). This was followed by immersion in Triton-X (0.3%; Koch Light,
Suffolk, UK) in lx phosphate-buffered saline (lx PBS for 15 minutes) after which
sections were washed twice in lx PBS (5 minutes). Tissue sections were then
digested in trizma-HCl (100 mM, pH 8; Sigma), EDTA (50 mM; Sigma) containing
proteinase K (30 minutes, 37°C; Sigma), then washed in glycine(0.1%; Merck) in lx
PBS. Sections were then postfixed in paraformaldehyde (4%; Fisher Scientific),
washed in lx PBS (2x5 minutes) followed by acetylation in acetic anhydride
(0.25%; Sigma) in triethanolamine (0.1 M, pH 8; Sigma), washed in lx PBS (1x3
minutes), dehydrated in graded alcohols, and air-dried. Sections were incubated with
prehybridization buffer made up of diethylpyrocarbonate water, sodium chloride (5
M), trizma base (1 M), 50x Denhardt's (Sigma), salmon testes DNA (Sigma), EDTA
(250 mM; Sigma), and yeast tRNA (G1BCO-BRL Products, Paisley, UK) in
deionized formamide (50°C x 2 hours; Sigma). Hybridization was then carried out
by incubation with 35S-labeled riboprobe (1 x 106 cpm) in hybridization buffer
containing diethylpyrocarbonate water, sodium chloride (5 M), trizma base (1 M),
50x Denhardt's, salmon testes DNA, EDTA (250 mM), and yeast tRNA in deionized
formamide (50°C x 16 hours). After hybridization, sections were washed in SSC (15
minutes) and incubated with Rnase A (100 pg/ml, 37°Cfor 1 hour; Sigma). Sections
were then washed to increasing stringencies to a maximum ofO.lx SSC (60°C for 1
hour). After dehydration through graded alcohols, sections were placed against
hyperfilm Bmax (2 weeks at 4°C; Amersham) and autoradiographs developed. After
this, sections were dipped in photographic emulsion (NTB-2; Kodak, Rochester, NY)
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and exposed (4°C for 3 weeks) before being developed and counterstained with
hematoxylin and eosin (Sigma).
Measurement ofGR
Areas of specific mRNA expression of GR on tissue sections were identified by the
appearance of silver grains. Grain counting (SEE-Scan Image Analysis Systems UK)
was performed on antisense and corresponding sense sections. Background counts
(counts from sense sections) were subtracted from antisense counts and results
expressed as absolute grain counts above background. Human liver was used as
positive control sections.
Statistics
Data are expressed as means + SE or multiples of background. Differences between
patient groups were tested by unpaired Student's t tests.
Results
Baseline characteristics
Characteristics of the participants are shown in Table 3.1. The groups were well
matched for anthropometric, clinical and biochemical variables except that patients
with diabetes (DM) had significantly higher HbAic, and a trend towards higher
triglycerides than controls. The 10 patients with DM and 11 healthy controls were
representative of both groups studied in chapter 2 (see table 3.1).
Distribution ofGR
The results of the in situ hybridisation studies are shown in table 3.2 and figures 3.1,






































































































































































































DM Controls P value
Epidermis 28 ±2 26 ±2 0.40
Sweat Gland 29 ±4 35 ±3 0.55
Sweat duct 30 ±4 35 ± 3 0.56
Sebaceous gland 21 ±2 17 ± 2 0.15
Venules 100 ±20 91 ±20 0.59
Arterioles 100 ± 18 81 ± 12 0.32
Table 3.2. Comparison of GR mRNA distribution in the skin between DM
patients and healthy controls.
Data are mean ± SE for silver grain counts
Counts are per pM2 after subtraction of background counts with sense probes.
Figure 3.1. Positive controls.
Human in situ hybridization studies for GR in liver. Silver grains denote areas of
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Figure 3.2. Distribution of GR in human skin - 1.
Comparison ofHuman in situ hybridization studies for GR in skin between sense and
antisense slides. Silver grains denote areas ofmRNA expression. (A) Dermis, (B)
Sebaceous glands, (C) Sweat glands. Magnification X40
Sense Antisense
D
Figure 3.3. Distribution of GR in skin - 2.
Comparison of human in situ hybridization studies for GR in skin between sense and
antisense slides. Silver grains denote areas ofmRNA expression. (D) Sweat ducts,
(E) Venules, (F) Arterioles. Magnification X40
Control DM
A
Figure 3.4. Distribution of GR in human skin in DM and healthy controls- 1.
Comparison ofHuman in situ hybridization studies for GR in skin between DM and
healthy control slides. Silver grains denote areas ofmRNA expression. (A) Dennis,
(B) Sebaceous glands, (C) Sweat glands. Magnification X40
Control DM
D
Figure 3.5. Distribution of GR in human skin in DM and healthy controls - 2.
Comparison of human in situ hybridization studies for GR in skin between DM and
healthy control slides. Silver grains denote areas ofmRNA expression. (D) Sweat
ducts, (E) Venules, (F) Arterioles. Magnification X40
sweat ducts, sebaceous glands, venules and arterioles. Expression was highest in the
arterioles and venules.
Comparison ofGR mRNA counts between DM and Controls.
GR mRNA counts for each region in DM and control patients are shown in table 3.2
and figure 3.4 and 3.5. No differences in GR mRNA were seen between DM and
controls for any region.
Correlations with in vivo glucocorticoid sensitivity
There was no correlation between GR mRNA concentrations from any region and
intensity of skin blanching.
Discussion
This study investigated the distribution of the GR in human skin tissue and attempted
to determine whether alterations in expression of this receptor could explain the
difference in dermal response to glucocorticoid seen between patients with T2DM or
glucose intolerance and healthy controls. In this study we demonstrated expression
of GR in the epidermis, sweat glands, sweat ducts, sebaceous glands, venules and
arterioles of the skin. However no difference in distribution or mRNA levels of this
receptor were found between patients with hyperglycaemia and normal healthy
controls. Furthermore there was no correlation between GR concentrations from any
region and intensity of skin blanching. These finding suggest that the differences
which are seen in the dermal response to glucocorticoids between patients with
T2DM or glucose intolerance and healthy controls cannot be explained by alteration
in the intracellular concentration ofGRs.
Previous studies in rats have demonstrated that GRs are found in both the epidermis
and dermis of the skin (Karstilla et al., 1994). In the dermis they are found in hair
follicles, sweat glands sebaceous glands and vessels (Karstilla et al., 1994). In
humans, studies looking at the localisation of GR have tended to focus on the
epidermis, where GRs have been found in the highest concentration in the basal and
langerhans cells (Serres et al., 1996). This is the first study which has used in situ
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hybridization techniques to look at the expression of the GR in human skin. Previous
human studies, using monoclonal antibody techniques, have demonstrated the
presence of 11J3-HSD1 in human skin in a similar distribution as found in our study
(Teelucksingh et al., 1991). This indirectly validates our finding as 11(3-HSD1 tends
to be found in close proximity to the GR (Monder, 1991).
Although increased dermal sensitivity to glucocorticoids has been shown to predict
sensitivity to glucocorticoids in the bronchi, it does not always correlate with that
seen in other tissues (Brown et al., 1991) (Walker et al., 1996). In normal healthy
male volunteers no correlation has been found between dermal sensitivity to
glucocorticoids and sensitivity of blood leukocytes (Panarelli et al., 1998) (Ebrecht et
al., 2000). Furthermore individuals with hypertension who show increased dermal
sensitivity to glucocorticoids, suppress their plasma concentration of Cortisol
normally to a 0.25mg dose of dexamethasone, indicating that tissue sensitivity to
glucocorticoids must be tissue specific (Walker et al., 1996).
One possible explanation for this variation in tissue responsiveness to
glucocorticoids could be tissue specific alterations in GR expression. Rats exposed
to dexamethasone in utero who are born small and develop insulin resistance and
hypertension as adults, show increased glucocorticoid receptor expression in their
liver but decreased central glucocorticoid receptor expression (Benediktsson et al.,
1993) (Lindsay et al., 1996). Similarly, men with insulin resistance, who show
normal suppression of plasma Cortisol with dexamethasone, have increased
expression of the GR in their muscle (Reynolds et al., 2002).
At the start of this study we felt that the differences seen in the dermal response to
glucocorticoids between patients with hyperglycaemia and normal controls would be
explained by differences in the expression of the GR. Although we admit that in situ
hybridisation is arguably only semi-quantitative, the finding in this study that there is
no difference in the distribution or mRNA levels of this receptor between patients
with hyperglycaemia and normal healthy controls makes this highly unlikely.
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These findings do not exonerate GRs. Alterations in activity or affinity of the GR
could still play a role in the differences seen in the dermal response between patients
with hyperglycaemia and normal controls. It is now known that there are two
isoforms of the GR, GR alpha to which binding of glucocorticoids produces a normal
biological response and GR beta to which binding produces no response (Gagliardo
et ah, 2001) (Hamilos et al., 2001). The in situ hybridisation techniques used in this
study are unable to distinguish between these two isoforms, meaning that although
there is no difference in total GR expression between the groups there could be
differences in the relative ratio of the alpha and beta isoforms. Similarly
polymorphisms of the GR gene have been described that can be associated with
increased sensitivity to glucocorticoids (Huizenga et al., 1998) (Panarelli et al., 1998)
or glucocorticoid resistance in vivo (Weaver et al., 1992) (Brandon et al., 1989).
Thus differences in polymorphisms of the GR could explain the differences in the
dermal response to glucocorticoid seen between patients with hyperglycaemia and
normal controls. Further research is needed to confirm or refute these ideas.
Conclusions
In summary I have demonstrated that in human skin, GRs are expressed in the
epidermis, sweat glands, sweat ducts, sebaceous glands, venules and arterioles of the
skin. Flowever, differences which are seen in the dermal response to glucocorticoids
between patients with T2DM or glucose intolerance and healthy controls cannot be




The effect of the 11P-hydroxysteroid
dehydrogenase inhibitor carbenoxolone on insulin
sensitivity in men with type 2 diabetes.
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Introduction
As mentioned in the introduction, oral treatment for patients with type 2 diabetes
(T2DM) is far from ideal. There is little choice of tablets, with only 5 classes of oral
hypoglycaemic tablets available for use, and many of these having intolerable side-
effects, such as excessive flatulence (a-glucosidase inhibitors), abdominal pain
(biguanides) and weight gain (sulpnonlyureas and thiazolidinediones). Furthermore
these tablets become less effective over time, due to a gradual increase in insulin
resistance combined with a decrease in insulin secretion, resulting in many
individuals needing insulin to control their diabetes (UKPDS, 1998). This means
that new oral treatments for T2DM are desperately needed.
For many years it has been known that Cortisol antagonises the action of insulin, i.e.
induces a state of insulin resistance. In the liver it increases glucose production, in
the periphery it impairs insulin-dependent glucose uptake and in the brain it
stimulates appetite (Rizza et al., 1982) (Holmang & Bjorntorp, 1992) (Stubbs &
York, 1991). In addition to these effects on insulin sensitivity, Cortisol also inhibits
insulin secretion from the pancreatic (3-cells (Delaunay et al., 1997) (Ling et al.,
1998) (Lambillotte et al., 1997). From this it would seem that drugs designed to
lower plasma Cortisol concentrations would be ideal for treating patients with T2DM.
Unfortunately though, Cortisol also plays a key role in regulating growth, salt and
water retention, maintaining blood pressure and enabling the body to respond to
stressful events meaning that lowering plasma Cortisol concentrations could have
many serious side-effects. If a way could be found to lower tissue concentrations of
Cortisol in the liver, fat and muscle without altering plasma Cortisol levels this could
be a safe and effective drug for treating T2DM.
As has been discussed in previous chapters, the relative activities of 11P-HSD1 and 2
determine the concentration of Cortisol seen in tissues. 11J3-HSD2 is expressed
principally in the distal nephron, where it inactivates Cortisol to cortisone, lowering
tissue Cortisol concentrations and thereby protecting non-specific mineralocorticoid
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receptors from Cortisol (Edwards et al., 1988) (Funder et al., 1988). llp-HSDl is
found in the liver, adipose tissue and muscle where it tends to increase tissue Cortisol
concentrations by reactivating Cortisol from cortisone (Seckl & Walker, 2001).
Recent studies in mice have highlighted that the activity of 11 P-HSD 1 can change
drastically without unduly affecting plasma Cortisol concentrations. Furthermore,
these changes can have profound effects on the metabolic phenotype of the animals.
Animals with 11 P-HSD 1 knockout have normal or marginally increased plasma
glucocorticoid levels but cannot regenerate glucocorticoid within cells in liver and
adipose tissue. As a result, they are protected from insulin resistance,
hyperglycaemia (Kotelevtsev et al., 1997) and weight gain (Morton, N.M., et al.,
unpublished observations) induced by high fat feeding (Morton et al., 2001).
Similarly, down-regulation of lip-HSDl expression following administration of
oestradiol to male rats is associated with decreased hepatic gluconeogenesis
(Jamieson et al., 1998). Conversely, mice with transgenic over-expression of 11P-
FISD1 selectively in adipose tissue under the aP2 promoter have increased intra-
adipose glucocorticoid concentrations, despite no change in plasma levels (Masuzaki
et al., 2001). These animals develop central obesity, insulin resistance, and
hyperglycaemia. Mice with transgenic overexpression selectively in the liver under
the ApoE promoter also show insulin resistance and hyperlipidaemia (Paterson J,
Mullins JJ, Seckl JR et al., personal communication). These finding confirm that
pharmacological inhibition of 11P-HSD1 can lower intracellular Cortisol
concentrations in liver and adipose tissue, without altering circulating Cortisol
concentrations or responses to stress, and thus is an exciting potential therapy in
T2DM.
At present, only relatively non-selective inhibitors of lip-HSDl are available for
human use. The principal active constituent of confectionary liquorice,
glycyrrhetinic acid, and its hemisuccinate derivative carbenoxolone, are potent
inhibitors of both llp-HSDl and 11 P-HSD type 2 (Monder et al., 1989). Inhibition
of llp-HSD2 with liquorice derivatives results in cortisol-dependent
mineralocorticoid excess with hypertension and hypokalaemic alkalosis (Stewart et
69
al, 1987) (Stewart et al., 1990). However, in addition, carbenoxolone inhibits
regeneration of Cortisol from cortisone by 1 lp-HSDl in liver (Stewart et al., 1990)
(Andrew et al., 2002) suggesting that it might well improve insulin sensitivity. In
healthy men, carbenoxolone was found to improve insulin sensitivity, as measured
by an increase in glucose infusion rate during a euglycaemic hyperinsulinaemic
clamp (Walker et al., 1994). In this study there was no effect on peripheral glucose
uptake, measured by arteriovenous sampling across the forearm, so it was inferred
that carbenoxolone was working by lowering intrahepatic Cortisol concentrations
with a resulting improvement of insulin dependent suppression of hepatic glucose
production.
Aims
The aim of this study was to characterise the mechanism of action of carbenoxolone
on insulin sensitivity in healthy men, and quantify its effects for the first time in
patients with type 2 diabetes. The selection of patients most likely to respond to
11P-HSDI inhibition was an important consideration. In obese patients, there is
tissue-specific dysregulation of lip-HSDl resulting in increased regeneration of
Cortisol in adipose tissue (Rask et al., 2001) (Rask et al., 2003) (Paulmyer-Lacroix et
al,. 2002), but decreased activity in liver (Rask et al., 2001) (Stewart et al., 1999). In
contrast, in lean patients with type 2 diabetes we found only a minor decrease in
hepatic lip-HSDl activity and no change in the enzyme in adipose tissue (see
chapter 2) (Andrews et al., 2002). It is now established that carbenoxolone does not
inhibits 11P-HSD1 in adipose tissue, but does inhibit in liver (Livingstone & Walker,
2003). For these reasons, we recruited only lean patients with type 2 diabetes and




Six men with T2DM (as defined by WHO criteria) were recruited from the diabetes
clinics at the Western General Hospital, Edinburgh, UK and 6 normal healthy male
controls recruited by advertisement. All patients managed their diabetes by diet
alone and were free of clinical or biochemical evidence of retinopathy, nephropathy
and neuropathy at their last annual review.
The exclusion criteria included
□ Therapy for any other medical conditions - medication may have interfered
with measurement being made.
□ Major psychiatric disorder - depression is known to affect Cortisol activity
(Asfeldt, 1969) and thus may have influenced the effect of carbenoxolone.
□ Weight loss >5 kg in the previous 3 months - weight loss of this degree
tends to indicate poor glycaemic control and possible type 1 diabetes.
□ Blood pressure >160/90 mmHg - Carbenoxolone is known to increase blood
pressure by effecting llp-HSD 2 in the kidney (Stewart et al., 1987)
(Stewart et al., 1990).
□ Body mass index >32 kg/m2 - individuals with obesity have been shown to
have decreased activity of liver 11(3-HSD 1 (Rask et al., 2001) (Stewart et
al., 1999), the target in this study.
□ Glucocorticoid therapy by any route in the previous 3 months - this affects
Cortisol activity and thus may have influenced the effect of carbenoxolone.
□ Abnormal renal or hepatic function on biochemical screening - the major
site of action of carbenoxolone is the liver and kidney (Stewart et al., 1990)
Healthy control subjects were matched for, age, weight, height, body mass index and




Participants were initially contacted by phone and asked it they would like further
information about the trial. Those who did were sent written information. After a
cooling off period of 2 weeks, they were invited to participate in the trial and a first
appointment was arranged for those who were interested.
Randomisation
Participants took carbenoxolone (100 mg 8 hourly by mouth for 7 days) or placebo in
a double-bind randomised crossover trial with phases separated by at least 3 months
washout (see figure 4.1). Packets of tablets were made up by the pharmacy and
distributed in number order as participants entered the trial. The codes were kept by
an independent researcher and not broken until completion of the study.
Protocol (seefigure 4.2)
The participants met with the researcher on 7 occasions.
Visit 1 - Baseline measurements - duration 30 minutes
Once participants wishing to enter the trial had been formally consented the
researcher performed baseline measurements and blood tests. A brief medical
history and examination was made and measurements of sitting blood pressure (using
a T'akeda UA-751 sphygmomanometer), height and weight were taken. Blood was
obtained for full blood count, urea and electrolytes, HbAiC, liver function tests,
thyroid function tests, cholesterol and triglycerides.
At the end of this visit a timetable for subsequent visits was agreed and recorded on a
timetable sheet
Visit 2 -provision of tablets - duration 15 minutes
Participants attended at 09:00 h for measurement of weight. They were then issued
with their study medication and asked to take the tablets, either placebo or




7days 3 months 7days
Phase a Washout Phase b
Figure 4.1. Design of trial.
Participants took carbenoxolone (lOOmg every 8 hours, orally for 7 days) or placebo
in a double blind, randomised, cross-over trial with phases separated by a 3 month
washout period.
- 1 month First contact





Participants contacted by phone, if interested first
appointment arranged.
Visit 1 (30 minutes)
Formal consent, history and examination and baseline
measurements (blood pressure height and weight and blood
specimen)
1 week




Participants weighed and provided with tablets
Visit 3 (15 minutes)
Participants weighed, blood taken for U+Es and meal choice
for visit 4 made.
Participant asked to attendat 17:00 h the night of the 7th day ofeach
phase.
2 weeks Visit 4 (20 hours)
Standard meal at 17;30h, thereafter only oral intake was




3 month washout period
Visit 5 (15 minutes)
Participants weighed and provided with tablets
Visit 6(15 minutes)
Participants weighed, blood taken for U+Es and meal choice
for visit 7 made.
Participant asked to attend at 17:00 h the night of the 7' day ofeach
phase.
16 weeks Visit 7 (20 hours)
Standard meal at 17:30h, thereafter only oral intake was
water. 22:00 h commencement of euglycaemic clamp study.
Figure 4.2. Timetable for study.
Visit 3 ~ further measurements - duration 15 minutes
Four days later participants returned for measurement of weight, blood pressure and
plasma electrolytes, as carbenoxolone can elevate blood pressure, lead to sodium
retention and induce hypokalaemia. If the participant developed hypertension (blood
pressure >160/100), signs of heart failure (>5% gain in weight), or hypokalaemia
(potassium <3.2 mmol/1) they were withdrawn from the study
Visit 4 - measurement ofinsulin sensitivity - duration 20 hours
On day seven participants returned to the Clinical Research Facility for an overnight
stay with measurement of insulin sensitivity by a hyperinsulinaemic normoglycaemic
clamp the next morning (see protocol). At the end of this visit participants
underwent a washout period for 3 months and then repeated visits 2- 4 using
placebo/carbenoxolone (figure 4.1).
Compliance
Compliance with study medication was monitored by tablet counting and by
measuring plasma carbenoxolone levels in samples obtained at 07:00 h on the day of
the clamp study. No subjects had to with draw due to adverse effects.
Euglycaemic damp protocol (figure 4.3)
Participants were asked to attend the Clinical Research Facility at 17:30h for a
standardised meal. This is was to ensure that the amount of carbohydrate and fat
taken before the clamp was similar in all groups, as variation in levels of
carbohydrate and fat taken prior to a hyperglycaemic normoglycaemic clamp have
been shown to affect insulin sensitivity (Robertson et al., 2002). After this standard
meal their only oral intake was water.
Cannulae were placed in an antecubital vein for infusions and retrogradely in a
contralateral dorsal hand vein; the hand was kept in a hot box for arterialised blood
sampling. The clamp was divided into three phases;
Phase 1. From 22:00-07:30h, an overnight clamp was employed to ensure that
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Figure 4.3. Protocol for clamp study.
The clamp is divided into 3 phases: Phase 1 - from 22:00-07:30h, an overnight clamp
was employed to ensure that controls and DM patients started the next phase with
similar plasma glucose concentrations, Phase 2 - from 07:30-10:30h, a
hyperinsulinaemic normoglucagonaemic normoglycaemic clamp was performed and
phase 3 - from 10:30-12:30h a hyperinsulinaemic hyperglucagonaemic
normoglycaemic clamp was performed. Arrows indicate the timing of the blood
sampling.
plasma glucose concentrations. Blood glucose was measured at least every 15
minutes and intravenous insulin was administered at variable rate, if required,
to maintain glucose at 5.0mM. From 04:00h, 13C6-glucose was infused (at 4
mg /kg/h after priming with 4 mg/kg). In the last half hour of this phase
measurements of basal parameters were made.
Phase 2. From 07:30-10:30h, a hyperinsulinaemic normoglucagonaemic
normoglycaemic clamp was performed with infusions of insulin
(0.4mU/kg/min), somatostatin (0.25mg/h), glucagon (1.5r|g/kg/min), growth
hormone (3r|g/kg/min) and 20% glucose. The 20% glucose infusion rate was
varied to maintain arterialised blood glucose at 5.0mM.
Phase 3. From 10:30-12:30h, a hyperinsulinaemic hyperglucagonaemic
normoglycaemic clamp was performed by increasing the glucagon infusion rate
from 1.5r]g/kg/min to 6.0r|g/kg/min while maintaining other infusions.
In addition to frequent samples for bedside blood glucose monitoring, blood samples
were obtained as indicated in Figure 4.3, which were immediately centrifuged and
the plasma frozen and stored at -SOX until analysis.
Laboratory analyses
Enzyme immunoassays (from Eurogenetics Tasah corporations UK Ltd) were used
to measure plasma insulin, growth hormone, and C-peptide. Electrolytes were
measured on a Vitras 950 (Ortho clinical diagnostics) and glucose on a Cabas Mira
Plus (Roche). Triglycerides, total cholesterol and HDL cholesterol were measured
using ELISA kits (TG, CHOL and HDL C-plus, respectively)(Roche Diagnostics,
Mannheim, Germany). HbAic was measured by ion exchange high performance
liquid chromatography (Variant 11, Biorad). Radioimmunoassays were used to
measure Cortisol (McConway & Chapman, 1986) and glucagon (Orskov et al., 1968).
Free fatty acids were measured by a colorimetric technique (Wako, Neuss,
Germany). Carbenoxolone was measured by high pressure liquid chromatography
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with ultraviolet detection (at 254nm) using 18a-glycyrrhetinic acid as internal
standard.
Enrichment of glucose isotopomers was analysed as its acetylated di-0-
isopropylidene derivative (Hachey et al., 2001) using a gas-chromatograph
quadrupole mass spectrometer (Voyager, Thermoquest, Manchester, UK). Electron
impact ionisation was used with selective monitoring of masses 287-293.
Enrichment of lactate isotopomers was analysed as its propyl-
amideheptafluorobutyric acid using electron impact ionisation with selective
monitoring of masses 327-330 (Tserng et al., 1984). Measured isotopomer
distributions were corrected for natural 13C enrichment at all masses as described
previously (Fernandez et al., 1996), using software provided by Dr. Henri
Brunengraber (Western Reserve University, Cleveland, OH).
I carried out the measurements for Cortisol. Measurements of insulin, C-peptide,
growth hormone glucose, urea and electrolytes, HbAic, triglycerides, total
cholesterol and HDL cholesterol were carried out by the local biochemistry
laboratory under the supervision of Mrs Susan Walker. Carbenoxolone
measurements were performed by Jill Campbell. Glucagon and free fatty acids were
carried out in the biochemistry laboratory at the Newcastle Royal Infirmary under the
supervision of Dr Mark Walker. Mrs Wendy Barron and Dr Olav Rooyackers
analysed the glucoses and lactates.
Calculation ofglucose kinetic parameters
Rates of glucose appearance (Ra) and peripheral glucose disposal (Rd) were
calculated from steady state enrichment of the plasma glucose pool with |3C6-
glucose, using mean data obtained in the basal state (07:00-07:30h), during
hyperinsulinaemia (10:00-10:30h) and with the addition of hyperglucagonaemia
(12:00-12:30h). All enrichments during these periods were confirmed as steady state
by regression coefficients for seven measurements against time not significantly
different from zero. Glucose and lactate enrichments achieved in plateau were
similar to those reported by Tayek and Katz (Tayek & Katz, 1996). The glucose
production rate was calculated by subtracting the glucose infusion rate from Ra.
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Gluconeogenesis rates were calculated at the same intervals from the enrichment of
the lactate pool with 13C3/13C6-lactate, according to the steady state formulas
described by Tayek and Katz (Tayek & Katz, 1996). Glycogenolysis was calculated
as (glucose production rate) - (gluconeogenesis rate).
Statistics
Data are expressed as means + SE. Effects of carbenoxolone within groups were
examined by paired Student's t tests. Differences between patient groups were tested
by unpaired Student's t tests.
Results
Baseline characteristics
DM and control men were well-matched for age (59±3 vs 58± 3 y, DM vs controls,
p=0.94), body mass index (29.2±1.3 vs 29.1±0.9, p=0.94) and waist/hip
circumference ratio (0.95±0.01 vs 0.92±0.03, p=0.43). Glycaemic control was
excellent in all DM patients, so that HbAic was only marginally higher than in
controls (6.8±0.4 vs 6.0+0.1%, p=0.06). HDL cholesterol was lower in DM patients
(Table 4.1).
Effects ofcarhenoxolone on bloodpressure, plasma electrolytes and lipids
Tablet count and plasma carbenoxolone levels confirmed good compliance with
study medication (Table 4.1). Carbenoxolone levels tended to be higher in DM than
controls (p=0.09). Carbenoxolone raised blood pressure and lowed plasma
potassium in both groups as expected, although the effect on plasma potassium was
only statistically significant in the DM patients. In contrast, in the control group
carbenoxolone decreased fasting plasma cholesterol and tended to increase HDL
cholesterol; these effects were not observed in DM patients.
Effects ofcarbenoxolone on glucose kinetic parameters
Technical success ofclamps
The 'technical success' of the clamps is shown in Figure 4.4. Plasma glucose
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Figure 4.4. Measurement during clamp studies
Data are mean + SEM. For clarity only limited time points are shown for each
measurement. O and • Healthy controls; □ and ■ patients with diabetes, O and □,
after placebo; • and ■, after carbenoxolone. *, P<0.05 vs. all the other groups (by
paired t test vs. controls and by paired t test vs. DM group during carbenoxolone
treatment).
both groups with and without carbenoxolone (Figure 4.4b). To achieve this, insulin
was infused at low doses overnight in 5 of the DM patients and 3 of the control
subjects (controls after placebo 0.3 ± 0.1 units/h, controls after carbenoxolone
0.4±0.2 units/h, DM after placebo 1.0 1 0.6 units/h, DM after carbenoxolone 1.310.3
units/h). The resulting plasma insulin levels at 07:00-07:30 h tended to be higher in
DM patients, irrespective of carbenoxolone therapy (Figure 4.4c). Thereafter, the
anticipated degree of hyperinsulinaemia was achieved by infusion of 0.4 mU/kg/min
insulin, but resulting insulin concentrations were higher in DM subjects after placebo
than in other groups. The incremental rise in insulin concentrations was similar in
each group. C-peptide was similar at baseline and suppressed in all subjects during
hyperinsulinaemia (Figure 4.4d). Growth hormone was similar at baseline and
'clamped' successfully in all participants, except one DM patient after carbenoxolone
whose growth hormone rose to >15 mU/1 from 12:00-12:30 h (Figure 4.4g). Plasma
glucagon levels were not different at baseline, and were 'clamped' as intended to
physiological levels by infusion of 1.5 ng/kg/min and high levels by infusion of 6.0
ng/kg/min (Figure 4.4f). Plasma Cortisol followed the normal diurnal rhythm in all
groups (Figure 4.4h).
Effect on insulin sensitivity
Glucose was infused at variable rate during hyperinsulinaemia. The rate of glucose
infusion plateaued to similar rates in all groups within one hour (Figure 4.4a). There
was a non-significant trend for higher absolute infusion rates in healthy controls after
carbenoxolone. Free fatty acid levels were not different at baseline and were
suppressed similarly during hyperinsulinaemia (Figure 4.4e). Total glucose disposal
(Rd)(Figure 4.5a) was stimulated by insulin and rose further with the addition of
hyperglucagonaemia, especially in control subjects, but was unaffected by
carbenoxolone in either group.
Effect on glucose production, glucoenogenesis andglycogenolysis
Glucose production rates were not different at baseline, suppressed during
hyperinsulinaemia, and stimulated during hyperglucagonaemia (Figure 4.5b). These
changes in glucose production during the clamp were associated with the expected
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Figure 4.5. Kinetic parameters derived from [ Ce] glucose tracer
measurements.
Data are mean + SEM. □, Basal measurements from 07:00-07:30h; ■,
measurements during the hyperinsulinemia from 10:00-10:30h, □, measurements
during hyperinsulinemia and hyperglucagonemia from 12:00-12:30h. *, P<0.05, **,
P<0.01 (between the groups indicated by paired t test).
changes in gluconeogenesis (Figure 4.5c) and glycogenolysis (Figure 4.5d), both of
which were suppressed by hyperinsulinaemia and stimulated by
hyperglucagonaemia. Carbenoxolone prevented the increase in glucose production
rate during hyperglucagonaemia in DM subjects only. This was attributable to
reduced glycogenolysis with no significant difference in gluconeogenesis.
Effect ofdifferent carbenoxolone concentrations
The influences of inter-individual variations in plasma carbenoxolone concentrations
was investigated for each of the variables that were significantly different between
carbenoxolone and placebo phases in either group. In Pearsons simple correlations,
plasma levels of carbenoxolone were not significantly associated with the difference
between measurements during carbenoxolone and placebo phases. Multiple
regression was employed to explore whether differences in the effects of
carbenoxolone between DM and controls could be accounted for by differences in
plasma carbenoxolone levels. Explanatory variables were plasma carbenoxolone
concentrations and diagnosis (DM or control, coded as 0 and 1). These models did
not show any independent effect of carbenoxolone concentrations.
Discussion
Previous research in mice, rats and healthy humans suggests that inhibition of lip-
HSD1 lowers intrahepatic glucocorticoid concentrations and thereby reduces hepatic
glucose production and enhances lipid catabolism (Seckl & Walker, 2001). In
addition, more recent evidence suggests that inhibition of 11(3-HSD1 in adipose
tissue will increase peripheral glucose uptake and suppress lipolysis (Masuzaki et al.,
2001). This report extends previous studies using the non-selective lip-HSD
inhibitor, carbenoxolone (Monder et al., 1989) (Stewart et al., 1990) (Walker et al.,
1994). We examined in detail its site of action on glucose metabolism in healthy
men, and tested its effects in patients with T2DM, a patient group which might
benefit from therapeutic use of selective lip-HSDl inhibitors in future. We
employed a detailed protocol to control for variables which are sometimes neglected
during euglycaemic clamp studies, including overnight preparation of subjects to
avoid effects of baseline hyperglycaemia (Neilsen et al., 1998) (Vaag et al., 1995),
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successful 'clamping' of growth hormone and glucagon levels, and stable isotope
tracer measurement of gluconeogenesis. We have shown that one week of
carbenoxolone administration decreased glucagon-stimulated glucose production and
glycogenolysis in patients with T2DM but not healthy subjects, and decreased total
cholesterol in healthy controls but not patients with T2DM. Carbenoxolone had no
effects on gluconeogenesis, peripheral glucose uptake or insulin-mediated
suppression of plasma free fatty acids in either the healthy control subjects or the
patients with T2DM. These observations reinforce the potential value of 1 lp-HSDl
inhibitors in enhancing hepatic insulin sensitivity and lipid catabolism.
An important consideration in designing this study to test the utility of lip-HSDl
inhibition in metabolic disease was raised by observations that there are tissue-
specific alterations in enzyme activity in obesity. Thus, lip-HSDl is increased in
adipose tissue but decreased in liver in obesity (Paulmyer-Lacroix et al., 2002) (Rask
et al., 2001) (Rask et al., 2003) (Stewart et al., 1999) (Livingstone et al., 1999). In
contrast, lean patients with type 2 diabetes do not have marked dysregulation of
either adipose or hepatic 1 lp-HSDl (Kerstens et al., 2000) (Andrews et al., 2002).
In order to avoid the potential confounding effects of obesity, and to exclude any
unknown effects of oral hypoglycaemic or antihypertensive agents, we selected non-
obese normotensive patients with T2DM controlled by dietary therapy alone. The
result was that patients in this study were not typical of T2DM. Indeed, they had
near-normal blood glucose and HbAic levels, a small requirement for overnight
insulin infusion to obtain fasting euglycaemia, and only minor differences in plasma
lipids (Table 4.1). Following overnight euglycaemia with insulin infusion as
required, glucose production, free fatty acids, and glucagon levels were not elevated
in these patients with T2DM, and glucose disposal was not measurably impaired.
Nonetheless, effects of carbenoxolone differed between healthy controls and patients
with T2DM; an effect on cholesterol was only evident in healthy controls, and
measurable effects on glucose production were only evident in patients with T2DM.
In a previous study, it has been shown that the same regime of carbenoxolone
administration to healthy men resulted in enhanced insulin sensitivity, as measured
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by increased glucose infusion rate during a hyperglycaemic clamp (Walker et al.,
1994). A key difference, however, is that the previous study was performed with a
higher insulin infusion rate, achieved higher insulin concentrations (-70 mU/1
compared with -30 mU/1 here), and was designed to examine effects on insulin-
stimulated glucose uptake rather than glucose production (Rizza et al., 1981). Also,
growth hormone and glucagon levels were not clamped in the previous study and the
participants were younger. In the current study, there was a trend for a similar
magnitude of increase in glucose infusion rate in healthy controls (means differed by
-7% previously, and by -17% here; see Figure 4.4a), but this did not reach statistical
significance. Glucose production was marginally, but not significantly, lower in
healthy men after carbenoxolone in the current study. This contrasts with the
statistically significant effects of carbenoxolone on glucose kinetics in patients with
T2DM.
For unknown reasons, plasma carbenoxolone levels tended to be higher in the
patients with T2DM than in controls (see table 4.1), so that the effects of
carbenoxolone could have been under estimated in control subjects. Single
measurements of plasma carbenoxolone concentrations were included in this study
principally as a qualitative assessment of compliance. A more detailed
pharmacokinetic study would be required to confirm that this difference did not
occur by chance. Importantly, however, in multiple regression analysis the
variations in carbenoxolone concentrations between individuals did not account for
the different effects of carbenoxolone in patients with T2DM and healthy controls.
Insulin concentrations during the clamp studies were also higher in patients with
T2DM during placebo therapy than in all other groups (see figure 4.4c), which may
lead to underestimation of the effects of carbenoxolone in patients with T2DM.
Against this background, it is unclear whether quantitative or qualitative differences
explain the discrepancies between effects of carbenoxolone in health and diabetes,
although, we suspect the former.
This is the first report of the effects of carbenoxolone, or any 11J3-HSD inhibitor, in
patients with T2DM. It shows that carbenoxolone affects glucose production, as
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inferred indirectly from a previous report {Walker et al., 1994}, but the mechanism
of the effect was not expected. In 11 (3-HSD1 knockout mice a key feature is
impaired up-regulation of gluconeogenic enzymes, such as PEPCK, on fasting
(Kotelevtsev et al., 1997). Glucocorticoids are known to oppose the effect of insulin
in regulating expression of gluconeogenic enzymes (Andrews & Walker, 1999).
However, carbenoxolone did not alter gluconeogenesis after overnight fast, during
hyperinsulinaemia, or during hyperglucagonaemia. One consideration in this
paradox is that the contribution of the kidney to gluconeogenesis in man remains
unquantified. By inhibiting inactivation of Cortisol by 11(3-HSD2 in kidney (Stewart
et al., 1990), carbenoxolone increases intrarenal Cortisol concentrations, which might
enhance renal gluconeogenesis in compensation. To resolve this will require studies
either with selective 11P-HSD1 inhibitors or with cannulation of the hepatic and/or
renal veins. The kidney is not, however, a major site of glycogen storage.
Glucocorticoids have complex effects on glycogenic and glycogenolytic enzymes,
which predict increased turnover and amplification of the effect of other signals
(Andrews & Walker, 1999) (Rooney et al., 1994). Thus, the observation that
carbenoxolone attenuated net glucagon-induced glycogenolysis is consistent with
lowering of intrahepatic Cortisol concentrations.
A more recently recognised consequence of changes in intra-hepatic glucocorticoid
concentrations is the effect on lipid metabolism (Morton et al., 2001). The effects of
carbenoxolone in the liver are the most likely explanation for the decrease in total
cholesterol observed in healthy controls. In lip-HSDl knockout mice, hepatic lipid
catabolism is markedly increased while synthesis is relatively normal, resulting in
elevated HDL-cholesterol and reduced total cholesterol (Morton et al., 2001).
However, the importance of enhanced lipid catabolism in man, and comparison of
effects in healthy controls and patients with T2DM, needs to be re-assessed with a
longer duration of carbenoxolone administration, since plasma lipids take several
weeks to re-equilibrate following the introduction of conventional lipid-lowering
therapy.
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Liquorice derivatives, such as carbenoxolone and glycyrrhetinic acid, are potent
inhibitors of both isozymes of 1 lp-HSD in vitro and in cell culture (Monder et al.,
1989) (Rajan et al., 1996) (Yang, et al., 1997). However, in vivo they have
inconsistent effects, probably because of pharmacokinetic differences in access to
tissues. Thus, carbenoxolone, but not glycyrrhetinic acid, inhibits hepatic 11P-HSD1
in vivo in man, as judged by impaired generation of Cortisol after an oral dose of
cortisone but has no effect on adipose 11P-HSD1 activity (TC Sandeep et al.,
unpublished observations) (Livingstone & Walker, 2003). In animals, in vivo
inhibition of 1 ip-HSDs with carbenoxolone in other tissues is also inconsistent, for
example varying between different regions of CNS (Ajilore & Sapolsky, 1999)
(Jellinck et al., 1993). Indeed, in Zucker obese rats, in vivo administration of
carbenoxolone inhibits lip-HSDl in liver but not in adipose tissue (Livingstone &
Walker, 2003). In this study, relatively modest hyperinsulinaemia was employed in
order to approximate the ED50 for suppression of hepatic glucose production (Rizza
et al., 1981). For these reasons, the positive effects of carbenoxolone on hepatic
carbohydrate and lipid metabolism, but lack of effect on peripheral glucose uptake in
both the current and previous study (Walker et al., 1994), does not allow the
conclusion that inhibition of lip-HSDl in extrahepatic tissues, notably adipose
tissue, would not be beneficial. However, the acute effects of carbenoxolone on
hepatic insulin sensitivity were of modest magnitude. For more substantial effects on
glucose tolerance and glycaemic control in patients with T2DM, it appears likely that
11 (3-HSD1 inhibitors will be required to inhibit glucocorticoid regeneration in
adipose tissue as well as the liver. Reducing Cortisol action in adipose tissue may
then provide an increase in peripheral glucose disposal in addition to the reduced
glucose production observed with carbenoxolone.
Conclusion
In summary, these studies with a non-selective lip-HSD inhibitor illustrate the
potential value of inhibition of 1 lp-HSD 1 in lean hyperglycaemic patients. It may







Type 2 diabetes (T2DM) is the most common clinical form of diabetes, accounting
for 90% of all cases. In the UK about 1.4 million people are known to suffer with
this disease, however, this figure is predicted to triple over the next 10 years Unlike
Type 1 diabetes, the pathogenesis of T2DM remains only partly understood. Both
insulin resistance and impaired insulin secretion are required for the development of
disease but what order these abnormalities occur in and what causes them remains
unknown.
Recent research has suggested that it is unlikely that one primary cause for T2DM
will be found and that both genetic and environmental factors will contribute to the
development of this disease. Furthermore the finding that impaired glucose
intolerance, insulin resistance, essential hypertension, obesity and coronary heart
disease occur together more commonly than would be expected by chance, suggests
that many of the factors found to play a part in the pathogenesis of T2DM will also
be important in the development of these diseases (Reavan, 1988).
For many years it has been known that Cortisol antagonises the action of insulin, i.e.
induces a state of insulin resistance. In the liver it increases glucose production, in
the periphery it impairs insulin-dependent glucose uptake and in the brain it
stimulates appetite (Rizza et a!., 1982) (Holmang & Bjorntorp, 1992) (Stubbs &
York, 1991). In addition to these effects on insulin sensitivity, Cortisol also inhibits
insulin secretion from the pancreatic P-cells (Delaunay et al., 1997) (Ling et al.,
1998). Furthermore it is common knowledge that conditions characterised by
excessive Cortisol concentrations, such as Cushing's disease, are associated with
hypertension, obesity, coronary artery disease and glucose intolerance. For this
reason Cortisol was one of the first hormones to be implicated in the pathogenesis of
T2DM and its associated diseases.
However, early studies found that crude measures of Cortisol secretion were normal
in these individuals and so little advanced further in this field. In the late 1980s two
enzymes 1 lbeta-hydroxysteroid dehydrogenase type 1 (lip-HSD 1) and llbeta-
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hydroxysteroid dehydrogenase type 2 (lip-HSD 2) were cloned (Agarwal et al.,
1989) (Agarwal et al., 1994). These control the conversion of Cortisol to cortisone
and vice versa in the tissues meaning that tissues may be exposed to a relative excess
ofCortisol without any increase in Cortisol secretion or plasma Cortisol concentrations
(Seckl & Walker, 2001).
Cortisol activity and the metabolic syndrome
Individuals with hypertension were one of the first groups to be studied. They were
noted to exhibit normal Cortisol secretion, but have reduced inactivation of Cortisol
by 3 ip-HSD 2 and enhanced tissue sensitivity to Cortisol (Soro et al., 1995) (Walker
et al., 1992) (Walker et al., 1996). Abnormalities were also found in obese
individuals with an increase in 24 hour Cortisol secretion in spite of enhanced
feedback sensitivity. Again, plasma Cortisol concentrations were not elevated,
perhaps because of an increase in peripheral clearance of Cortisol (Strain et al ., 1982)
(Ljung et al., 1996) (Andrew et al., 1998) (Rask et al., 2001). These findings led
people to suggest that abnormalities in Cortisol could be one of the common factors
involved in the pathogenesis of diabetes and its associated conditions (Bjorntorp et
al., 1999).
Cortisol activity in patients with type 2 diabetes
Against this background, I decided to investigate whether abnormalities in Cortisol
secretion, metabolism or sensitivity exist in patients with type 2 diabetes or glucose
intolerance. Previous studies in this area had been conducted in heterogeneous
groups with type 1 and type 2 diabetes (Mortimore et al., 1956) (Lentle & Thomas,
1964) (Huther & Scholz, 1970) (Tsigos et al., 1993) (Hudson et al., 1984) (Kaye et
al., 1992), or had inadequately controlled for confounding factors of sex, co-existing
obesity, hypertension, poor glycaemic control and diabetic complications making
interpretation difficult (Couch, 1992) (Dullaart et al., 1995) (Roy et al., 1993)
(Stewart et al., 1990) (Lentle & Thomas, 1964) (Walker et al., 1998).
In this thesis I have examined Cortisol secretion, metabolism and sensitivity in non-
obese, normotensive, diet-controlled male patients with type 2 diabetes mellitus or
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impaired glucose tolerance. These individuals did exhibit abnormalities in Cortisol
activity. Specifically they showed:
1) Normal Cortisol secretion and circulating levels in the face of enhanced
negative feedback sensitivity
2) Enhanced in vivo peripheral tissue sensitivity to glucocorticoids
3) Impaired hepatic lip-HSD 1 activity but normal adipose lip-HSD 1
activity, suggesting tissue-specific alterations in llfi-HSD 1 activity.
4) Increased relative excretion of A-ring reduced metabolites of Cortisol.
These findings suggest that isolated hyperglycaemia is associated with some, but not
all, of the changes in Cortisol metabolism and action which have been observed in
subjects with hypertension and obesity, and adds further weight to the hypothesis that
abnormalities in Cortisol action may be important in the pathogenesis of T2DM and
its associated conditions.
Cortisol secretion
The finding of normal 24h secretion in the face of this enhanced feedback sensitivity
suggests that another factor is driving Cortisol secretion. This could be increased
metabolism by 5a-reductase, enhanced by some yet to be defined mechanism which
is associated with relative insulin deficiency and/or hyperglycaemia or by
inappropriate central drive to the HPA axis which is consistent with the observation
that habituation of Cortisol in response to repeated sampling is impaired in
hyperglycaemic men (Tsigos et al., 1993) (Reynolds et ah, 2001). Further research is
required in this area to try and determine which of these it is.
11/3-HSDs activity
In obese humans lip-HSD 1 is decreased in liver (Stewart et ah, 1999) but increased
in adipose tissue (Rask et ah, 2002) (Paulmyer-Lacroix et ah, 2002) (Rask et ah,
2001). Here, in non-obese hyperglycaemic men, hepatic first pass conversion of
cortisone to Cortisol was impaired, albeit to a lesser extent than in obese subjects
(Rask et ah, 2001) (Stewart et ah, 1999). However, lip-HSD 1 activity in gluteal
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adipose tissue was normal. These data suggest that hepatic dysregulation is related
to insulin action while adipose dysregulation is determined by some other factor
associated with obesity, or indeed may be a primary mechanism in obesity (Bujalska
et al., 1997) (Masuzaki et al., 2001). There are two possible explanations for these
tissue specific alterations in (3-HSD 1 activity; 1) that local growth factors such as
TNFa, interleukinip and leptin regulate 11(3-HSD 1 expression as has been shown in
vitro (Tomlinson et ah, 2001); or 2) that there is a different type (polymorphism) of
11J3-HSD 1 in each tissue.
Vascular sensitivity
The finding that dermal vascular sensitivity to beclomethasone dipropionate is
increased in patients with type 2 diabetes mellitus or impaired glucose tolerance
suggests that glucocorticoid receptors are more readily activated in dermal vessels.
This could be explained by increased access of hormones to the intracellular
glucocorticoid receptors (GR), increased GR number, affinity or signalling, or altered
sensitivity of the dermal blood vessels to the products of the glucocorticoid target
genes.
Previous studies have demonstrated that there is little difference in the in vitro
vasodilation or vasocontrictive responses between healthy control subjects and
patients with T2DM (Andrews et ah, 1999). Furthermore, in this thesis, no
differences in distribution or concentration of GR mRNA between patients with
hyperglycaemia and normal healthy controls was found. This suggests that either
alteration in the relative activity of the 1 l(3-HSDs or differences in polymorphisms of
the GR will explain the increase in the dermal vascular sensitivity to beclomethasone
dipropionate which is seen in patients with type 2 diabetes mellitus or impaired
glucose tolerance.
Although data presented in this thesis add to the body of evidence that suggests that
abnormalities in Cortisol activity are important in the pathogenesis of T2DM and its
related diseases, it by no means proves this. One could argue that these
abnormalities are present as a result of the diseases rather than the cause of them. In
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order for pathogenesis to be proven, these abnormalities must be shown to occur
before the disease develops and must also be shown to be altered by those factors
which are known to protect against disease states, in the case of T2DM this being
diet and exercise. Thus longitudinal and interventional studies will be needed.
Novel treatments for type 2 diabetes
As I mentioned earlier, much of the action of Cortisol depends on it opposing the
action of insulin, namely inducing a state of insulin resistance. From this it would
seem that drugs designed to lower plasma Cortisol concentrations would be ideal for
treating patients with T2DM. Unfortunately though, Cortisol also plays a key role in
regulating growth, salt and water retention, maintaining blood pressure and enabling
the body to respond to stressful events meaning that lowering plasma Cortisol
concentrations could have many serious side-effects. If a way could be found to
lower tissue concentrations of Cortisol in the liver, fat and muscle without altering
plasma Cortisol levels this could be a safe and effective drug for treating T2DM.
Confirmation in animal studies that alteration in lip-HSDl expression did not
unduly affect plasma Cortisol concentrations {Kotelevtsev, Holmes, et al. 1997 1164
/id}{Masuzaki, Paterson, et al. 2001 1573 /id} suggested that pharmacological
inhibition of 11P-HSD1 might be an exciting potential therapy in T2DM. At present,
only relatively non-selective inhibitors of lip-HSDl are available for human use.
The principal active constituent of confectionary liquorice, glycyrrhetinic acid, and
its hemisuccinate derivative carbenoxolone, are potent inhibitors of both lip-HSDl
and lip-HSD type 2 {Monder. Stewart, et al. 1989 165 /id}. Inhibition of 11P-
HSD2 with liquorice derivatives results in cortisol-dependent mineralocorticoid
excess with hypertension and hypokalaemic alkalosis {Stewart, Valentino, et al.
1987 27 /id}{Stewart, Wallace, et al. 1990 12 /id}. However, in addition,
carbenoxolone inhibits regeneration of Cortisol from cortisone by llp-HSDl in liver
{Stewart, Wallace, et al. 1990 12 /id}{Andrew, Smith, et al. 2002 1580 /id}
suggesting that it might well improve insulin sensitivity.
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A previous study in healthy men had found that carbenoxolone improved insulin
sensitivity, as measured by an increase in glucose infusion rate during a euglycaemic
hyperinsulinaemic clamp {Walker, Connacher, et al. 1994 760 /id}. In this study
there was no effect on peripheral glucose uptake, measured by arteriovenous
sampling across the forearm, so it was inferred that carbenoxolone was working by
lowering intrahepatic Cortisol concentrations with a resulting improvement of insulin
dependent suppression of hepatic glucose production.
Effect ofcarbenoxolone in patients with type 2 diabetes
In the second study described in this thesis I characterised the mechanism of action
of carbenoxolone on insulin sensitivity in healthy men, and quantified its effects for
the first time in patients with T2DM. In doing so I found that carbenoxolone
decreased glucagon-stimulated glucose production and glycogenolysis in patients
with T2DM but not healthy subjects, and decreased total cholesterol in healthy but
not patients with T2DM. Carbenoxolone also had no effects on gluconeogenesis or
peripheral glucose uptake in either the healthy control subjects or the patients with
T2DM. These observations reinforce the potential value of 11P-HSD1 inhibitors in
enhancing hepatic insulin sensitivity and lipid catabolism.
The fact that carbenoxolone did not alter gluconeogenesis came as somewhat of a
surprise, especially as animal studies has suggested that glucocorticoids are potent
regulators of the expression of gluconeogenic enzymes (Andrews & Walker, 1999)
and that lip-HSDl knockout animals show reduced PEPCK and other
gluconeogenic enzymes (Kotelvtsev et al., 1997). One consideration in this paradox
is that the contribution of the kidney to gluconeogenesis in man remains
unquantified. By inhibiting inactivation of Cortisol by 11(3-HSD2 in kidney (Stewart
et al., 1990), carbenoxolone increases intrarenal Cortisol concentrations, which might
enhance renal gluconeogenesis in compensation. To resolve this will require studies
either with selective 1 lp-HSDl inhibitors or with cannulation of hepatic and/or renal
vein.
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The findings that carbenoxolone attenuated net glucagon-induced glycogenolysis in
patients with T2DM and that it decreased total cholesterol in healthy controls is
consistent with lowering of intrahepatic Cortisol concentrations. In lip-HSDl
knockout mice, animals that have low hepatic concentrations of Cortisol, hepatic lipid
catabolism is markedly increased while synthesis is relatively normal, resulting in
elevated HDL-cholesterol and reduced total cholesterol (Morton et al., 2001).
Furthermore glucocorticoids are known to upregulate glycogenolytic enzymes
(Andrews & Walker, 1999) (Rooney et ah, 1994).
In this study, relatively modest hyperinsulinaemia was employed in order to
approximate the ED50 for suppression of hepatic glucose production (Rizza et ah,
1981). For these reasons, the positive effects of carbenoxolone on hepatic
carbohydrate and lipid metabolism, but lack of effect on peripheral glucose uptake,
does not allow the conclusion that inhibition of lip-HSDl in extrahepatic tissues,
notably adipose tissue, would not be beneficial. However, the acute effects of
carbenoxolone on hepatic insulin sensitivity were of modest magnitude. For more
substantial effects on glucose tolerance and glycaemic control in patients with
T2DM, it appears likely that lip-HSDl inhibitors will be required to inhibit
glucocorticoid regeneration in adipose tissue as well as the liver.
Potential treatmentsfor thefuture
The liver is central in glucose homeostasis and has a major causative role in T2DM
with as much as 90% of hepatic glucose output due to increased gluconeogenesis.
As was demonstrated in the introduction of this thesis a major site of action of
glucocorticoids is on the expression and activation of enzymes involved in
gluconeogenesis. It thus seems reasonable that if drugs could be targeted at reducing
Cortisol concentrations in the liver then they could have considerable influence on
blood glucose concentrations. This has been highlighted in a recent study in which a
selective inhibitor of lip-HSD 1 decreased blood glucose concentrations in
hyperglycaemic mice (Alberts et al., 2002). Present drug treatment has little impact
on hepatic glucose output suggesting that drugs targeted here could provide an
additional tool for the treatment ofT2DM.
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This thesis has demonstrated that local inhibition of Cortisol production by inhibition
of 11P-HSD 1 could be a novel target for the treatment of T2DM If drugs to inhibit
IIP-HSD 1 are to be designed they must be specific for this isoenzyme as any
inhibition of 11P-HSD 2 will result in intolerable side effects of hypertension, salt
retention and hyperkalemia. Furthermore these drugs must not cross react with other
enzymes or receptors. If these criteria can be met then an effective new treatment for
diabetes is possible.
In summary this thesis has demonstrated that abnormalities in Cortisol activity are
present in patients with T2DM and that inhibition of lip-HSDl might be a novel
therapeutic target for the treatment of T2DM. Future research is now needed to
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Effects of the 11/3-Hydroxysteroid Dehydrogenase
Inhibitor Carbenoxolone on Insulin Sensitivity in Men
with Type 2 Diabetes
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11/3-Hydroxysteroid dehydrogenase type 1 (11/3-HSD1) regen¬
erates Cortisol from inactive cortisone in liver and adipose
tissue. Inhibition of 11 0-HSD1 offers a novel potential therapy
to lower intracellular Cortisol concentrations and thereby en¬
hance insulin sensitivity and hepatic lipid catabolism in type
2 diabetes, obesity, and hyperlipidemia. We evaluated this
approach using the nonselective 11 /J-IISI) inhibitor, carben¬
oxolone, in healthy men and lean male patients with type 2
diabetes.
Six diet-controlled nonobese diabetic patients with hemo¬
globin Alc less than 8%, and sixmatched controls participated
in a double-blind, cross-over comparison of carbenoxolone
(100 mg every 8 h, orally, for 7 d) and placebo. They were
admitted overnight for infusions of insulin (as required to
maintain arterialized plasma glucose of 5.0 mM) and
[13Ce]glucose. Glucose kinetics were measured in the fasted
state from 0700-0730 h, during a 3-h euglycemic hyperinsu-
linemic clamp (including somatostatin infusion and replace¬
ment of physiological Gil and glucagon levels), and during a
2-h euglycemic hyperinsulinemic clamp with a 4-fold increase
in glucagon levels. Data are the mean ± sem.
Carbenoxolone had the expected effects of raising blood
pressure and lowering plasma potassium. Carbenoxolone re¬
duced total cholesterol in healthy subjects (5.25 ± 0.34 vs.
4.78 ± 0.40 mM; P < 0.01), but had no effect on other serum
lipids or on cholesterol in diabetic patients. Carbenoxolone
did not affect the rate of glucose disposal or the suppression
of free fatty acids during hyperinsulinemia. Dowever, carben¬
oxolone reduced the glucose production rate during hyper-
glucagonemia in diabetic patients (1.90 ± 0.2 vs. 1.53 ± 0.3
mg/kg-min; P < 0.05). This was attributable to reduced glyco-
genolysis (1.31 ± 0.2 vs. 1.01 ± 0.2 mg/kg min; P < 0.005) rather
than altered gluconeogenesis.
These observations reinforce the potential metabolic
benefits of inhibiting 11/5-USD1 in the liver of patients with
type 2 diabetes. Further studies in obesity and hyperlipid-
emia are now warranted. However, clinically useful thera¬
peutic effects will probably require selective 11/1-HSD1 in¬
hibitors that lower intraadipose Cortisol levels and enhance
peripheral glucose uptake. (J Clin Endocrinol Metab 88:
285-291, 2003)
n0-HYDROXYSTEROID dehydrogenase type 1 (11/3-HSD1) is an enzyme that regenerates the active
glucocorticoid Cortisol from its inactive metabolite corti¬
sone (1). Its potential importance in obesity and type 2
diabetes mellitus has been thrown into sharp focus by
recent observations in mice. Animals with 11/3-HSD1
knockout have normal or marginally increased plasma
glucocorticoid levels,but cannot regenerate glucocorticoid
within cells in liver and adipose tissue. As a result, they
are protected from the insulin resistance, hyperglycemia
(2], and weight gain (Morton, N. M., et al., unpublished
observations) induced by high fat feeding (3). Similarly,
down-regulation of 11/3-HSD1 expression after the admin¬
istration of estradiol to male rats is associated with de¬
creased markers of hepatic gluconeogenesis (4). Con¬
versely, mice with transgenic overexpression of 11/3-HSD1
selectively in adipose tissue under the aP2 promoter have
increased intraadipose glucocorticoid concentrations de¬
spite no change in plasma levels (5). These animals have
a dramatic phenotype of central obesity, insulin resistance,
and hyperglycemia. Mice with transgenic overexpression
Abbreviations: DM, Diabetes mellitus: IlbA lc, hemoglobin Alc; HDL,
high density lipoprotein; 11/3-HSD1, 11/3-hydroxysteroid dehydroge¬
nase typel;Ra, rate of glucose appearance; Rd, rate of peripheral glucose
disposal.
selectively in liver under the apolipoprotein E promoter
also show insulin resistance and hyperlipidemia (Pater-
son, J. M., et al., unpublished observations). In idiopathic
obesity in man 11/3-EISD1 activity is selectively increased
in adipose tissue (6-8) to a similar degree as the increase
in transgenic overexpressing mice. Thus, increased 11/3-
HSD1 in adipose tissue may be a key mechanism deter¬
mining the predisposition to obesity in man in what has
been coined Cushing's disease of the omentum (9). Phar¬
macological inhibition of 110-HSD1 to lower intracellular
Cortisol concentrations in liver and adipose tissue, without
altering circulating Cortisol concentrations or responses to
stress, is an exciting potential therapy in type 2 diabetes
and obesity.
Relatively nonselective inhibitors of 11/3-HSD1 are avail¬
able for human use. The principal active constituent of con¬
fectionary liquorice, glycyrrhetinic acid, and its hemisucci-
nate derivative, carbenoxolone, are potent inhibitors of both
11/3-HSD1 and its isoenzyme, 11/3-HSD2 (10). 11/3-HSD2 is
expressed principally in the distal nephron, where it inacti¬
vates Cortisol to cortisone and thereby protects mineralocor-
ticoid receptors from Cortisol (11,12). Inhibition of 11/3TISD2
with liquorice derivatives results in cortisol-dependent min-
eralocorticoid excess with hypertension and hypokalemic
alkalosis (13, 14). However, in addition carbenoxolone in-
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hibits regeneration of Cortisol from cortisone by lljS-HSDl in
liver (14,15). In a previous study of healthy men we showed
that carbenoxolone increased insulin sensitivity, as mea¬
sured by an increase in glucose infusion rate during eugly-
cemic hyperinsulinemic clamp (16). There was no effect on
peripheral glucose uptake, measured by arterio-venous sam¬
pling across the forearm, so it was inferred that carbenox¬
olone lowers intrahepatic Cortisol concentrations and thereby
prevents insulin-dependent suppression of hepatic glucose
production.
In the present study we aimed to characterize the mech¬
anism of action of carbenoxolone on insulin sensitivity in
healthy men and quantify its effects for the first time in
patients with type 2 diabetes. The selection of patients most
likely to respond to 11/3-HSD1 inhibition was an important
consideration. In obese patients there is tissue-specific dys-
regulation of lljS-HSDl, resulting in increased regeneration
of Cortisol in adipose tissue (6-8) but decreased activity in
liver (6,17). In contrast, in lean patients with type 2 diabetes
we found a relatively small decrease in hepatic 11/3-HSD1
activity and no change in the enzyme in adipose tissue (18).
It is not established that carbenoxolone effectively inhibits
11/3-HSD1 in adipose tissue, but it does inhibit 11J3-HSD1 in
liver (Livingstone, D. E. W., et al., unpublished observations)
(14). For these reasons we recruited only lean patients with
type 2 diabetes in the current study and aimed principally to
study the effects of carbenoxolone in the liver.
Subjects and Methods
Participants
We studied six men with type 2 diabetes mellitus (diagnosed <3 yr
previously by WHO criteria; DM group) recruited from our clinic and
six normal healthy controls recruited by advertisement. Patients were
treated with diet alone, without oral hypoglycemic agents or insulin, and
were free of retinopathy, nephropathy, and neuropathy at their most
recent annual review. Exclusion criteria included body mass index
greater than 32 kg/m2, weight loss greater than 5 kg in the previous 3
months, therapy for any other medical conditions, including dyslipi-
demia and hypertension, blood pressure greater than 160/90 mm Hg,
major psychiatric disorder, abnormal renal or thyroid function on bio¬
chemical screening, or glucocorticoid therapy by any route in the pre¬
vious 3 months. Healthy control men were matched for age, weight,
height, body mass index, and blood pressure. Local ethical committee
approval and written informed consent were obtained.
Protocol
Participants took carbenoxolone (100 mg every 8 h, orally, for 7 d) or
placebo in a double-blind, randomized, cross-over trial with phases
separated by at least 3 months of washout. This dose of carbenoxolone
has been shown previously to inhibit conversion of cortisone to Cortisol
in man (14, 15). On d 4 of each phase measurements of weight, blood
pressure and plasma electrolytes were made to avoid adverse effects of
carbenoxolone (hypokalemia and sodium retention), but no subject had
to be withdrawn. On the evening of the seventh day of each phase,
participants were admitted to the Clinical Research Facility for clamp
studies. Compliance with study medication was monitored by tablet
counting and by measuring plasma carbenoxolone levels in samples
obtained at 0700 h on the eighth day.
Euglycemic clamp protocol
Participants attended the clinical research facility at 1730 h for a
standardized meal. Thereafter their only oral intake was water. Can¬
nulas were placed in an antecubital vein for infusions and retrogradely
in a contralateral dorsal hand vein; the hand was kept in a hot box for
arterialized blood sampling. The clamp was divided into three phases
(Fig- 1)-
Phase 1. From 2200-0730 h, an overnight clamp was employed to ensure
that controls and DM patients started the hyperinsulinemic clamps with
similar plasma glucose concentrations and to measure basal parameters.
Blood glucose was measured at least every 15 min, and iv insulin was
administered at variable rates, if required, tomaintain glucose at 5.0mm.
From 0400 h, [nCJglucose was infused (at 5mg/kg-h after primingwith
5 mg/kg).
Phase 2. From 0730-1030 h, a hyperinsulinemic, normoglucagonemic,
normoglycemic clamp was performed with infusions of insulin (0.4
mU/kg-min), somatostatin (0.25 mg/h), glucagon (1.5 ng/kg-min), GH
(3 ng/kg-min), and 20% glucose. The 20% glucose infusion rate was
varied to maintain arterialized blood glucose at 5.0 mm.
Phase 3. From 1030-1230 h, a hyperinsulinemic, hyperglucagonemic,
normoglycemic clamp was performed by increasing the glucagon in¬
fusion rate from 1.5 to 6.0 ng/kg-min whilemaintaining other infusions.
In addition to frequent samples for bedside blood glucose monitor¬
ing, blood samples were obtained as indicated in Fig. 1. Blood was
immediately centrifuged, and the plasma was frozen and stored at -80
C until analysis.
Laboratory analyses
Enzyme immunoassays (Eurogenetics Tasah Corp. UK Ltd., Hamp¬
ton, UK) were used to measure plasma insulin, GH, and C peptide.
Electrolytes were measured with a Vitras 950 (Ortho Diagnostics, Rari-
tan, NJ), and glucose was determined on a Cabas Mira Plus (Roche,
Mannheim, Germany). Triglycerides, total cholesterol, and high density
lipoprotein (HDL) cholesterol were measured using ELISA kits (TG,
CHOL, and HDL C-plus, respectively; Roche). Hemoglobin Au. (HbA,,.)
was measured by ion exchange HPLC (Variant 11, Bio-Rad Laboratories,
Inc., Richmond, CA). RIAs were used to measure Cortisol (19) and
glucagon (20). Free fatty acids were measured by a colorimetric tech¬
nique (Wako, Neuss, Germany). Carbenoxolone wasmeasured by HPLC
with UV detection (at 254 nm) using 18«-glycyrrhetinic acid as an in¬
ternal standard.
Enrichment of glucose isotopomers was analyzed as its acetylated
di-O-isopropylidene derivative (21) using a gas chromatograph quad-
rupole mass spectrometer (Voyager, Thermoquest, Manchester, UK).
Electron impact ionization was used with selectivemonitoring ofmasses
287-293. Enrichment of lactate isotopomers was analyzed as its propyl-
amideheptafluorobutyric acid using electron impact ionization with se¬
lective monitoring of masses 327-330 (22). Measured isotopomer dis¬
tributions were corrected for natural nC enrichment at all masses as
described previously (23), using software provided by Dr. Henri
Brunengraber (Western Reserve University, Cleveland, OH). Coeffi¬
cients of variation for enrichment measurements for both glucose and
lactate were less than 5%, as assessed from quality control samples
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Fig. 1. Protocol for clamp study. Arrows indicate the timing ofblood
sampling.
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Calculation ofglucose kinetic parameters
Rates of glucose appearance (RJ and peripheral glucose disposal (Rd)
were calculated from steady state enrichment of the plasma glucose pool
with !1 *C6]glucose, using mean data obtained in the basal state (0700-
0730 h), during hyperinsulinemia (1000-1030 h), and with the addition
of hyperglucagonemia (1200-1230 h). All enrichments during these pe¬
riods were confirmed as steady state by regression coefficients for seven
measurements against time not significantly different from zero. Glu¬
cose and lactate enrichments achieved in plasma at plateau were similar
to those reported by Tayek and Katz (24). The glucose production rate
was calculated by subtracting the glucose infusion rate from Rv Glu-
coneogenesis rates were calculated at the same intervals according to the
steady state formulas described by Tayek and Katz (24). Glycogenolysis
was calculated as (glucose production rate) - (gluconeogenesis rate).
Statistics
Data are expressed as the mean ± sem. The effects of carbenoxolone
within groups were examined by paired t tests. Differences between
patient groups were tested by unpaired f tests. Multiple regression was
used to explore whether interindividual differences in the effects of
carbenoxolone were attributable to differences in achieved plasma level
of carbenoxolone or differences between DM patients and controls (an¬
alyzed as 0 or 1).
Results
Baseline characteristics
DM and control men were well matched for age (59 ± 3
vs. 58 ± 3 yr, respectively; P = 0.94), body mass index (29.2 ±
1.3 vs. 29.1 ± 0.9; P 0.94), and waist/hip circumference
ratio (0.95 ± 0.01 vs. 0.92 ± 0.03; P — 0.43). Glycemic control
was excellent in all DM patients, so that HbAlc was only
marginally higher than in controls (6.8 ± 0.4% vs. 6.0 ± 0.1%;
P = 0.06). HDL cholesterol was lower in DM patients
(Table 1).
Effects of carbenoxolone on blood pressure, plasma
electrolytes, and lipids
Tablet count and plasma carbenoxolone levels confirmed
good compliance with study medication (Table 1). Carben¬
oxolone levels tended to be higher in DM than controls (P =
0.09). Carbenoxolone had the expected effects to raise blood
pressure and lower plasma potassium in both groups, al¬
though the effect on plasma potassium was only statistically
significant in the DM patients. In contrast, in the control
group carbenoxolone decreased fasting plasma cholesterol
and tended to increase TIDL cholesterol; these effects were
not observed in DM patients.
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Effects of carbenoxolone on glucose kinetic parameters
The technical success of the clamps is shown in Fig. 2.
Plasma glucose was maintained similarly close to 5.0 mM
throughout in both groups with and without carbenoxolone
(Fig. 2b). To achieve this insulin was infused at low doses
overnight in five of the DM patients and three of the control
subjects (controls after placebo, 0.3 ± 0.1 U/h; controls after
carbenoxolone, 0.4 ± 0.2 U/h; DM after placebo, 1.0 ± 0.6
U/h; DM after carbenoxolone, 1.3 ± 0.3 U/h). The resulting
plasma insulin levels at 0700 - 0730 h tended to be higher in
DM patients regardless of carbenoxolone therapy (Fig. 2c).
Thereafter, the anticipated degree of hyperinsulinemia was
achieved by infusion of 0.4 mU/kg-min insulin, but resulting
insulin concentrations were higher in DM subjects after pla¬
cebo than in other groups. C Peptide levels were similar at
baseline and were suppressed in all subjects during hyper¬
insulinemia (Fig. 2d). GIT levels were similar at baseline and
were clamped successfully in all participants except one DM
patient after carbenoxolone whose GFI level rose to more
than 15 mU/liter from 1200-1230 h (Fig. 2g). Plasma gluca¬
gon levels were not different at baseline and were clamped,
as intended, to physiological levels by infusion of 1.5 ng/
kg-min and to high levels by infusion of 6.0 ng/kg-min (Fig.
2f). Plasma Cortisol followed the normal diurnal rhythm in all
groups (Fig. 2h).
Glucose was infused at variable rates during hyperinsu¬
linemia. The rate of glucose infusion plateaued to similar
rates in all groups within 1 h (Fig. 2a). There was a nonsig¬
nificant trend for higher absolute infusion rates in healthy
controls after carbenoxolone consistentwith increased whole
body insulin sensitivity as previously reported (16). This was
not attributable to differences in peripheral insulin sensitiv¬
ity. Free fatty acid levels were not different at baseline and
were suppressed similarly during hyperinsulinemia (Fig.
2e). R(l (Fig. 3a) was stimulated, as expected, by insulin and
rose further with the addition of hyperglucagonemia, espe¬
cially in control subjects, but was unaffected by carbenox¬
olone in either group.
Glucose production rates were not different at baseline,
were suppressed during hyperinsulinemia, and were stim¬
ulated during hyperglucagonemia (Fig. 3b). These changes in
glucose production during the clamp were associated with
the expected changes in gluconeogenesis (Fig. 3c) and gly-
TABLE 1. Effect of carbenoloxone on clinical characteristics and biochemistry
Controls Diabetic patients
Placebo Carbenoxolone Placebo Carbenoxolone
Weight (kg) 89.5 ± 5.9 89.9 ± 5.7 83.0 ± 5.8 84.2 ± 5.6
Systolic blood pressure (mm Hg) 132 ± 8 149 ± 6'' 130 ± 6 148 ± 6*
Diastolic blood pressure (mm Hg) 79 i. 4 84 ".V 4° 78 ± 5 84 if. 6"
Plasma potassium (mM) 4.38 ± 0.08 4.12 ± 0.14 4.30 ± 0.10 4.07 ± 0.12"
Plasma total cholesterol (mM) 5.25 ± 0.34 4.78 ± 0.40'' 4.28 ± 0.70 4.33 ± 0.33
HDL cholesterol (mM) 1.28 ± 0.15 1.42 0.15 0.89 ± 0.07£ 0.95 ± 0.09c
Plasma triglycerides (mM) 1.75 if 0.62 1.16 i 0.37 1.27 ± 0.37 1.00 ± 0.21
Plasma carbenoloxone (pg/liter) All <10 46.8 ±11.8* All <10 88.3 ± 18.5*
Data are mean ± SE.
" P < 0.05 and * P < 0.01 in paired Student's t test vs. placebo.
c P < 0.05 in Student's I test vs. control group.
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Fig. 2. Direct measurements during clamp study. Data are the mean ± sem. For clarity, only limited time points are shown for each
measurement. O and •, Healthy controls; □ and ■, diabetic patients. O and □, After placebo; • and ■, after carbenoxoione. *, P < 0.05 us.
all other groups (by unpaired I. tests us. controls and by paired t tests us. DM group during carbenoxoione treatment).
cogenolysis (Fig. 3d), both of which were suppressed by
hyperinsulinemia and stimulated by hyperglucagonemia. By
contrast with the lack of effect on peripheral glucose uptake,
carbenoxoione prevented the increase in the glucose pro¬
duction rate during hyperglucagonemia inDM subjects only.
This was attributable to reduced glycogenolysis, with no
significant difference in gluconeogenesis.
The influence of interindividual variations in plasma car¬
benoxoione concentrations was investigated for each of the
variables that were significantly different between carben¬
oxoione and placebo phases in either group. In Pearson sim¬
ple correlations, plasma levels of carbenoxoione were not
significantly associated with the difference between mea¬
surements during carbenoxoione and placebo phases. Mul-
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Fig. 3. Kinetic parameters derived from P3C6]glucose tracer mea¬
surements. Data are the mean ± sem. □, Basal measurements from
0700-0730 h; H, measurements during hyperinsulinemia from
1000-1030 h; M, measurements during hyperinsulinemia and hyper-
glucagonemia from 1200-1230 h. *, P < 0.05; **, P < 0.01 (between
the groups indicated, by paired t tests).
tiple regression was employed to explore whether differ¬
ences in the effects of carbenoxolone between DM and
controls could be accounted for by differences in plasma
carbenoxolone levels. Explanatory variables were plasma
carbenoxolone concentration and diagnosis (DM or control,
coded as 0 and 1). These models did not show any indepen¬
dent effect of plasma carbenoxolone concentration.
Discussion
Previous research in mice, rats, and healthy humans sug¬
gests that inhibition of 11/3-HSD1 lowers intrahepatic glu¬
cocorticoid concentrations and thereby reduces hepatic glu¬
cose production and enhances lipid catabolism (1). In
addition, more recent evidence suggests that inhibition of
11/3-HSD1 in adipose tissue will increase peripheral glucose
uptake and suppress lipolysis (5). This report extends pre¬
vious studies using the nonselective 11/3-HSD inhibitor, car¬
benoxolone (10, 14). We examined in detail its site of action
on glucose metabolism in healthy men and tested its effects
in patients with type 2 diabetes, a patient group that might
be expected to benefit from any future development of se¬
lective llfl-HSDl inhibitors. We employed a detailed pro¬
tocol to control for variables that are sometimes neglected
during euglycemic clamp studies, including overnight prep¬
aration of subjects to avoid effects of baseline hyperglycemia
(25, 26), clamping of GH and glucagon levels, and stable
isotope tracer measurement of gluconeogenesis. We showed
that 1 wk of carbenoxolone administration decreased gluca-
gon-stimulated glucose production and glycogenolysis in
diabetic, but not healthy, subjects and decreased total cho¬
lesterol in healthy, but not diabetic, subjects. Carbenoxolone
had no effect on gluconeogenesis, peripheral glucose uptake,
or insulin-mediated suppression of plasma free fatty acids.
These observations reinforce the potential value of 11/3-
HSD1 inhibitors in enhancing hepatic insulin sensitivity and
lipid cataholism.
An important consideration in designing this study to test
the utility of 11/3-HSD1 inhibition in metabolic disease was
raised by observations that there are tissue-specific alter¬
ations in enzyme activity in obesity. Thus, llfi-HSDl is in¬
creased in adipose tissue, but decreased in liver in obesity
(6-8, 17, 27). In contrast, lean patients with type 2 diabetes
have normal adipose 11/3-HSD1 and less marked down-
regulation of hepatic conversion of cortisone to Cortisol (18,
28). To avoid the potential confounding effects of obesity and
to exclude any unknown effects of oral hypoglycemic or
antihypertensive agents, we selected nonobese normoten-
sive patients with type 2 diabetes controlled by dietary ther¬
apy alone. The result was that patients in this study were not
typical of type 2 diabetes. Indeed, they had near-normal
blood glucose and HbAlc levels, a small requirement for
overnight insulin infusion to obtain fasting euglycemia, and
only minor differences in plasma lipids. After overnight
euglycemia with insulin infusion as required, glucose pro¬
duction, free fatty acids, and glucagon levels were not ele¬
vated in these diabetic patients, and glucose disposal was not
measurably impaired. Nonetheless, the effects of carben¬
oxolone differed between healthy controls and diabetic pa¬
tients; an effect on cholesterol was only evident in healthy
controls, and measurable effects on glucose production were
only evident in diabetic patients.
In a previous study we showed that the same regime of
carbenoxolone administration to healthy men resulted in
enhanced insulin sensitivity, as measured by increased glu¬
cose infusion rate during a hyperinsulinemic clamp (16). A
key difference, however, is that the previous study was per¬
formed with a higher insulin infusion rate and achieved
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higher concentrations (~70 mU/liter compared with ~30
mU/liter here) designed to examine effects on insulin-stim¬
ulated glucose uptake rather than glucose production (29).
Also, GH and glucagon levels were not clamped previously,
and the participants were younger. In the current study there
was a trend for a similar magnitude of increase in glucose
infusion rate in healthy controls (means differed by ~7%
previously and by ~17% here), but it did not reach statistical
significance. Glucose production was marginally, but not
significantly, lower in healthy men after carbenoxolone treat¬
ment in the current study. This contrasts with the statistically
significant effects of carbenoxolone on glucose kinetics in
diabetic patients. By analogy with other insulin-sensitizing
therapies it might be anticipated that the effects of carben¬
oxolone would be smaller in healthy controls than in diabetic
patients, because, for example, troglitazone induced around
twice the increase in insulin sensitivity in diabetic patients
(30) as it did in healthy men (31). Further, plasma carben¬
oxolone levels tended to be higher in the diabetic patients
than in controls, so that the effect of carbenoxolone could
have been underestimated in control subjects. Single mea¬
surements of plasma carbenoxolone concentrations were in¬
cluded in this study principally as a qualitative assessment
of compliance, and more detailed pharmacokinetic studies
would be required to confirm that this difference did not
occur by chance. Importantly, however, in multiple regres¬
sion analysis the variations in carbenoxolone concentrations
between individuals did not account for different effects of
carbenoxolone in DM patients and controls. Finally, insulin
levels during the clamp studies were higher in the diabetic
patients during placebo therapy than in all other groups,
which may lead to underestimation of the effects of carben¬
oxolone in the diabetic patients. Against this background, it
is unclear whether quantitative or qualitative differences
explain the discrepancies between the effects of carbenox¬
olone in health and diabetes, although we suspect the former.
This is the first report of the effects of carbenoxolone, or
any J1B-IISD inhibitor, in diabetic patients. It shows that
carbenoxolone affects glucose production, as inferred indi¬
rectly from our previous report (16), but the mechanism of
the effect was not expected. In lljS-HSDl knockout mice a
key feature is impaired up-regulation of gluconeogenic en¬
zymes, such as phosphoenolpyruvate carboxykinase, on fast¬
ing (2). Glucocorticoids are known to oppose the effect of
insulin in regulating the expression of gluconeogenic en¬
zymes (32). However, carbenoxolone did not alter glucone-
ogenesis after overnight fast, during hyperinsulinemia, or
during hyperglucagonemia. One consideration in this par¬
adox is that the contribution of the kidney to gluconeogenesis
in man remains unquantified. By inhibiting inactivation of
Cortisol by 11/1-HSD2 in kidney (14) carbenoxolone increases
intrarenal Cortisol concentrations, which might enhance re¬
nal gluconeogenesis in compensation. To resolve this will
require studies either with selective 110-HSD1 inhibitors or
with cannulation of hepatic and/or renal vein. The kidney is
not, however, a major site of glycogen storage. Glucocorti¬
coids have complex effects on glycogenic and glycogenolytic
enzymes, which predict increased turnover and amplifica¬
tion of the effect of other signals (32, 33). Thus, the obser¬
vation that carbenoxolone attenuated net glucagon-induced
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glycogenolysis is consistent with lowering of intrahepatic
Cortisol concentrations.
A more recently recognized consequence of changes in
intrahepatic glucocorticoid concentrations is the effect on
lipid metabolism (3). The effects of carbenoxolone in the liver
are the most likely explanation for the decrease in total cho¬
lesterol observed in healthy controls. In 1 Ij3-HSD1 knockout
mice hepatic lipid catabolism is markedly increased, while
synthesis is apparently normal, resulting in reduced serum
triglycerides and total cholesterol (3). In addition, altered
apolipoprotein Al expression in these animals may account
for higher HDL cholesterol (3). However, the importance of
enhanced lipid catabolism in man and comparison of effects
in healthy controls and diabetic patients should be reassessed
with a longer duration of carbenoxolone administration, be¬
cause plasma lipids take several weeks to reequilibrate after
the introduction of conventional lipid-lowering therapy.
Liquorice derivatives, such as carbenoxolone and glycyr-
rhetinic acid, are potent inhibitors of both isozymes of 11/3-
HSD in vitro and in cell culture (10, 34-36). Llowever, in vivo
they have inconsistent effects, probably because of pharma¬
cokinetic differences in access to tissues. Thus, carbenox¬
olone, but not glycyrrhetinic acid, inhibits hepatic 11J3-HSD1
in vivo in man, as judged by impaired generation of Cortisol
after an oral dose of cortisone. In animals, in vivo inhibition
of 11 /3-I ISDs with carbenoxolone in other tissues is also in¬
consistent, for example varying between different regions of
the central nervous system (37, 38). Indeed, in Zucker obese
rats in vivo administration of carbenoxolone inhibits 11/3-
HSD1 in liver, but not in adipose tissue (Livingstone,
D. E. W., et al., unpublished observations). In the current
study relatively modest hyperinsulinemia was employed to
approximate the ED50 for suppression of hepatic glucose
production (29). For these reasons the positive effects of
carbenoxolone on hepatic carbohydrate and lipid metabo¬
lism but lack of effect on peripheral glucose uptake in both
the current and previous study (16) do not allow the con¬
clusion that inhibition of 11/i-HSDl in extrahepatic tissues,
notably adipose tissue, would not be beneficial. However,
the acute effects of carbenoxolone on hepatic insulin sensi¬
tivity were ofmodest magnitude in the lean group ofpatients
studied here. For more substantial effects on glucose toler¬
ance and glycemic control in patients with diabetes, it ap¬
pears likely that 11/3-HSD1 inhibitors will be required to
inhibit glucocorticoid regeneration in adipose tissue as well
as liver. Reducing Cortisol action in adipose tissue may then
provide an increase in peripheral glucose disposal in addi¬
tion to the reduced glucose production observed with car¬
benoxolone. Further, given the up-regulation of adipose 11/3-
HSD1 in obesity (6-8), but not in lean patients with type 2
diabetes (18), inhibition of adipose is likely to be of the most
benefit in obese patients.
In summary, these studies with a nonselective Ilj3-HSD
inhibitor illustrate the potential value of inhibition of 11/3-
HSD1 in lean hyperglycemic patients. It will now be impor¬
tant to establish whether similar benefits can be obtained in
obese patients and patients with dyslipidemia. However, by
inhibiting renal 11/3-HSD2, carbenoxolone has unacceptable
long-term side-effects, including raising blood pressure, so
that exploiting this approach for useful therapy will require
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either simultaneous blockade of renal mineralocorticoid re¬
ceptors or the long-awaited development of selective 11/3-
HSD1 inhibitors.
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Abnormal Cortisol Metabolism and Tissue Sensitivity to
Cortisol in Patients with Glucose Intolerance
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Recent evidence suggests that increased Cortisol secretion,
altered Cortisol metabolism, and/or increased tissue sensitiv¬
ity to Cortisol may link insulin resistance, hypertension, and
obesity. Whether these changes are important in type 2 dia¬
betes mellitus (DM) is unknown.
We performed an integrated assessment of glucocorticoid
secretion, metabolism, and action in 25 unmedicated lean
male patientswith hyperglycemia (20with type 2 diabetes and
5 with impaired glucose intolerance by World Health Orga¬
nization criteria) and 25 healthy men, carefully matched for
bodymass index, age, and blood pressure. Data are mean ± se.
Patients with hyperglycemia (DM) had higher HbAlc (6.9 ±
0.2% us. 6.0 ± 0.1%, P < 0.0001) and triglycerides. Cortisol
secretion was not different, as judged by 0900 h plasma Cor¬
tisol and 24 h total urinary Cortisol metabolites. However, the
proportion of Cortisol excreted as 5«- and 5p-reduced metab¬
olites was increased in DM patients. Following an oral dose of
cortisone 25 mg, generation of plasma Cortisol by hepatic 11/3-
hydroxysteroid dehydrogenase type 1 (11/3-HSD 1) was im¬
paired in DM patients (area under the curve, 3617 ± 281 nM.2
h vs. 4475 ± 228; P < 0.005). In contrast, in sc gluteal fat biopsies
from 17 subjects (5 DM and 12 controls) in vitro 11/f-HSD 1
activity was not different (area under the curve, 128 ± 56%
conversion.30 h DM vs. 119 ± 21, P - 0.86). Sensitivity to glu¬
cocorticoids was increased in DM patients both centrally
(0900 h plasma Cortisol after overnight 250 jug oral dexameth-
asone 172 ± 16 DM us. 238 ± 20 nM, P < 0.01) and peripherally
(more intense forearm dermal blanching following overnight
topical beclomethasone; 0.56 ± 0.92 ratio to vehicle vs. 0.82 ±
0.69, P < 0.05).
In summary, in patients with glucose intolerance, Cortisol
secretion, although normal, is inappropriately high given en¬
hanced central and peripheral sensitivity to glucocorticoids.
Normal 11/S-IISD 1 activity in adipose tissue with impaired
hepatic conversion of cortisone to Cortisol suggests that
tissue-specific changes in 11/3-HSD 1 activity in hyperglyce¬
mia differ from those in primary obesity but may still be sus¬
ceptible to pharmacological inhibition of the enzyme to re¬
duce intracellular Cortisol concentrations. Thus, altered
Cortisol action occurs not only in obesity and hypertension
but also in glucose intolerance, and could therefore contrib¬
ute to the link between these multiple cardiovascular risk
factors. (./ Clin Endocrinol Metab 87: 5587-5593, 2002)
HYPERTENSION, OBESITY, coronary heart disease,and hyperlipidemia are extremely common in pa¬
tients with glucose intolerance or type 2 diabetes mellitus
(DM). These are associated with insulin resistance (1) in what
is referred to as the Metabolic Syndrome, but the reasons for
the associations between features of this syndrome remain
obscure. A similar association of cardiovascular risk factors
and insulin resistance occurs in Cushing's syndrome, due to
elevated circulating glucocorticoids. It has been proposed
that subtle abnormalities in Cortisol action are a missing link
between these factors in patients with the Metabolic Syn¬
drome (2-4).
The hypothalamic-pituitary-adrenal (HPA) axis controls
the secretion of Cortisol, with excessive secretion being in¬
hibited by negative feedback. In addition, tissue Cortisol con¬
centrations are controlled by the relative activity of 11/3-
hydroxysteroid dehydrogenase type 1 (11/3-HSD 1), which
converts inactive cortisone to active Cortisol, and 11/3-ITSD 2,
which converts Cortisol to cortisone (5). Tissues may thus be
exposed to a relative excess of Cortisol without any increase
in Cortisol secretion or plasma Cortisol concentrations. The
potential importance of 11/3-HSD 1 in the Metabolic Syn-
Abbreviations: DM, Type 2 diabetes mellitus or impaired glucose
tolerance; HPA, hypothalamic-pituitary-adrenal; 11/3-HSD, 11/3-hydroxy-
steroid dehydrogenase; THE, tetrahydrocortisone; THF, tetrahydrocortisol.
drome has been illustrated by recent experiments in mice.
11 /J-HSD 1 knockout mice are protected from insulin resis¬
tance, hyperglycemia, and dyslipidemia (6, 7), whereas mice
overexpressing 11/3-HSD 1 selectively in adipose tissue un¬
der the AP2 promoter are centrally obese, hyperglycemic,
and hyperlipidemic (8). Similarly, variations in glucocorti¬
coid receptor expression can influence tissue responses in¬
dependently of circulating glucocorticoid concentrations (9).
A number of cross-sectional cohort studies have found that
higher 0900 h plasma Cortisol and/or increased total 24 h
urinary Cortisol metabolite excretion is associated with in¬
sulin resistance, high blood pressure, hyperlipidemia, and
hyperglycemia (4, 10-16). Negative feedback control of the
HPA axis appears normal (17), however, and the activation
of the HPA axis in men with the Metabolic Syndrome may
reflect an increase in central drive to the hypothalamus (18,
19). Obese individuals also show subtle changes in Cortisol
activity with an increase in 24 h Cortisol secretion despite
normal (20) or enhanced (21) feedback sensitivity (as shown
by suppression of plasma Cortisol to 250 ,ug of dexametha-
sone). However, plasma Cortisol concentrations are not ele¬
vated, perhaps because peripheral metabolic clearance of
Cortisol, for example by 5a-reductase (22), is increased (23).
Tissue responses to glucocorticoids are also altered in pa¬
tients with features of the Metabolic Syndrome. In case-
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control studies, individuals with essential hypertension have
reduced inactivation of Cortisol by 11/3-HSD 2 (24-26) and
enhanced glucocorticoid-receptor-dependent tissue sensitiv¬
ity to Cortisol (as judged by enhanced dermal vasoconstric¬
tion following topical glucocorticoid application) (13,17). In
obesity, ll/l-HSD 2 activity and dermal glucocorticoid sen¬
sitivity are not enhanced, but there are tissue-specific
changes in 11/3TISD 1 activity, resulting in less reactivation
of cortisone to Cortisol in liver, but enhanced reactivation in
sc abdominal adipose (20, 27, 28). importantly, the magni¬
tude of increase in 11J3-HSD 1 activity in adipose tissue of
obese men is similar (about 3-fold) as results in dramatic
obesity and hyperglycemia in transgenic mice with 11 /3-HSD
1 overexpression in adipose tissue (8). This observation has
reinforced the concept that inhibition of 11 j3-HSD 1 would be
of therapeutic benefit in patients with the Metabolic Syn¬
drome (29).
Against this background, it is important to know whether
abnormalities in Cortisol secretion, metabolism, or sensitivity
exist in patients with type 2 diabetes or glucose intolerance,
but this may be difficult to establish because these differences
are confounded by contrasting effects of coexisting hyper¬
tension and obesity (30). Previous studies of Cortisol in pa¬
tients with DM have been conducted in heterogeneous
groups with type 1 and type 2 diabetes (31-38), or have been
inadequately controlled for confounding factors of sex, co¬
existing obesity, hypertension, poor glycemic control, and
diabetic complications, making interpretation difficult (39-
44). Moreover, no previous studies have examined tissue
responses to glucocorticoids in patients with diabetes, or
attempted to dissect tissue-specific changes in Cortisol me¬
tabolism. This study set strict criteria for patient selection to
examine Cortisol secretion, metabolism and sensitivity in
nonobese, normotensive, diet-controlled male patients with
DM or impaired glucose tolerance.
Subjects and Methods
Participants
We studied 25 men with DM or impaired glucose tolerance (as de¬
fined by WHO criteria for oral glucose tolerance tests) recruited from our
clinic, and 25 normal healthy controls recruited by advertisement. Ali
patients were controlled by diet alone, without oral hypoglycemic
agents or insulin, and were free of clinical or biochemical evidence of
retinopathy, nephropathy, and neuropathy at last annual review. Ex¬
clusion criteria included therapy for any other medical conditions,major
psychiatric disorder, weight loss more than 5 kg in the previous 3
months, blood pressure more than 160/90 mm Hg, body mass index
more than 32 kg/m2, glucocorticoid therapy by any route in previous 3
months, or abnormal renal or thyroid function on biochemical screening.
Control subjects were matched for weight, height, bodymass index, and
blood pressure. Local ethical committee approval and written informed
consent were obtained.
Protocol
Participants attended on one afternoon without fasting for a medical
examination, measurement of sitting blood pressure (using a Takeda
UA-751 sphygmomanometer), height, and weight. Blood was obtained
for full blood count, urea and electrolytes, HbAlc, liver function tests,
thyroid function tests, cholesterol, and triglycerides. Beclomethasone
dipropionate was then applied to the forearm and subjects returned the
following morning for assessment of dermal blanching (see below).
Following this visit, subjects collected a 24-h urine sample for total
Cortisol metabolites.
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On a second occasion, participants attended at 0830 h having fasted
from 2300 h the previous evening. They lay supine; an iv cannula was
sited and blood was taken 30 min later for Cortisol, Cortisol binding
globulin, glucose, and insulin.
On a third occasion, participants took 250 pg dexamethasone (Dec-
adron, Merck, West Drayton, UK) by mouth at 2300 h and fasted until
attending the following morning at 0830 h. An iv cannula was sited, and
30 min later blood was taken for Cortisol estimation. Participants then
took 25 mg cortisone acetate (Cortisyl, Hoechst Marion Roussel, Inc.,
Uxbridge, UK) by mouth and blood was taken for Cortisol every 15 min
for 2 h.
In vitro adipose 11 (j-HSD 1 activity
Seventeen subjects (5 DM and 12 controls) consented to return for a
500 mg sc fat biopsy to be taken from the gluteal region under local
anesthesia. Subcutaneous fat was frozen immediately at -70 C. After
thawing, it was homogenized in Krebs buffer at pH 7.4 and 750 pg/ml
protein was incubated at 37 C with nicotinamide adenine dinucleotide
phosphate (2 mil) and l,2,6,7-:'H4-cortisol (100 nM) for 30 h. Samples
were taken at 3, 6, 20, and 30 h for separation of Cortisol and cortisone
by HPLC with on-line liquid scintillation detection (20). 11/3-HSD 1
activity was measured in the dehydrogenase direction (i.e. Cortisol to
cortisone, rather than reductase cortisone to Cortisol) because dehydro¬
genase activity is more stable than reductase activity in vitro, and because
dehydrogenase is the preferred reaction when the enzyme is liberated
from its intracellular environment (5). Under these conditions, the con¬
version of Cortisol to cortisone is proportionate to the total protein
added, and therefore reflects 11/3-HSD 1 protein concentrations in the
biopsy sample.
Dermal vasoconstrictor response to glucocorticoids
This was performed as previously described (45). In brief, 50 pi
beclomethasone dipropionate (Sigma, St. Louis, MO) at 0,1, 5,10,100,
or 1000 pg/ml in 95% ethanol were applied in random order into 6
circles of 20-mm diameter on the volar surface of the nondominant
forearm. After the ethanol had evaporated, all sites were occluded with
Saran wrap (Dow Coming, Midland, MI) and left for 16-18 h. At 0800 h
the next day, the bandage was removed. An hour later, the intensity of
the blanching was read by an observer who was blind to the order of
application using a reflectance spectrophotometer (Erythemameter, Di-
astron Ltd., Andover, UK). This device measures the ratio of red/green
light reflected from the skin surface, called the erythema index. Because
red reflects oxyhemoglobin concentration and green reflects melanin
concentrations, the erythema index corrects for variations in skin color
between individuals. The erythema index for each test site was divided
by the erythema index for the site treated with vehicle alone to produce
a blanching index. The blanching index corrects for the nonspecific
variations in skin color that occur in different environments in the same
individuals. A lower blanching index indicates more intense blanching
Laboratory analyses
Plasma and urine samples were stored at -80 C and -20 C,
respectively.
RLAs were used to measure plasma Cortisol (46), dexamethasone
(Cozart Bioscience, Abingdon, UK), and corticosteroid binding globulin
(Medgenix Diagnostics, Fleurus, Belgium). Insulin was measured by
enzyme immunoassay (Eurogenetics UK Ltd., Hampton, UK). Glucose
was measured by an enzymatic technique (Cabas Mira Plus, Roche
Molecular Biochemicals, Mannheim, Germany). Ion exchange HPLC
was used to measure the HbAu. (Variant 11, Bio-Rad Laboratories, Inc.,
Hercules, CA).
Cortisol and its metabolites were measured in urine by electron impact
gas chromatography/mass spectrometry following Sep-pak C18 extrac¬
tion, hydrolysis with /3-glucuronidase, and formation of the methoxime-
trimethylsily! derivatives (47). Epi-cortisol and epi-tetrahydrocortisol were
used as internal standards. Total Cortisol metabolite excretion was calcu¬
lated as tetrahydrocortisols (THFs) + telrahydrocortisone (THE) + cortols
- cortolones (48). Relative metabolism by 5« and 5/3-reductases were in¬
ferred from the 5/3-THF/5o:-THF ratio. A-ring reduction of Cortisol was
inferred from the ratios of THFs/cortisol (49) and 5/3-reductase activity
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from the ratio of THE/cortisone.Whole-body equilibrium between Cortisol
and cortisone, determined by the balance of tissue-specific activities of
11/3-reductase and 11^-dehydrogenase activities, was inferred from the
ratio of THFs/THE. Renal llb-dehydrogenase activity was inferred from
the urinary free Cortisol /cortisone ratio (47, 50).
Statistics
Data are expressed as means ± se. All groups were compared by
Student's f test apart from the urine data, which were compared by
Mann Whitney U test, as these data were not normally distributed.




Characteristics of participants are shown in Table 1. The
groups were well matched for anthropometric, clinical, and
biochemical variables except that diabetic patients had
higher fasting plasma glucose, HbAlc, and triglycerides than
controls. Corticosteroid binding globulin and albumin did
not differ between the groups, so only total plasma Cortisol
was used in further analysis.
HPA axis activity
Fastingmorning plasma Cortisol (Table 1) and total urinary
Cortisol metabolite excretion rate (Table 2) were not different
between groups. However, the morning after 250 pig oral
dexamethasone, plasma Cortisol was lower in diabetic pa¬
tients (Table 1). This could notbe attributed to differences in
dexamethasone concentrations (Table 1).
Cortisol metabolism
Although total Cortisol metabolite excretion was not dif¬
ferent between groups, there were changes in relative me¬
tabolite excretion (Table 2). DM patients excreted less un-
metabolized Cortisol (P < 0.03) and cortisone (P = 0.07) and
tended to excrete more as 5/3-THE (P — 0.07). As a result,
ratios reflecting 5/3-reduction of Cortisol (5/3-TITF/cortisol,
P < 0.001) and cortisone (THE/cortisone, P < 0.005) were
increased in DM patients, and there was a trend for increased
5a-reduction of Cortisol (5a-THF/cortisol). Absolute excre¬
tion of other metabolites, and ratios reflecting 11/3-HSD2
(cortisol/cortisone) and overall 11/3-HSDs (THFs/TFIE),
were not different.
Hepatic 11/3-HSD 1 activity, measured as conversion of
orally administered cortisone to Cortisol, was impaired in the
DM group (Fig. 1; area under curve, 3617 ± 281 nM vs. 4475 ±
228 nM; ANOVA P < 0.005), with an increase in time taken
to reach maximum plasma Cortisol (111 ± 3 min us. 100 ± 4
min, P < 0.05). By simple regression, there was no relation¬
ship between hepatic 11/3-HSD 1 and any individual urinary
Cortisol metabolite or ratio. Adipose in vitro 11/3-HSD 1 ac¬
tivity was no different between the two groups (Fig. 2; area
under the curve, 119 ± 21% controls us. 128 T. 56% DM,
P = 0.8).
Peripheral tissue sensitivity to glucocorticoids
Dermal vasoconstriction to topical beclomethasone dipro-
pionate was more intense in the DM group than in the control
group (Fig. 3).
Discussion
This study demonstrates thatnonobesenormotensive men
with hyperglycemia exhibit abnormalities in Cortisol activity.
The differences in Cortisol metabolism and tissue sensitivity
were more striking than any differences in IIPA axis func¬
tion. Specifically, these patientswith DM or impaired glucose
tolerance show: 1) normal Cortisol secretion and circulating
levels in the face of enhanced negative feedback sensitivity
(as measured with dexamethasone); 2) enhanced in vivo pe¬
ripheral tissue sensitivity to glucocorticoids (as measured by
dermal blanching); 3) impaired hepatic 11/3-HSD 1 activity
but norma] adipose 11/3-HSD 1 activity, suggesting tissue-
specific alterations in 11/3-HSD 1 activity; and 4) increased
relative excretion of A-ring reduced metabolites of Cortisol.
These findings suggest that isolated hyperglycemia is asso¬
ciated with some, but not all, of the changes in Cortisol me¬
tabolism and action that have been observed in subjects with
hypertension or obesity and the Metabolic Syndrome. This
TABLE 1. Clinical characteristics and biochemistry
Controls Hyperglycemic Student's t test
(n = 25) patients (n — 25) P
Age (yr) 59 ± 2 58 ± 2 0.59
Body mass index (kg/m2) 27.2 ± 0.5 27.6 ,± 0.6 0.56
Systolic blood pressure (mm Hg) 130 ± 3 131 ± 2 0.66
Diastolic blood pressure (mm Hg) 78 ± 2 78 ± 1 0.78
Plasma creatinine (pM) 89.2 ± 2.6 89.8 ± 2.7 0.87
HbAlc (%) 6.0 ± 0.1 6.9 ± 0.2 <0.0001
Fasting plasma glucose (mM) 5.7 ± 0.2 8.2 ± 0.6 <0.0002
Fasting plasma insulin (mU/Iiter) 19.6 ± 4.2 21.4 ± 3.0 0.74
Plasma triglycerides (mM) 2.1 ± 0.2 3.5 A 0.6 <0.05
Total plasma cholesterol (mM) 5.6 ± 0.2 5.6 ± 0.2 0.92
Plasma albumin (g/liter) 42 ± 0.5 42 ± 0.8 0.50
0900 h plasma Cortisol (nM) 420 ± 30 428 ± 24 0.85
0900 h plasma Cortisol postdexamethasone 238 ± 20 172 .t. 16 <0.01
250 fig (nM)
Plasma dexamethasone postdexametbasone 0.40 ±0.11 0.41 ± 0.05 0.92
250 p.g (ng/ml)
Plasma Cortisol binding globulin (pg/inl) 31.9 ± 1.4 28.8 a 1.7 0.16
Data are mean ± SE.
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TABLE 2. Urinary Cortisol metabolites
Controls Hyperglycemic Mann-Whitney
(n = 25) patients (n — 25) U test P
Cortisol 100 ± 6 84 ± 9 0.03
Cortisone 112 ± 14 75 ± 6 0.07
5a-tetrahydrocortisol (5n-THF) 1197 ± 153 1196 ± 104 0.66
5j3-tetrahydrocortisol (5/i-THF) 1036 ± 95 1264 ± 90 0.07
Tetrahydrocortisone (THE) 2218 ± 685 1433 ± 105 0.13
Total Cortisol metabolites" 7691 1- 1336 7535 ± 1514 0.80
(5a-THF + 5P-THFVTHE 1.94 ± 0.19 1.80 i 0.11 0.47
5/3-THF/5a-THF 1.06 ± 0.11 1.19 ± 0.11 0.29
Cortisol/cortisone 1.09 ± 0.08 1.13 ± 0.05 0.97
5/3-THF/cortisol 11.0 ± 1.0 16.4 ± 1.0 0.001
5iv-Tt IF/cortisol 12.6 ± 1.6 16.5 ± 1.6 0.07
THE/co rtisone 15.8 ± 2.2 20.4 ± 1.2 0.005
--
> - -
Results for each steroid are micrograms per day; other results are ratios; mean :
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Fig. 1. In vivo hepatic llp-HSD 1 activity: conversion of oral corti¬
sone to plasma Cortisol. Subjects received oral dexamethasone 250 ug
at 2300 h the previous evening and 25 mg oral cortisone at 0900 h
(time 0; arrow). Data are mean ± se for controls (open symbols, n -
25) and DM patients (filled symbols, n = 25). By repeated measures
two-way ANOVA, plasma Cortisol was lower in diabetics (P < 0.005).
Asterisks show post hoc comparisons at each time point by least
squares difference tests: *, P < 0.02; **, P < 0.01; ***, P < 0.0001.
has implications for understanding underlying mechanisms
predisposing to hyperglycemia, determinants of altered glu¬
cocorticoid signaling, and therapeutic opportunities to ma¬
nipulate Cortisol action to improve metabolic control in DM.
Previous studies of Cortisol in patients with diabetes have
focused on individuals with type 1 diabetes. These showed
increased plasma and urinary free Cortisol levels among pa¬
tients with poor glycemic control and/or diabetic compli¬
cations (40-42, 51-53), but these abnormalities were less
marked in well controlled uncomplicated patients (40,54). A
number of older studies looking at patients with both type
1 and type 2 diabetes found less consistent abnormalities
(34-37, 55) but again showed higher plasma Cortisol con¬
centrations in patients with complications (32,37). Few stud¬
ies have included only patients with type 2 diabetes and
these did not show altered secretion (44, 57) or circulating
0 3 6 20 30
Incubation time (h)
Fig. 2. in vitro 11 (B-I1SI) 1 activity in sc fat biopsy. Data are mean ±
se for % conversion of Cortisol to cortisone at fixed protein concen¬
trations for control subjects (open symbol, n — 12) and DM patients
Ifilled symbols, n — 5). By repeated measures two-way ANOVA, there
was no difference between the two groups (P — 0.8).
levels (58) of Cortisol. However, obesity (22), gender and
blood pressure (13) affect Cortisol secretion and metabolism;
these factors were not controlled for in previous studies of
patients with diabetes. Against this background, the strength
of the current study is the careful matching of controls and
patients with type 2 diabetes or impaired glucose tolerance,
the focus on men only, and the exclusion of patients with
obesity, hypertension, and diabetes complications. The aim
was to isolate the influence of abnormal insulin action and
hyperglycemia from these confounding effects. This was
achieved in so far as the only detected differences in baseline
characteristics between patients and controls were in fasting
plasma glucose, HbAlc, and triglyceride levels. Fasting in¬
sulin levels were not different between groups, consistent
with relative insulin deficiency in the hyperglycemic pa¬
tients. To achieve this close matching with healthy controls,
however, necessitated selection of a group of patients with
extremely good metabolic control of their hyperglycemia. As
a result, the current study may underestimate effects of hy¬
perglycemia per se, but nonetheless will detect differences
that are intrinsic to patients who have pancreatic /3-cell
dysfunction.
Other studies have used conventional techniques to assess
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Fig. 3. Dermal vasoconstriction following topical beclomethasone
dipropionate. Blanching index was recorded following overnight top¬
ical application of beclomethasone dipropionate. A lower index indi¬
cates more intense blanching. Data are mean ± SE for controls (open
symbols, n = 25) and diabetics (filled symbols, n = 25). By repeated
measures two-way ANOVA, blanching was greater in diabetics (P -
0.05). Asterisks show post hoc comparisons at each dose by least
squares difference tests: **, P < 0.01.
Cortisol secretion, i.e. plasma Cortisol concentrations and uri¬
nary free Cortisol, which are relatively insensitive. Urinary
free Cortisol is a small fraction (<5%) of total Cortisol me¬
tabolite excretion, determined principally by free plasma
Cortisol clearance. The sum of the urinary metabolites of
Cortisol in 24 h urine, as used in this study, provides a better
assessment of 24 h secretion of Cortisol (48). Using this
method, the current study showed that Cortisol secretion
over 24 h is normal in lean patients with type 2 diabetes or
impaired glucose tolerance.
The rate of Cortisol secretion is controlled by central drive
to the HPA axis and by negative feedback suppression by
glucocorticoids. Dexamethasone suppression of plasma Cor¬
tisol is the conventional test to examine negative feedback.
Previous studies in patients with diabetes have used 1 mg of
dexamethasone (34, 35, 38), as is used in clinical practice to
detect Cushing's syndrome, and found that in most cases
suppression was normal. Interpretation of this test is qual¬
itative rather than quantitative, because the vast majority of
controls and patients suppress to below the detection limit
for plasma Cortisol. As previously described (16,17) we have
selected 250 p,g of dexamethasone as an approximate ED5n
dose to quantify more subtle variations in suppression
within the non-Cushing's range. Using this very low dose
test, we have shown that patients with type 2 diabetes have
greater sensitivity of the HPA axis to negative feedback. This
could not be accounted for by differences in dexamethasone
concentrations achieved. Although recent data suggest dif¬
ferences in the feedback response to synthetic and endoge¬
nous glucocorticoids in man (59), the finding of normal 24 h
secretion in the face of this enhanced feedback sensitivity
suggests that another factor is driving Cortisol secretion.
Obese individuals also show increased Cortisol secretion in
spite of normal or increased feedback sensitivity (21). Here,
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increased metabolic clearance of Cortisol (23), principally by
5a-reductase (14, 22) but with increased 5)3-reduced metab¬
olites also (20), may be a driving force for the increase in
Cortisol secretion. In this study, we found increased relative
excretion of 5a- and, most strikingly, 5/3-reduced Cortisol
metabolites in the absence of obesity in the hyperglycemic
group. Notably, it has been shown that insulin therapy re¬
duces excretion of 5a-reduced Cortisol metabolites (44). This
suggests that peripheral clearance of Cortisol is enhanced by
mechanisms directly associated with relative insulin defi¬
ciency and hyperglycemia. An alternative explanation is that
inappropriate central drive to the HPA, rather than enhanced
Cortisol clearance, is maintaining Cortisol secretion in the face
of enhanced feedback in these individuals. This is consistent,
for example, with the observation that habituation of Cortisol
in response to repeated sampling is impaired in hypergly¬
cemic men (19).
The finding of normal Cortisol secretion and circulating
Cortisol levels in hyperglycemic patients suggests that if Cor¬
tisol is to play a role in the pathogenesis of type 2 diabetes,
it will be determined by variations in peripheral tissue sen¬
sitivity to Cortisol. One important determinant of tissue re¬
sponse to Cortisol is the extent of metabolism of Cortisol
within the target tissues by 11/3-hydroxysteroid dehydroge¬
nases (11/3-HSDs). Two enzymes exist: 11/3-HSD 1, which
reactivates cortisone to Cortisol and serves to maintain ad¬
equate exposure of glucocorticoid receptors to Cortisol (5);
and 11/3-HSD 2, which converts Cortisol to cortisone and
prevents Cortisol from gaining inappropriate access to min-
eralocorticoid receptors. Overall activities of these enzymes
can be inferred from the balance of Cortisol and cortisone
metabolites in urine. These have been measured in previous
studies in patients with type 1 diabetes (41), in whom the
ratio of cortisol/cortisone metabolites was lower than in
controls, and type 2 diabetes (44), in which there was no
difference between relatively obese patients and controls.
However, these urinary ratios are insensitive to tissue-
specific changes in 11/3-HSD 1 activity (30). In obese rats (60)
and humans, 11 /3-HSD 1 is decreased in liver (61) but in¬
creased in adipose tissue (20, 27, 28). Here, in nonobese
hyperglycemic men, hepatic first pass conversion of corti¬
sone to Cortisol was impaired, albeit to a lesser extent than
in obese subjects (20, 61). However, there was no change in
adipose 11/3-HSD 1 activity, albeit that here we biopsied sc
fat from the gluteal region where previously we have biop¬
sied from the periumbilical region (20) and that relatively few
subjects (n — 17 of the original 50) returned for a biopsy.
Nonetheless, there is no trend to suggest that anything ap¬
proaching the approximately 3-fold differences observed in
obesity occur in lean hyperglycemic subjects. The mechanism
for tissue-specific dysregulation of 11/3-HSD 1 in obesity is
unknown (62, 63), but these data hint that hepatic dysregu¬
lation is related to insulin action, whereas adipose dysregu¬
lation is determined by some other factor associated with
obesity, or indeed may be a primary mechanism in obesity
(8, 64). We tested whether variations in A-ring reductase
activities might explain variation in hepatic 11/3-HSD 1 but
did not find any correlations. It is intriguing to speculate that
down-regulation of 11/3-HSD 1 is a compensatory mecha¬
nism to protect the liver from glucocorticoid excess in obesity
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and hyperglycemia; it may be that the lack of simultaneous
increase in adipose 11/3-HSD 1 explains why the group of
patients studied here are members of the unusual cohort with
impaired glucose tolerance without obesity. Importantly, in¬
hibition of 11/3-HSD 1 has been proposed as a therapy to
improve metabolic control in diabetes and obesity (29, 64);
these data suggest that sufficient 11 /3-HSD 1 activity exists in
patients with type 2 diabetes to make this strategy worth¬
while, although it remains to be seen whether inhibition in
liver and/or adipose tissue will be most influential.
Another factor that is important in determining the tissue
response to Cortisol is the expression and activity of glu¬
cocorticoid receptors, which is difficult to measure in vivo in
man. Studies comparing sensitivity to synthetic glucocorti¬
coid receptor agonists in different sites suggest that there can
be tissue-specific differences. For example, although sensi¬
tivity in skin correlates with that in lung (65), it may not
correlate with that in leukocytes (66) or in the HPA axis (67).
In this study, we show that dermal vascular sensitivity to
beclomethasone dipropionate is increased in patients with
glucose intolerance. Similar findings have been described in
hypertensive and insulin resistantmen (13,17). This provides
circumstantial evidence that glucocorticoid receptors are
more readily activated in dermal vessels, although there may
be confounding factors influencing the dermal blanching
response. Up-regulation of glucocorticoid receptor expres¬
sion has been implicated in the pathophysiology of insulin
resistance in animal models (68). Moreover, glucocorticoid
receptor mRNA levels in skeletal muscle are elevated in men
with insulin resistance (69, 70). These observations suggest
that therapeutic strategies to alter glucocorticoid action in
key insulin-sensitive target tissues are likely to be especially
beneficial in hyperglycemic patients.
In summary, we have demonstrated that patients with
type 2 diabetes or glucose intolerance exhibit abnormalities
in Cortisol action in the absence of hypertension or obesity.
These findings add further weight to the hypothesis that
abnormalities in Cortisol action may be a factor that links
insulin resistance, hypertension, glucose intolerance, and
obesity.
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Endothelium-derived hyperpolarizing factor and potassium use
different mechanisms to induce relaxation of human subcutaneous
resistance arteries
'C.-A. Mclntyre, 'C.H. Buckley, 'G.C. Jones, 'T.C. Sandeep, 'R.C. Andrews, 2A.I. Elliott,
3G.A. Gray, 'B.C. Williams, 2J.A. McKnight, B.R. Walker & * 'P.W.F. Hadoke
'Department of Medical Sciences, Western General Hospital, University of Edinburgh, Edinburgh; "Metabolic Unit, Western
General Hospital, University of Edinburgh, Edinburgh and "Department of Biomedical Sciences, Hugh Robson Building,
University of Edinburgh, Edinburgh
1 This investigation examined the hypothesis that release of K* accounts for EDHF activity by
comparing relaxant responses produced by ACh and KC1 in human subcutaneous resistance arteries.
2 Resistance arteries (internal diameter 244+ 12 ^m, n = 48) from human subcutaneous fat biopsies
were suspended in a wire myograph. Cumulative concentration-response curves were obtained for
ACh (10~9-3 x 10~5 M) and KC1 (2.5-25 mM) following contraction with noradrenaline (NA; 0.1 -
3 |/M).
3 ACh (Emax 99.07 + 9.61%; -LogIC50 7.03 ±0.22; n = 9) and KC1 (Emax 74.14 + 5.61%;
— LogIC50 2.12 + 0.07; n= 10)-induced relaxations were attenuated (PcO.0001) by removal of the
endothelium (Emax 8.21+5.39% and 11.56 + 8.49%, respectively; n — 6-7).
4 Indomethacin (10 /rM) did not alter ACh-induced relaxation whereas L-NOARG (100 /aM)
reduced this response (Emax 61.7±3.4%, PcO.OOOl; n = 6). The combination of ChTx (50 nM) and
apamin (30 nM) attenuated the L-NOARG-insensitive component of ACh-induced relaxation (Emax:
15.2+10.5%, PcO.002, n = 6) although these arteries retained the ability to relax in response to
100 nM SIN-1 (Emax 127.6± 13.0%, n = 3). Exposure to BaCl2 (30 yUM) and Ouabain (1 mM) did not
attenuate the l-NOARG resistant component of ACh-mediated relaxation (Emax, 76.09 + 8.92,
P = 0.16; n = 5).
5 KCl-mediated relaxation was unaffected by l-NOARG + indomethacin (Emax; 68.1+5.6%,
P = 0.33; n — 5) or the combination of l-NOARG/indomethacin/ChTx/apamin (Emax;
86.61 + 14.02%, F = 0.35; n = 6). In contrast, the combination of l-NOARG, indomethacin, ouabain
and BaCE abolished this response (Emax, 5.67 + 2.59%, P<0.0001, n = 6).
6 The characteristics of KCl-mediated relaxation differed from those of the nitric oxide/
prostaglandin-independent component of the response to ACh, and were endothelium-dependent,
indicating that K* does not act as an EDHF in human subcutaneous resistance arteries.
British Journal of Pharmacology (2001) 133, 902-908
Keywords: Endothelium-dependent relaxation; endothelium-derived hyperpolarizing factor; nitric oxide; potassium
channels; human resistance arteries
Abbreviations: ACh, acetylcholine; BSA, bovine serum albumin; ChTx, charybdotoxin; EDHF, endothelium-derived hyperpolar¬
izing factor; EDTA, ethylene diamine tetraacetic acid; F, Female; KPSS, high potassium physiological salt solution;
l-NOARG, NG-nitro-l-arginine; M, Male; NA, noradrenaline; NO, nitric oxide; PG, prostaglandin; PSS,
physiological salt solution; SIN-1, 3'-morpholinosydnonimine
Introduction
The vascular endothelium modulates agonist-dependent
relaxation by releasing substances such as nitric oxide (NO)
and prostaglandins (PGs) (Furchgott & Vanhoutte, 1989). In
some vessels, particularly those with a small diameter
(Shimokawa et al., 1996), a component of the endothelium-
dependent relaxation is insensitive to nitric oxide synthase
and cyclooxygenase inhibition (Nagao et al., 1992; Brandes et
al., 1997). This component appears to be mediated by
hyperpolarization of the vascular smooth muscle cells
(Brayden, 1990), suggesting the existence of a distinct
*Author for correspondence at: Department of Medical Sciences,
University of Edinburgh. Western General Hospital, Crewe Road,
Edinburgh, EH4 2XU; E-mail: phadoke@srvO.mcd.ed.ac.uk
endothelium-derived hyperpolarizing factor (EDHF) (Taylor
& Weston, 1988; Feletou & Vanhoutte, 1997).
The identity of EDHF has yet to be confirmed, although
activity of this factor has been attributed to epoxyeicosa-
trienoic acids (Hecker et al., 1994), endocannabinoids
(Randall et al., 1996), hydrogen peroxide (Matoba et al.,
2000) and the presence of myoendothelial gap junctions
(Chaytor et al., 1998). A recent study suggested that release
of K* into the myoendothelial space accounted for EDHF
activity in rat hepatic and mesenteric arteries (Edwards et al.,
1998). In this study, EDHF-mediated responses (but not
those to exogenous K ') were inhibited by using charybdo¬
toxin (ChTx) and apamin to block large (BKCa) and small
(SKCa) conductance calcium-activated potassium channels on
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the endothelium. In contrast, the combination of barium and
ouabain inhibited responses to Kl as well as to EDHF,
suggesting that both EDHF and K' cause smooth muscle
cell hyperpolarization through activation of inward rectifier
potassium channels (K[R) and Na +/K ' -ATPases. Subsequent
studies have, however, challenged the identification of K ^ as
EDHF by demonstrating differences in the characteristics of
EDHF and Kf-induced relaxation in rat mesenteric
(Doughty et al., 2000; Lacy et al., 2000), porcine coronary
and guinea-pig carotid arteries (Quignard et al., 1999).
Human resistance arteries have been used extensively to
examine the cardiovascular defects associated with the
development of a variety of different disease processes. A
large component of endothelium-dependent relaxation in
these arteries is mediated by EDHF (Nakashima et al.,
1993; Urakami-Harasawa et al., 1997; Wallerstedt &
Bodelsson, 1997) but the mechanism of this response has
not been elucidated. This investigation aimed to determine
whether K + accounted for EDHF activity in human
subcutaneous resistance arteries by comparing the NO-
independent, PG-independent component of ACh-induced




Biopsies of gluteal skin and subcutaneous fat
(2 cm x 1 cm x 1 cm) were obtained under local anaesthesia
(2% lignocaine hydrochloride; Astra, Herts, U.K.) from 26
healthy volunteers (20 Male, six Female; age 46 + 3 years).
Written informed consent and approval from the Lothian
Research Ethics Committee were obtained. Each biopsy was
immersed immediately in cold (4°C) physiological salt
solution (PSS) of the following composition (mM): NaCl
119, KC1 4.7, CaCE 2.5, MgS04 1.17, NaHCCE 24, KH2P04
1.18, K2EDTA 0.026 and D-glucose, 5.5. Dissection of these
biopsies provided 48 resistance artery sections (mean internal
diameter 244+12 /(m) for pharmacological analysis. Ring
segments of these arteries, 2 mm in length, were suspended
on two 40 pm stainless steel wires in a small vessel myograph
for measurement of isometric force. The myograph bath
contained PSS maintained at 37°C and perfused with 95%
02/5% C02. Following an equilibration period of 30 min,
the resting tension-internal circumference relationship was
determined by stepwise radial stretching and the vessels were
set to their optimum resting level (0.9 Lum, where L,0o is the
internal circumference the vessels would have when relaxed
and subjected to a pressure of 100 mmHg; Mulvany &
Halpern, 1977). After equilibration for a further 30 min,
vessel viability was assessed using a standard start procedure
(Aalkjaer et al., 1987). This consisted of five consecutive
stimulations lasting 3 min, each followed by a 5 min washout
period. The first, second and fifth contractions were
produced using a high (125 mM) potassium solution (KPSS;
made by equimolar substitution of KC1 for NaCl in PSS)
containing 10 pM noradrenaline (NA). The third was
obtained with NA (10 pM) alone and the fourth with KPSS
alone. The functional integrity of the endothelium was
assessed by adding ACh (0.1-10/(M) to vessels contracted
with sufficient NA (0.1 -3 pM) to produce 60-80% of the
response KPSS.
The contribution of EDHF to ACh-mediated relaxation
Sixteen resistance arteries (internal diameter 183+15 pm)
from 14 male subjects (age 57+ 12 years) were used for this
part of the investigation. After the standard start procedure,
a cumulative concentration-response curve to ACh (0.001 -
300 pM) was obtained following precontraction with a sub-
maximal concentration (0.1—3 pM) of NA (to produce a
contraction of ~60-80% the maximum response to KPSS).
The artery was washed with PSS (37°C) and the procedure
repeated following incubation with either; (a) indomethacin
(10 pM for 45 min, n — 6), (b) NG-nitro-l-Arginine (l-
NOARG; 100 pM for 45 min, n = 6), or (c) l-NOARG
(100 pM for 45 min), plus charybdotoxin (ChTx; 50 nM for
10 min) and apamin (30 nM for 10 min, n = 6). Arteries were
exposed to only one antagonist except for two of those
initially incubated with indomethacin which were subse¬
quently exposed to the combination l-NOARG + ChTx + a-
pamin. Three of the arteries incubated with l-
NOARG +ChTx + apamin, were also exposed to a single
concentration (100 pM) of the exogenous NO donor, 3'-
morpholinosydnonimine (S1N-1) once the concentration-
response curve to ACh had been completed.
Comparison of K+-induced relaxation with the EDHF-
mediated component of ACh-evoked relaxation
Thirty-two resistance arteries (internal diameter 273+ 14 pm)
obtained from 12 subjects (six male, six female; age
32 + 4 years) were used for this part of the investigation.
The endothelium was removed from some arteries by rubbing
the luminal surface with a single hair. Cumulative concentra¬
tion-response curves were obtained using ACh (0.001 —
300 pM) and KC1 (2.5-25 mM), in intact (w = 9-IO) and
denuded (n = 6- 7) arteries, after pre-contraction (to produce
a contraction of ~60-80% the maximum response to KPSS)
with a sub-maximal concentration of NA (0.1-3yuM).
Responses to KC1 were repeated following incubation with
a combination of either (a) l-NOARG (100 pM) + indo¬
methacin (10 pM; 45 min, n = 5); (b) l-NOARG
(100 /rM) +indomethacin (10 pM for 45 min) plus charybdo¬
toxin (ChTx; 50 nM for 10 min) and apamin (30 nM for
10 min, n = 6) or (c) l-NOARG (100 /(M) +indomethacin
(10 ^M for 45 min) plus BaCE (30 pM for 10 min) and
ouabain (1 mm for 10 min, n = 6). Concentration-response
curves to ACh were also produced in the arteries exposed to
the combinations described for groups (b) and (c).
Drugs
All salts were obtained from BDH Laboratory supplies,
(Poole, Dorset, U.K). All drugs were purchased from Sigma,
(Poole, Dorset, U.K.), except for 3' morpholinosydnonimine,
charybdotoxin and apamin which were obtained from Alexis
Corporation Ltd (Nottingham, U.K.). Acetylcholine chloride,
ouabain, barium chloride and noradrenaline bitartrate were
dissolved in distilled water; indomethacin in 1.5 x 10~"' M
Na2COi (final bath concentration of Na2CO? did not exceed
0.015 mM) and apamin in 0.05 M acetic acid (final bath
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concentration of acetic acid did not exceed 0.15 mM).
Charybdotoxin was dissolved in a Tris buffer (10 mM,
pH 7.5) containing 0.1% BSA, 100 mM NaCl and 1 mM
EDTA (final bath concentrations of NaCl and EDTA did not
exceed 5 and 0.05 mM, respectively). 0.01% BSA was added
to the myograph chamber before applying the toxins. Stock
solutions were stored at — 20°C, thawed as required and
subsequent dilutions made in distilled water. The concentra¬
tions quoted are final molar concentrations in the organ bath.
Statistics
All values are presented as mean ± standard error mean
(s.e.mean) from n experiments (where n represents the
number of subjects). Relaxation responses to ACh and KC1
are expressed as a percentage of the initial NA-induced
precontraction. The concentration of agonist required to
produce 50% of the maximum response (IC50) was obtained
by fitting the Hill equation to the data using curve fitting
software (Fig. P, Biosoft, Cambridge, U.K.) and is expressed
as the negative logarithm of the IC5n (—logIC5o). Compar¬
isons of maximum relaxation and — logIC50 values were
made using Student's paired or unpaired /-test, as appro¬
priate, and significance was assumed when PcO.05.
Results
The contribution of EDHF to ACh-induced relaxation
ACh caused approximately 80-100% relaxation in intact
human subcutaneous resistance arteries following pre-con-
traction with a sub-maximal concentration of NA (0.1 — 3 pM;
Figure 1). None of the inhibitors caused an increase in either
the resting tone of the arteries or the response to the pre¬
contracting concentration of NA.
Incubation with indomethacin (Figure la) did not alter the
magnitude (Emax, 97.56±1.83%, n — 6) or sensitivity
(—logIC5o, 7.24 + 0.20, n = 6) of ACh-evoked relaxation when
compared with controls (90.80±4.69%, P = 0.18 and
7.23 ±0.25 P — 0.96, respectively; n = 6). In contrast, exposure
to l-NOARG (Figure lb) resulted in a significant
(P< 0.0001), although not total, reduction in maximum
relaxation (61.68 + 3.38%, n = 6) compared with controls
(91.55 ±3.95%, n = 6) with a corresponding reduction in
sensitivity (—logIC50, 6.41+0.10 vs 7.19 + 0.13, respectively,
P< 0.005; n = 6). Arteries exposed to the combination of L-
NOARG plus ChTx and apamin demonstrated almost total
attenuation of ACh-mediated relaxation (Emax, 15.2+10.5%,
n = 6) despite producing a full concentration-response curve
before exposure to these inhibitors (Emax, 92.59 ±3.65%,
P< 0.002; — logIC50, 7.70 ±0.30, n = 6). These arteries main¬
tained their ability to relax in response to exogenous NO, as
SIN-1 (100 /im) caused complete relaxation in the presence of
l-NOARG, "ChTx and apamin (127.6± 13.0%; n — 3).
Comparison of K+ -induced relaxation with the EDHF-
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Figure 1 Cumulative concentration-response curves to ACh (10~9-
3x 10~5 M) before and after incubation with the following combina¬
tion of inhbitors (a) the cyclooxygenase inhibitor indomethacin
(10 fiM for 45 min), (b) the NO synthase inhibitor l-NOARG
(100 pM for 45 min) or (c) l-NOARG (100 /tM for 45 min) plus the
K' channel blockers ChTx (50 nM for 10 min) and apamin (30 nM
for 10 min). Results are shown as mean + s.e.mean, for (n) arteries.
Relaxation responses were obtained using potassium in 10
arteries with an intact endothelium and responses to ACh
were also tested in nine of these. Typical relaxation responses
were obtained with ACh (Emax, 99.07±9.61%; — logIC50,
7.03 ±0.224; n = 9), which produced a sustained concentra¬
tion-dependent relaxation (Figure 2). In contrast, although
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Figure 2 Comparison of ACh- and KCl-mediated relaxation, (a) Representative traces showing (i) relaxation responses of an
intact artery to acetylcholine and K.C1 and (ii) the effect of removal of the endothelium on these responses, (b) Cumulative
concentration-response curves for (i) acetylcholine and (ii) KC1 obtained in arteries with and without an intact endothelium or in the
presence of L-NOARG (100 jim) and indomethacin (10 /tM) alone or combined with either ChTx (50 nM) and apamin (30 nM) or
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potassium also relaxed these resistance arteries (Emax,
74.14 + 5.61%, IC50, 6.09± 1.17 mm; -loglC5(), 2.12±0.07,
n =10), the response to this compound (Figure 2) was
inconsistent and was superseded by a reversal of the initial
relaxation response as the concentration of KC1 rose (>15-
25 mm). As expected, removal of the endothelium virtually
abolished responses to ACh (13.34 + 6.16%, n = 7, P<0.0001)
but also abolished potassium-mediated relaxation (Emax,
15.53±9.18%, n = 6, /><0.001) (Figure 2).
The potassium-induced relaxation was not affected by
incubation with l-NOARG and indomethacin (Emax,
68.1 ±5.6%, P = 0.51; IC50, 5.74±1.86mm; -logIC50,
2.34 + 0.15, P = 0.33, n = 5) or with the combination of l-
NOARG with indomethacin, ChTx and apamin (Emax,
86.61 ± 14.02%; F = 0.35; IC50, 6.78 ±2.90 mm; -logIC50,
2.68 ±0.52, P = 0.23, n = 6). Indeed the maximum relaxation
evoked by potassium tended to be larger in the latter group.
Exposure of vessels to the combination of BaCE and ouabain
resulted in an increase in basal tone of 0.40 ±0.17 mN
(equivalent to 16.6 ±7.4% of the maximum response to
KPSS; tt=ll). This tended to be larger in arteries used for
producing responses to ACh (22.4 ±17.6% KPSS; n = 5) than
in those subsequently exposed to KC1 (12.0 ±5.6% KPSS;
n = 6). Once this contraction had stabilized, vessels were
contracted with sufficient NA (0.1-3 /im) to produce a
contraction 60-80% the size of the maximum response to
KPSS (responses to ACh obtained in one artery were
discarded as the combination of BaCE plus ouabain
produced a contraction equivalent to 80% of the response
to KPSS). Potassium-induced relaxation was totally abolished
by incubation with the combination of l-NOARG with
indomethacin, BaCE and ouabain (5.7 ±2.6%; n = 6;
PcO.0001). In contrast, a considerable ACh-induced relaxa¬
tion remained evident following exposure to this combination
of inhibitors although there was a trend towards reduced
relaxation that did not achieve significance (Emax,
76.09 ±8.92%; P = 0.16; -logIC50, 6.47±0.23; P = 0.11,
n — 5).
Discussion
Previous investigations have demonstrated that an NO/PG-
independent component of ACh-evoked relaxation is
mediated by EDHF (Nakashima et al., 1993; Urakami-
Harasawa et al., 1997; Wallerstedt & Bodelsson, 1997).
Studies in arteries from experimental animals have suggested
that K' accounts for EDHF activity (Edwards et al., 1998).
In order to clarify whether K' acts as an EDHF in human
arteries, this investigation compared potassium-induced and
EDHF-induced relaxation responses in subcutaneous resis¬
tance arteries isolated from biopsies of gluteal fat. The
characteristics of potassium-induced relaxation were different
from the EDHF-mediated response and, of significance, were
abolished by removal of the endothelium. Taken together,
this suggests that release of endothelium-derived K+ into the
myoendothelial space does not account for EDHF activity in
human subcutaneous resistance arteries.
Comparison with previous investigations indicates that the
ChTx/ apamin-sensitive, NO-independent component of
ACh-evoked relaxation is mediated by EDHF. In rat
mesenteric arteries contracted with an a-adrenoceptor
agonist, the NO-independent component of ACh-mediated
relaxation was caused by smooth muscle cell hyperpolarisa-
tion (Plane & Garland, 1996). This response is abolished by
the combination of ChTx and apamin (Zygmunt &
Hogestatt, 1996), probably by inhibition of BKCa and SKCa
on the endothelium (Doughty et al., 1999). The persistence of
a significant NO-independent (EDHF-mediated) relaxation in
response to ACh is consistent with previous studies of human
subcutaneous (Woolfson & Poston, 1990; Deng et al., 1995;
Hillier et al., 1998), omental (Ohlmann et al., 1997),
gastroepiploic (Urakami-Harasawa et al., 1997), coronary
(Nakashima et al., 1993) and pial (Petersson et al., 1995)
arteries. Incomplete inhibition is unlikely to account for
residual relaxation as a lower concentration of l-NOARG
(3 x 10~5 m) abolished ACh-induced, endothelium-dependent
relaxation in the rat aorta, pulmonary and iliac arteries
(Nagao et a!., 1992). Furthermore, incomplete inhibition of
ACh-mediated relaxation was not overcome by increasing the
concentration of l-NOARG (100-300 fiM; Brandes et al.,
1997) or by the combined application of two different l-
arginine analogues (Plane & Garland, 1996; Plane et al.,
1997). The failure of indomethacin to attenuate ACh-
mediated relaxation in the present study confirms that
prostanoids do not contribute to this response in the human
gluteal, subcutaneous resistance artery. This is also consistent
with previous studies, in our own and other laboratories, in
which indomethacin was shown to have no effect on ACh-or
bradykinin-mediated relaxation of human gluteal resistance
arteries when applied alone or in combination with NO
synthase inhibitors (Hillier et al., 1998; Buckley et al., 1999).
The mechanism of endothelium-dependent relaxation of
human resistance arteries may depend upon the origin of a
particular vessel, however, as bradykinin-mediated relaxation
of human omental arteries has an indomethacin-sensitive
component which becomes evident in the presence of an NO
inhibitor (Ohlmann et al., 1997).
The ability of exogenous potassium to relax human gluteal
resistance arteries compares with results obtained in
resistance arteries from experimental animals (Edwards et
al., 1998); Quignard et al., 1999; Doughty et al., 2000; Lacy
et al., 2000). The identification of K+ as an. EDHF in the
earlier study was based on a comparison with the NO/PG-
independent component of the response to ACh (Edwards et
al., 1998); responses to both ACh and exogenous K* were
abolished by inhibition of KiR and Na + /K* ATPase,
indicating a common mechanism. Exogenous K\ however,
produced an endothelium-independent hyperpolarization of
smooth muscle cells that was unaffected by the combination
of ChTx and apamin. This is consistent with ACh stimulating
release of Kf from endothelial cells via ChTx/ apamin-
sensitive channels. In the present study, however, the
characteristics of potassium-induced and EDHF-mediated
relaxation were different: whereas the ACh-induced relaxa¬
tion was highly reproducible and sustained, relaxation
responses to potassium were more variable and reversed
readily at higher K ' concentrations. This is consistent with a
recent study showing that exogenous K+ will only produce, a
reproducible, sustained relaxation of rat resistance arteries if
they are bathed in a Kreb's solution lacking K+ ions (Lacy et
al., 2000). More striking, however, was the demonstration
that, as in the rat mesenteric (Lacy et al., 2000) and renal
(Jiang & Dusting, 2001) arteries, potassium-mediated relaxa-
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tion of human subcutaneous arteries was abolished by
removal of the endothelium. This indicates an obligatory
role for the endothelium in K ^-mediated relaxation, suggest¬
ing that it may be mediated by a further endothelium-derived
factor or is dependent upon myoendothelial gap junctions
(Doughty et al., 2000). Finally, the inability of barium and
ouabain to inhibit ACh-mediated relaxation, whilst abolish¬
ing responses to potassium, indicated that these compounds
caused relaxation via different mechanisms. This observation
contrasts with the study by Edwards et al. (1998) but is
consistent with data obtained in subsequent investigations
(Quignard et al., 1999; Lacy et al., 2000). The ability of K +
to relax only a proportion (— 30%) of rat mesenteric
resistance arteries in one study (Doughty et al., 2000)
suggests that this response may even vary in different regions
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Glucocorticoids and insulin resistance: old
hormones, new targets
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ABSTRACT
Insulin resistance has been proposed as a mediator of the association between risk factors for
cardiovascular disease in the population. The clinical syndrome of glucocorticoid excess
(Cushing's syndrome) is associated with glucose intolerance, obesity and hypertension. By
opposing the actions of insulin, glucocorticoids could contribute to insulin resistance and its
association with other cardiovascular risk factors. In this review, we describe briefly the known
mechanisms of insulin resistance and highlight the potential mechanisms for the effect of
glucocorticoids. We then discuss factors which modulate the influence of glucocorticoids on
insulin sensitivity; this highlights a novel therapeutic strategy to manipulate glucocorticoid
action which may prove to be a useful tool in treating subjects with insulin resistance. Finally, we
describe evidence from human studies that glucocorticoids make an important contribution to
the pathophysiology of insulin resistance in the population.
INTRODUCTION
Risk factors for cardiovascular disease include hyper¬
tension, glucose intolerance and dyslipidaemia. There is
evidence that these abnormalities are associated with each
other more frequently than expected by chance: this
cluster has been referred to as 'Reaven's Syndrome X'
[1], or the 'Metabolic Syndrome'. In the last decade,
further associations with this syndrome have been
described, including low birthweight [2,3], central obes¬
ity [4], abnormalities of thrombosis and fibrinolysis,
impaired endothelium-dependent vasodilatation [5], re¬
productive dysfunction in women [6] and insulin re¬
sistance. Insulin resistance can be defined as impaired
sensitivity to the effects of insulin on carbohydrate
metabolism. The pathophysiology of the metabolic
syndrome remains poorly understood, but many have
suggested mechanisms whereby insulin resistance could
underlie the association between all other features.
Indeed, some go as far as referring to this cluster of
abnormalities as the 'Insulin Resistance Syndrome'.
Glucocorticoid hormones (mainly Cortisol in man;
corticosterone in rodents) are produced in the adrenal
cortex under the control of the hypothalamic-
pituitary-adrenal axis. They play a key role in regulating
salt and water metabolism, blood pressure, immune
function and metabolism. In essence, glucocorticoids are
most important at times of stress, when they provide a
longer-term signal to damp many of the acute responses
to illness and 're-set' metabolism in favour of providing
substrates for oxidative metabolism. The importance of
glucocorticoids is exemplified in clinical syndromes of
deficiency (Addison's disease or hypopituitarism) and
excess (Cushing's syndrome). Cortisol deficiency is
characterized by postural hypotension, weight loss and
hypoglycaemia; Cortisol excess is characterized by hy¬
pertension, central obesity and glucose intolerance. Part
of the mechanism for these effects of Cortisol depends on
opposing the actions of insulin, i.e. inducing a state of
insulin resistance.
In this review, we describe briefly the known mechan¬
isms of insulin resistance and highlight the potential
Key words: adipose tissue, glucocorticoid hormones, glucocorticoid receptors, gluconeogenesis, hydroxysteroid dehydrogenases,
insulin.
Abbreviations: ACTH, adrenocorticotrophic hormone; 11/f-HSD, 11/f-hydroxysteroid dehydrogenase; CBG, Cortisol binding
globulin; PEP-CK, phosphoenolpyruvate carboxykinase.
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relevance of glucocorticoids. We then discuss factors
which modulate the influence of glucocorticoids on
insulin sensitivity; this highlights a novel therapeutic
strategy to manipulate glucocorticoid action which may
prove useful in treating subjects with insulin resistance.
Finally, we describe evidence from human studies that
glucocorticoids make an important contribution to the
pathophysiology of insulin resistance in subjects with the
metabolic syndrome.
HOW DO GLUCOCORTICOIDS INDUCE
INSULIN RESISTANCE?
Insulin is synthesized and released from pancreatic //-
cells in response to elevations in plasma glucose concen¬
trations, specific amino acids (e.g. arginine), potassium
and parasympathetic nervous system tone. It acts on a
cell-surface receptor comprising two a and two //
subunits which signal through phosphorylation of insulin
receptor substrate proteins. Its actions can be divided
into regulation of long-term growth and short-term
metabolism; these are mediated by different intracellular
second messenger signalling pathways [7],
The term 'insulin resistance' is usually used to refer to
the acute regulation of carbohydrate metabolism by
insulin. It has been quantified by numerous methods,
usually involving measurement of the plasma insulin
concentration relative to plasma glucose concentration,
or the amount of glucose infused to maintain euglycaemia
at a fixed insulin concentration [8]. Insulin resistance may
reflect impaired insulin-dependent down-regulation of
hepatic glucose release and/or impaired insulin-mediated
increase in peripheral glucose uptake. Which of these
variables is most important in the metabolic syndrome
remains controversial, and there is probably a con¬
tribution from each. Enhanced hepatic glucose release
may be most important in subjects with glucose in¬
tolerance [9] whereas impaired peripheral glucose uptake
may be the major defect in subjects with normal glucose
tolerance [10]. In patients with severe insulin resistance,
more than 50 mutations of the insulin receptor and three
mutations of the insulin receptor substrate-1 protein have
been characterized [7,11], However, these mutations are
rare and do not explain insulin resistance in the vast
majority of patients.
Glucocorticoids are so named because it was recog¬
nized long ago that one of their actions is on carbohydrate
metabolism [12]. In addition to the insulin resistance that
characterizes Cushing's syndrome, manipulation of Cor¬
tisol levels within the physiological range also alters
insulin sensitivity in man [13]. Although subject to the
limitations of measurement of hepatic glucose output in
man, the effect of glucocorticoids in vivo appears to
include both impaired insulin-dependent glucose uptake
in the periphery and enhanced gluconeogenesis in the
liver [14,15]. In addition, glucocorticoids oppose other
actions of insulin, including its effect to reduce central
appetite [16]. Numerous effects of glucocorticoids have
been demonstrated in vitro that could contribute to these
effects on carbohydrate metabolism. These are sum¬
marized below.
In addition to their effects on insulin sensitivity,
glucocorticoids inhibit insulin secretion from pancreatic
//-cells [17-19], On the other hand, central actions of
glucocorticoids may enhance vagal stimulation of insulin
secretion [20]. The balance of these effects may be
important in determining whether insulin resistance is
accompanied by compensatory hyperinsulinaemia or
hyperglycemia, and may explain in part why only some
patients with Cushing's syndrome develop glucose in¬
tolerance [21].
Generalized abnormalities in target organ
responses to insulin
Numerous studies have examined whether gluco¬
corticoids have a global effect to inhibit insulin receptor
binding or second messenger signalling but no consensus
has emerged. Studies in man have found that gluco¬
corticoids can decrease insulin receptor binding affinity
without decreasing insulin receptor numbers [22,23],
decrease receptor number and affinity [24], have no effect
on receptor affinity or number [25] or increase receptor
number without affecting affinity [15]. Furthermore,
where in vivo and in vitro studies have been carried out
simultaneously, they have not been in agreement [23,26].
It seems reasonable to conclude that the small changes in
insulin receptor number or binding affinity are not
sufficient to explain the degree of insulin resistance seen
with glucocorticoids. Moreover, the discrepancy between
in vitro and in vivo observations is likely to reflect
difficulty in controlling for indirect, potentially com¬
pensatory, effects of glucocorticoids. For example, very
few experiments have controlled for the hyperinsu¬
linaemia induced by glucocorticoids. When compen¬
satory hyperinsulinaemia was prevented by streptozo-
tocin treatment in rats, glucocorticoid-induced changes
in insulin receptor number, insulin receptor substrate-1
(IRS-1) and phosphorylation were abolished [27].
Tissue-specific determinants of insulin
response
The effect of insulin receptor activation differs between
tissues, since it depends primarily on altered activity of
glucose transporters in peripheral tissues such as fat and
skeletal muscle and enzymes influencing glycogen
storage, glycolysis and gluconeogenesis in the liver. The
effects of glucocorticoids on these pathways are illus¬
trated in Figures 1 and 2.
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FigureH Effects of glucocorticoids on peripheral glucose
uptake
A schematic lor an archetypal insulin-sensitive cell is shown. In adipocytes,
lipogenic pathways predominate whereas in skeletal muscle either oxidative
metabolism (ol pyruvate or free fatty acids) or glycogen synthesis predominates,
GLUT 4 is expressed principally in skeletal muscle and lipoprotein lipase principally
in adipose tissue. Actions of glucocorticoids (grey arrows) and insulin (striped
arrows) are shown either as positive (arrow up) or negative (arrow down) effects.
The major effects of glucocorticoids may be to reduce insulin-mediated
vasodilatation, reduce translocation of GLUT 4 to the cell surface and enhance
lipolysis, perhaps by inducing local synthesis of adrenaline (see text), thereby
increasing free fatty acid competition with pyruvate for mitochondrial oxidative
metabolism.
Metabolic determinants of peripheral glucose uptake
The first determinant of insulin-dependent peripheral
glucose uptake is the availability on the cell membrane of
the GLUT 4 transporter, which is expressed mainly in
skeletal muscle and is increased by insulin. To date,
mutations in GLUT 4 have not been associated with
insulin resistance [28], The expression of GLUT 4 is, in
fact, increased by glucocorticoids in skeletal muscle and
adipose tissue. However, translocation of GLUT 4 to the
cell surface in response to insulin and to other stimuli
(e.g. hypoxia) is inhibited in the presence of gluco¬
corticoids [29-33].
The rate of glucose transport also depends on the
gradient of glucose concentration across the cell mem¬
brane. This is influenced both by local delivery of glucose,
determined in euglycaemic conditions by blood flow,
and by the rate of removal of glucose by oxidation of
pyruvate inside the cell membrane (Figure 1). Oxidation
of pyruvate is influenced by competing substrates in¬
cluding non-esterified free fatty acids. Acute admin¬
istration of free fatty acids results in insulin resistance
[34]. Free fatty acids are increased in some subjects with
the metabolic syndrome, especially those who are obese.
Acipimox and nicotinic acid, which lower free fatty acid
concentrations, also increase insulin sensitivity [35],
However, chronic administration of free fatty acids does
not induce insulin resistance [36], and free fatty acids may
be elevated in insulin-resistant subjects because of im¬
paired insulin-dependent down-regulation of lipolysis.
Thus, as for other associations of insulin resistance,
elevated free fatty acids could both result from, and
contribute to, impaired insulin-dependent glucose
uptake.
Increased lipolysis may be important in gluco-
corticoid-induced insulin resistance, since this is reversed
by inhibiting lipolysis [37] or lipid oxidation [38] (Figure
1). Again, however, cause and effect are difficult to
elucidate because free fatty acids have been reported to
influence glucocorticoid receptor binding [39,40]. In¬
creased lipolysis induced by glucocorticoids may be
mediated indirectly, by up-regulation of phenyl-
ethanolamine A-methyltransferase [41], an enzyme ex¬
pressed in skeletal muscle that converts noradrenaline
into adrenaline. Inhibition of phenylethanolamine N-
methyltransferase ameliorates glucocorticoid-induced
insulin resistance [41]. Alternatively, effects on lipolysis
may be mediated via up-regulation of peroxisome-
proliferator-activated y receptors, for which the insulin-
sensitizing thiazolidinediones are exogenous ligands but
endogenous ligands have yet to be identified [42],
Finally, glucocorticoids may increase circulating free
fatty acids by inhibiting lipoprotein lipase (Figure 1) [43].
Non-metabolic determinants of peripheral glucose uptake
Recent work by Baron et al. [44] has demonstrated that
insulin induces endothelium-dependent vasodilatation,
probably mediated by increased nitric oxide synthesis or
action. It has been suggested that this action contributes
to enhanced glucose uptake in response to insulin and
other vasodilator stimuli, particularly in skeletal muscle.
Moreover, this model suggests that the impaired endo¬
thelium-dependent vasodilatation in subjects with
features of the metabolic syndrome (hypercholesterol-
aemia [45], hypertension [46] or diabetes mellitus) could
both result from, and contribute to, impaired insulin
action in skeletal muscle. However, others have found
that increased blood flow and glucose uptake during
hyperinsulinaemia are dissociated in man [47].
Glucocorticoids may also influence this determinant of
insulin sensitivity. We have recently shown that gluco¬
corticoids impair endothelium-dependent vasodilatation
in humans in vivo ([48]; G. Mangos, B. Walker, J. Kelly,
D.Webb and J. Whitworth, unpublished work) and
therefore, if this is an important mechanism dictating
glucose delivery, it may also be a site where insulin action
is counterbalanced by glucocorticoids (Figure 1).
Hepatic glucose release
The pathways determining the balance between glycogen
synthesis and glucose oxidation versus glycogenolysis
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Gluconeogenesis Glycolysis
Citric acid cycle Lactate
Figurc-2 Effects of glucocorticoids on hepatic glucose meta¬
bolism
The principal metabolic fates of glucose in the liver are shown. Actions of
glucocorticoids (grey arrows) and insulin (striped arrows) are shown either as
positive (arrow up) or negative (arrow down) effects. In some respects, insulin and
glucocorticoids oppose each other's actions, particularly on gluconeogenesis (PEP-
CK) and release of glucose from glucose 6-phosphate. In other respects, however,
insulin and glucocorticoids do not oppose each other, especially in promoting
oxidative glycolysis and increasing turnover between glucose 6-phosphate and
glycogen.
and gluconeogenesis are summarized in Figure 2. Ab¬
normalities in hepatic glucose release aremost likely to be
manifest as increased fasting plasma glucose, as observed
in Type II diabetes mellitus but not always in association
with other features of the metabolic syndrome. Until
very recent advances in stable isotope methodology, it
was more difficult to measure hepatic than peripheral
glucose metabolism in man and the mechanisms of
hepatic insulin resistance remain obscure. One element of
insulin signalling which may be specific to the liver, and
which has not been accounted for in previous human
studies, is the importance of insulin pulsatility [49]. Like
other peptide receptors, the insulin receptor responds to
specific patterns of change in insulin concentration as
well as to the absolute level. The pulsatile pattern of
insulin release is altered at an early stage in dysfunction of
the pancreatic //-cell.
In the liver, contrasting effects of insulin and gluco¬
corticoids are well-characterized in animal models [12]
(Figure 2). A key effect appears to be the counter-
regulation by insulin and glucocorticoids of the rate-
limiting enzyme in gluconeogenesis, phosphoenol-
pyruvate carboxykinase (PEP-CK) [50]. However, there
is a conflicting literature concerning the effects of
glucocorticoids on hepatic glucose metabolism in man,
which has been reported to be increased [14,25] or not
affected [51,52]. These differences may reflect the diffi¬
culties of measurement in man, rather than any true
discrepancy between species. Specifically, they could be
accounted for by increased glucose/glucose 6-phosphate
cycling, which confounds many of the tracer measure¬
ments of hepatic glucose output. Glucocorticoid effects
on insulin pulsatility have yet to be reported, although as
described above, glucocorticoids do influence /? ceil
function.
FACTORS WHICH MODULATE THE EFFECT
OF GLUCOCORTICOIDS ON INSULIN
SENSITIVITY
Having described the numerous potential sites of action
of glucocorticoids on insulin sensitivity, we will now
address the importance of altered glucocorticoid action in
insulin resistance. This requires an understanding of the
factors which modulate glucocorticoid action, which are
shown in Figure 3.
Plasma Cortisol concentrations
An important determinant of glucocorticoid action is the
circulating concentration of Cortisol. This is influenced
both by the rate of Cortisol secretion from the adrenal
cortex, controlled principally by adrenocorticotrophic
hormone (ACTH), and by the metabolic clearance rate of
Cortisol. Cortisol circulates in plasma in three states:
5-10% circulates unbound, being 'free' to cross cell
membranes and interact with receptors; 70-75% is
bound to corticosteroid binding globulin (CBG); and
15-20% is bound to albumin. CBG and albumin there¬
fore act to buffer the free Cortisol concentration, but
these are saturated within the high physiological range so
that there are large excursions in free plasma Cortisol
concentrations between peaks (in the morning in man
and during stress) and troughs (at night in man).
Tissue sensitivity to Cortisol
In addition to the influence of changes in circulating
Cortisol levels, the last decade has seen the recognition of
the importance of tissue-specific variations in the mech¬
anisms dictating target organ sensitivity to gluco¬
corticoids. Cortisol can activate either glucocorticoid
(type 2 corticosteroid) or mineralocorticoid (type 1
corticosteroid) receptors, and indeed has higher affinity
for the latter [53]. Glucocorticoid receptors are more
widely distributed and act as high-capacity, low-affinity
receptors that are occupied mostly during the circadian
peak of plasma Cortisol levels in the morning in man. In
contrast, mineralocorticoid receptors have a more re¬
stricted localization. At some sites, e.g. in hippocampus
and hypothalamus, they act as low-capacity, high-affinity
receptors that are fully occupied by Cortisol during the
circadian peak, but variably occupied during the noc¬
turnal trough of Cortisol secretion in man, and may be
involved in negative-feedback control of the hypothal-
amic-pituitary-adrenal axis [54]. At other sites, e.g. in
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Figure 3 Factors determining glucocorticoid action
Schematic indicates the hypothalamicnpi tuitarynadrenal axis controlling secretion ol both active glucocorticoid (Cortisol) and inactive cortisone. These steroids circulate
in similar iree concentrations although free Cortisol is in equilibrium with a pool of Cortisol bound to CBG and albumin. Also shown is a schematic target cell, in which
interconversion of Cortisol and cortisone by ll/7-HSDs dictates access of glucocorticoid to receptors (A) and subsequent regulation of target genes, including those
responsible for negative feedback. CAR. corticotrophin-releasing hormone.
distal nephron, sweat glands and colon, they do not bind
Cortisol and act as receptors for the much lower plasma
concentrations of aldosterone, thereby regulating salt
balance [55],
For some time, it was a paradox that mineralocorticoid
receptors could bind Cortisol at some sites but not at
others. This paradox was explained by the activity at
aldosterone target sites of an enzyme, ll//-hydroxy-
steroid dehydrogenase type 2 (11//-HSD2), which in¬
activates Cortisol by converting it into the metabolite
cortisone. When this mechanism is defective, as in a rare
congenital syndrome of 11/7-HSD2 mutations [56], or
after administration of the 11//-HSD inhibitor liquorice
[57], then Cortisol gains inappropriate access to mineralo¬
corticoid receptors and induces sodium retention, hypo-
kalaemia and hypertension [58,59].
This model of enzyme-mediated regulation of ligand
access to intracellular receptors is not unique to mineralo¬
corticoid receptors. For example, thyroxine is also
activated in target tissues to tri-iodothyronine by 5'-
monodeiodinases, testosterone is activated by 5z-re-
ductase to dihydrotestosterone, and similar mechanisms
influence activation of vitamin D and retinoid receptors
[60]. Very recently it has emerged that the access of
Cortisol to glucocorticoid receptors is also regulated by
an enzyme, and that this is relevant to the effects of
Cortisol on insulin sensitivity.
Modulation of insulin sensitivity by 11 (1-HSD
type I
Before the cloning of 11/7-HSD2 [61,62], which catalyses
the inactivation of Cortisol to cortisone, a different
isoenzyme (11/7-HSD type 1; 11//-HSD1) had been
cloned [63], 11/7-FISD1 catalyses the same dehydrogenase
reaction in solution in vitro, but is now recognized to
function predominantly as a reductase, re-activating
cortisone to Cortisol in many tissues, including in whole
cells in culture [64-68], in perfused organs [69] and in
vivo in man [70]. 11//-HSD1 is widely distributed,
including in liver, adipose tissue and skeletal muscle. We
hypothesize that its function in liver is to ensure adequate
Figured Contrasting influence of 11|3-HSDs on Cortisol
sensitivity in liver and kidney
Predominant conversion ol Cortisol into cortisone by the dehydrogenase II/7-HSD2
in kidney results in protection of local mineralocorticoid receptors (MA).
Predominant conversion of cortisone into Cortisol by the reductase II/7-HSDI in
liver results in enhanced activation of glucocorticoid receptors (GA).
activation of low-affinity glucocorticoid receptors, by re¬
activating cortisone into Cortisol (Figure 4). The evidence
given below supports this hypothesis.
1. Circulating levels of cortisone in man are approxi¬
mately 50 nM, and are not protein bound or subject to
circadian variation [70]. This compares with free plasma
Cortisol concentrations of 50-100 nM in the morning and
approximately 10 nM in the evening. There is therefore
an ample supply of substrate cortisone for re-activation
to Cortisol by 11/7-HSD1.
2. The ratio of cortisol/cortisone in human hepatic
vein is approximately five-fold higher than in arterial
plasma [70], confirming that 11/7-F1SD1 functions as a
reductase in human liver. Similarly, administration of
cortisone by mouth, which is delivered to the liver by the
portal circulation, results in high circulating Cortisol
concentrations but negligible circulating cortisone con¬
centrations [71].
3. Administration of the liquorice derivative, carbeno-
xolone, inhibits the conversion of cortisone into Cortisol
in man [71] and also inhibits hepatic 11//-HSD1 activity
in isolated perfused rat liver [69], Carbenoxolone also
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Figure 5 Effect of carbenoxolone on insulin sensitivity
Seven healthy males participated in a double-Wind cross-over study comparing
carbenoxolone (CBX: 100 mg 8 hourly lor 8 days) with placebo. Euglycaemic
hyperinsulinaemic clamps were performed with measurement ol forearm glucose
uptake by plethysmography and collection ol arterialized and deep forearm vein
samples. Whole-body insulin sensitivity is represented by the M value (in
yzmol ■ min"' • kg"1), or rate of dextrose infusion to maintain euglycaemia in the
face of constant insulin infusion. Forearm insulin sensitivity is represented as
forearm glucose uptake in yzmol ■ mm-1 • 100 ml-'. Bars are S.E.M. Carbenoxolone
increased whole-body insulin sensitivity without affecting peripheral insulin
sensitivity, consistent with lowering intrahepatic Cortisol concentrations as a result
of inhibition of 11/f-HSD I reductase activity. (Results from [72].)
results in enhanced whole-body insulin sensitivity mea¬
sured by the euglycaemic hyperinsulinaemic clamp tech¬
nique, but does not alter peripheral insulin sensitivity
measured by forearm glucose uptake [72] (Figure 5). This
suggests that inhibition of hepatic 11/7-HSD1 in man
results in lower intrahepatic Cortisol concentrations
which in turn is associated with enhanced insulin-
dependent down-regulation of hepatic glucose output.
4. In rats, oestrogen represses 11//-HSD1 expression
in liver [73]. The direct effect of oestrogen, demonstrated
in adrenalectomized rats, is to induce a rise in the
gluconeogenic enzyme PEP-CK. However, in non-
adrenalectomized rats with intact glucocorticoid secre¬
tion, oestrogen suppresses PEP-CK [74], consistent with
enhanced insulin sensitivity due to lower re-activation of
glucocorticoids in the liver by 11/i-HSDl.
5. Transgenic deletion of the 11/7-HSD1 gene in mice
results in an inability to convert 11-dehydrocortico-
sterone into corticosterone (the equivalent of cortisone
and Cortisol, respectively, in man) and, despite elevated
plasma corticosterone concentrations, is associated with
impaired induction of hepatic gluconeogenic enzymes on
starvation [75],
An additional level of complexity may influence the
interaction between 11//-HSD1 and insulin action since
insulin potently represses 11/f-HSDl expression [65,76],
It remains to be established whether 11//-HSD1 also
influences insulin sensitivity in peripheral tissues such as
skeletal muscle and fat. However, even if the effect is
restricted to the liver, specific inhibitors of I1/7-HSD1
might provide a useful therapeutic strategy to enhance
insulin sensitivity in many different syndromes asso¬
ciated with insulin resistance.
EVIDENCE THAT GLUCOCORTICOID
ACTIVITY IS INCREASED IN SUBJECTS WITH
INSULIN RESISTANCE
From the above it is clear that excessive activity of
glucocorticoids - whether by increased circulating levels
of Cortisol, increased glucocorticoid receptor sensitivity
to Cortisol or altered Cortisol metabolism - is a plausible
contributor to insulin resistance and could explain its
association with hypertension, central obesity, dyslipi-
daemia and endothelial dysfunction. In addition, admin¬
istration of glucocorticoids to rats in utero results in
lower birthweight offspring which subsequently exhibit
insulin resistance and hypertension [77,78], hence gluco¬
corticoid excess provides a potential mechanism to
explain the association of low birthweight with the
metabolic syndrome [2,3],
A series of recent studies have examined the relation¬
ship between aspects of Cortisol secretion and tissue
action and cardiovascular risk factors.
Plasma Cortisol concentrations and the
hypothalamicnpituitarynadrenal axis
In a large cross-sectional study we recently observed that
plasma Cortisol concentrations measured at 09.00 h are
higher in adult men who were born with lower birth¬
weight, and are associated with relative hypertension,
insulin resistance, glucose intolerance and hyper-
triglyceridaemia [79] (Figure 6). Similar results have been
obtained in other cohorts [80,81]. More recent data
confirm that these men have evidence of chronic ac¬
tivation of the hypothalamic-pituitary-adrenal axis
[81a]. The rate of Cortisol secretion is also increased in
young men with a familial predisposition to essential
hypertension but not in men with a similar elevation of
blood pressure whose parents had low blood pressure
[82], This suggests that increased Cortisol secretion is an
early, and perhaps inherited, feature of essential hyper¬
tension.
However, primary activation of the hypothalamic-
pituitary-adrenal axis may not be responsible for in¬
creased Cortisol secretion in all circumstances charac¬
terized by insulin resistance. The insulin resistance
associated with obesity is in many ways distinct from
insulin resistance in lean subjects, not least because it can
usually be reversed by weight loss. Abnormalities of
glucocorticoids are also different in lean and obese
insulin-resistant subjects. The higher plasma Cortisol
observed in the studies described above appears to co-
segregate with insulin resistance but not with obesity.
Indeed, plasma Cortisol is lower in obese subjects [83].
We have attributed this to enhanced metabolic clearance
of Cortisol by the enzyme 5a-reductase which is ex¬
pressed in liver and fat [84], The tendency to lower
plasma Cortisol may result in a compensatory increase in
corticotrophin-releasing hormone, ACTH and Cortisol
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Figure 6 Plasma Cortisol is elevated in subjects with glucose
intolerance
In a cross-sectional study ol 370 men aged 60R70 years in Hertfordshire, England,
plasma Cortisol was measured at 09.00 h alter an overnight last. Mean plasma
glucose concentrations measured simultaneously and 2 h alter a 75-g oral glucose
tolerance test are shown for individuals in each of the quintiles ol the distribution
ol plasma Cortisol concentration. Higher plasma Cortisol is associated with relative
lasting hyperglycaemia and glucose intolerance. Similar associations were observed
for insulin sensitivity, blood pressure and triacylgiycerol levels. (Results Irom [79].)
secretion which may explain evidence of increased
Cortisol secretion in primary obesity [85,86]. The same
effect has been invoked to explain the increased drive to
adrenal steroidogenesis in the insulin-resistant polycystic
ovarian syndrome [87], in which subjects are also usually
obese. The mechanism of activation of the hypothalamic—
pituitary-adrenal axis in non-obese subjects with insulin
resistance remains uncertain, but may be distinct from
that in obese subjects.
Glucocorticoid receptors
Assessment of glucocorticoid receptor sensitivity in man
is difficult. Dexamethasone suppression tests assess
central negative-feedback suppression of ACTH and
Cortisol secretion. Although the response to dexa¬
methasone is variably reported as increased or impaired
in obesity [88,89], it has not been reported to be abnormal
in essential hypertension or lean insulin-resistant sub¬
jects.
An alternative test of peripheral glucocorticoid re¬
ceptor sensitivity in vivo involves measuring the intensity
of dermal blanching after topical administration of
synthetic glucocorticoids. We found that this response is
increased in patients with essential hypertension [90], in
young adults with a familial predisposition to hyper¬
tension [82] and in men with relative glucose intolerance
and insulin resistance [82]. Moreover, the dermal vaso¬
constrictor response to glucocorticoids is increased in
healthy subjects who carry a polymorphism of the
glucocorticoid receptor gene [91] which is more common
in those with a familial predisposition to hypertension
[92] and is associated with greater hyperinsulinaemia in
obese subjects [93].
Glucocorticoid receptor function can also be measured
ex vivo in leucocytes. Although these measurements do
not relate to the polymorphism associated with increased
dermal sensitivity [91], glucocorticoid receptors have a
higher affinity for dexamethasone in leucocytes from
subjects predisposed to hypertension [82]. On the other
hand, in established essential hypertension, gluco¬
corticoid receptor binding may be impaired [94].
These data suggest that glucocorticoid receptor sen¬
sitivity may be increased in the metabolic syndrome in
peripheral tissues, but not in central tissues responsible
for negative feedback. This inference has remarkable
parallels in an animal model of the metabolic syndrome.
In rats exposed to dexamethasone in utero who are born
small and develop insulin resistance and hypertension as
adults [77,78], glucocorticoid receptor expression is
increased in their liver in association with up-regulation
of the gluconeogenic enzyme PEP-CK [95]. However,
central glucocorticoid receptor expression is down-
regulated, explaining why these animals are relatively
hypercorticosteronaemic [96]. It will be important to
establish the mechanism for this apparent tissue-specific
regulation of glucocorticoid receptor expression.
I I (i-Hydroxysteroid dehydrogenases
Cortisol metabolism by 1 l//-HSDs is also altered in
subjects with insulin resistance, although these data are
less consistent than the information concerning the
glucocorticoid receptor. Insulin is a major inhibitor of
11/7-HSD1 expression [65,76] so it would not be sur¬
prising if insulin resistance was associated with dif¬
ferences in the activity of this isoenzyme. In patients with
essential hypertension, and in obese men, we and others
have demonstrated a higher ratio of the metabolites of
Cortisol to those of cortisone and impaired conversion of
labelled Cortisol into cortisone [82,84,97,98]. However,
in patients with the insulin resistance associated with
polycystic ovarian syndrome, the reverse has been
observed in some studies [99]. More sophisticated meth¬
ods to dissect out the contribution of 11//-HSD1 and 11/7-
HSD2 in different tissues will be required to understand
whether dysregulation of pre-receptor metabolism has a
significant impact on activation of corticosteroid recep¬
tors in insulin-resistant subjects.
CONCLUSIONS
When Reaven and Hoffman described the associations
between insulin resistance and other cardiovascular risk
factors, they hypothesized that the insulin resistance
might be the primary defect underlying the other features
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[1], This hypothesis is plausible if one allows the
argument that only some aspects of insulin action are
included in the resistance syndrome. Thus, resistance to
the actions of insulin on glucose metabolism leads to
relative hyperglycaemia with compensatory hyper-
insulinaemia; but if the effects of insulin are maintained
- for example with respect to tissue growth, renal salt
excretion [100] and adrenal androgen steroidogenesis-
then the hyperinsulinaemia may promote atherogenesis,
hypertension and polycystic ovarian syndrome respect¬
ively.
This hypothesis has become more complicated with
time and has proved difficult to test. For example, the
association between insulin resistance and endothelial
dysfunction can only be explained by a primary resistance
to insulin if both glucose metabolism and the endo¬
thelium are resistant to insulin action. Similarly, the
association between low birthweight and subsequent
insulin resistance could be explained if the insulin
resistance includes insulin-mediated growth and devel¬
opment in utero. However, in support of the original
hypothesis, there are rare examples ofmutations resulting
in dissociation of the growth-promoting and glucose-
regulating actions of insulin [101], Moreover, although
homozygous mutations of the insulin receptor cause a
clinical syndrome including lipoatrophy [7], transgenic
animals with global insulin resistance due to hetero¬
zygous multiple mutations of the insulin receptor sig¬
nalling pathway do turn out to be obese with other
features of the metabolic syndrome [102]. Finally, newer
drugs which enhance insulin sensitivity and improve
glucose tolerance [35] also improve other aspects of the
metabolic syndrome, including reproductive function [6]
and, in animals at least, blood pressure.
In the absence of a clear understanding of the cause of
insulin resistance in most subjects, and given that
uncertainty remains about whether insulin resistance is
an important primary mediator in the metabolic syn¬
drome, there is scope to consider alternative hypotheses
to explain these associations. For example, both insulin
resistance and other cardiovascular risk factors may result
from a common primary abnormality. This review
illustrates the plausibility of a hypothesis that enhanced
activity of Cortisol contributes to insulin resistance, and
that manipulation of Cortisol action provides a novel
therapeutic target to enhance insulin sensitivity. Clearly,
further work is required to address whether alterations in
Cortisol secretion and sensitivity are causes or con¬
sequences of insulin resistance, to understand the mol¬
ecular mechanisms for these alterations, and to charac¬
terize in more detail the targets for glucocorticoid effects
on insulin sensitivity.
Cortisol and insulin were both discovered in the same
era, and in an early phase of endocrine research. Both
have transformed clinical practice in this century. Argu¬
ably, insulin has stolen the limelight in recent years, and
Cortisol has been eclipsed by research into numerous
' novel' cardiovascular hormones. However, as illustrated
in this review, you can teach an old dog new tricks.
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Cortisol Metabolism in Healthy Young Adults: Sexual
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ABSTRACT
Cortisol is metabolized irreversibly by A-ring reductases (5a- and
5/3-reductases) and reversibly (to cortisone) by 11/3-hydroxysteroid
dehydrogenases (ll/3HSDs). In rats, estradiol down-regulates
11£>HSD1 expression. In humans, ratios of urinary cortisol/cortisone
metabolites differ in men and women. In this study, urinary Cortisol
metabolites and hepatic 11/3HSD1 activity were measured in healthy
young men and women at different phases of the menstrual cycle.
Tenmen and 10womenwith regularmenstrual cycles collected a 24-h
urine sample, took 250 ixg oral dexamethasone at 2300 h, took 25 mg oral
cortisone at 0900 h (after fasting), and had blood sampled for plasma
Cortisol estimation over the subsequent 150 min. Women repeated the
tests in random order in menstrual, follicular, and luteal phases.
Women excreted disproportionately less A-ring-reduced metabo¬
lites of Cortisol [median 5a-tetrahydrocortisol, 1811 (interquartile
range, 1391-2300) jig/day in menstrual phase vs. 2723 (interquartile
range, 2454—3154) in men (P = 0.01); 5/3-tetrahydrocortisol, 1600
(interquartile range, 1419-1968)us. 2197 (interquartilerange, 1748—
2995; P = 0.03)] but similar amounts of Cortisol, cortisone, and tet-
rahydrocortisone. Analogous differences were observed in urinary
excretion of androgen metabolites. Conversion of cortisone to Cortisol
on hepatic first pass metabolism was not different (peak plasma
Cortisol, 733 ± 60 nmol/L in women vs. 684 ± 53 nmol/L in men;
mean ± SEM; P = 0.55). There were no differences in Cortisol or
androgen metabolism between phases of the menstrual cycle.
We conclude that sexual dimorphism in Cortisol metabolite excre¬
tion is attributable to less A-ring reduction of Cortisol in women,
rather than less reactivation ofcortisone to Cortisol by 11/3HSD1. This
difference is not influenced acutely by gonadal steroids. 11/3HSD1 has
been suggested to modulate insulin sensitivity and body fat distri¬
bution, but caution must be exercised in extrapolating inferences
about its regulation from rodents toman. A-Ring reductasesmay have
an equally important influence on metabolic clearance ofCortisol and
intracellular Cortisol concentrations. (J Clin Endocrinol Metab 84:
3316-3321, 1999)
CORTISOL IS metabolized by several enzymes (Fig. 1),including irreversible inactivation by A-ring reducta¬
ses (5«- and 5J3-reductases) and reversible interconversion to
inactive cortisone. Interconversion with cortisone is cata¬
lyzed by 11/3-hydroxysteroid dehydrogenases (11 (IHSDs),
which are now recognized to play a crucial role in modu¬
lating activation of corticosteroid receptors. 11/3HSD type 2
(1, 2) inactivates Cortisol in the distal nephron, thereby pro¬
tecting mineralocorticoid receptors from inappropriate acti¬
vation by Cortisol. Congenital or acquired defects in
11/3HSD2 result in cortisol-dependent mineralocorticoid ex¬
cess (3-5). More recently, the role of 11/3HSD type 1 (6) has
been defined. This enzyme reactivates cortisone in many
sites, including liver and adipose tissue (7-9), where it ap¬
pears to maintain adequate exposure of glucocorticoid re¬
ceptors to Cortisol (10-12). Defects in 11 /3HSD1 result in
enhanced sensitivity to insulin. Increased activity of
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11/3HSD1 has been postulated to be important in insulin
resistance syndromes, particularly obesity (9, 13, 14).
A number of studies in rodents, many of which preceded
the cloning of distinct 11 /iHSD l and 11J3HSD2 isozymes, have
examined the regulation of these enzymes. In brief, 11 /3HSD2
is constitutive and appears to present an effective barrier to
glucocorticoid access to mineralocorticoid receptors under all
conditions. By contrast, 11 (3HSD1 is regulated by glucocorti¬
coids (15), thyroid hormones (16), insulin (15), GH (17), cyto¬
kines (18), and gonadal steroids (17, 19-21). Regulation of
11 flHSDl by gonadal steroids is of particular interest, because
sex-specific differences in enzyme activity could contribute to
differences in body fat distribution and susceptibility to car¬
diovascular risk factors associated with insulin resistance.
In rats, 11 /3HSD1 expression and activity in liver are mark¬
edly lower in females than in males (21). Estradiol admin¬
istration to gonadectomized rats potently represses
11/3HSD1 expression, an effect that depends at least in part
on changes in the pattern of GH secretion (17). Evidence of
whether estrogen regulates 11/3HSD1 in humans is surpris¬
ingly limited. In premenopausal healthy women, the ratio of
urinary metabolites of Cortisol to cortisone has been reported
to be lower than that in men (22), but the characteristics of
participants in that study were not described in detail. The
same trend was observed in hypopituitary patients (23), but
clearly there are potential confounding effects of hormonal
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Fig. 1. Principal metabolites of Cortisol (A) and androgens (B) mea¬
sured in urine by gas chromatography and mass spectrometry. Dotted
arrows indicate that more than one step is involved.
replacement therapies in this group. In healthy postmeno¬
pausal women, the ratio of Cortisol/cortisone metabolites
was higher than that in men and was not influenced by
estrogen replacement therapy (14).
In this study, we sought to clarify whether sex-specific dif¬
ference in Cortisol metabolism are observed in healthy young
adults and to establish whether changes in urinary Cortisol/
cortisone metabolites could be attributed to differences in he¬
patic conversion of cortisone to Cortisol by 11/3HSD1. In addi¬
tion, we sought differences in these indexes of Cortisol
metabolism in different phases of the menstrual cycle.
Experimental Subjects
Lothian Research ethics committee approval and written informed
consent were obtained. All participants were white Caucasians. Ten
healthymen and 10 healthy women with regular endogenous menstrual
cycles (between 24-34 days) were recruited by advertisement. Their
characteristics are shown in Table 1. Groups were matched for age and
body mass index. Inclusion criteria were: age, 20-45 yr; blood pressure,
less than 160/90mm Hg;no regular medication; no use of glucocorticoid
therapy by any route during the previous 3 months; no psychiatric
illness in the previous 3 months; and no abnormality of renal, thyroid,
or liver function on biochemical screening.
Materials and Methods
Clinical protocol
Men were studied on one occasion. Women were studied on three
occasions, in random order, during menstrual (2-5 days after starting
menstruation), follicular (19-16 days before the next expected menstru¬
ation), or luteal (9-5 days before next menstruation) phases. All studies
were completed in the winter months (December to March), and men
and women were studied in parallel to avoid confounding effects of
seasonal changes in steroid metabolite excretion (24).
On each occasion, subjects collected a 24-h urine sample, took 250 jxg
oral dexamethasone at 2300 h, and attended next day at 0830 h after an
overnight fast. A venous cannula was inserted, and blood was with¬
drawn after 25 min for Cortisol and, in women, estradiol and proges¬
terone determinations. After 30 min, 25 mg oral cortisone acetate was
administered, and blood was sampled during the next 150 min for
plasma Cortisol determination. The dose of dexamethasone was selected
to lower baseline plasma Cortisol so that a rise could be readily detected
after cortisone administration without giving so much that dexameth¬
asone metabolites might interfere with cortisone metabolism (25).
Laboratory measurements
Cortisol and its metabolites in urine were measured by gas chroma¬








Age (yr) 27.8 ± 1.5 28.6 ± 1.7 0.61
(22-35) (20-40)
Ht (m) 1.80 ± 0.02 1.63 ± 0.02 <0.0001
(1.73-1.91) (1.55-1.71)
Wt (kg) 77.4 ± 3.7 65.9 ± 3.8 0.04
(60.3-96.7) (47.8-94.5)
Body mass index (kg/m2) 23.9 ± 1.0 24.9 ± 1.6 0.63
(18.6-27.3) (18.4-34.3)
Waist circumference (cm) 87 ± 2 76 ± 4 0.02
(71-99) (61-97)
Hip circumference (cm) 100 ± 2 97 ± 3 0.34
(91-113) (80-110)
Waist/hip ratio 0.87 ± 0.01 0.78 ± 0.02 0.002
(0.78-0.91) (0.66-0.92)
Data are themean ± SEM (range). Values for females were recorded
during the menstrual phase.
traction, hydrolysis with /3-glucuronidase, and formation of methoxime-
trimethylsilyl derivatives as previously described (26). Epi-cortisol and
epi-tetrahydrocortisol were used as internal standards, which were
added to samples before extraction. Peaks of interest were quantified by
the ratio of (area under the peak)/(area under neighboring internal
standard peak), rather than the ratio of peak height against a line ex¬
trapolated from bracketed internal standards as used by many other
groups. Ratios were compared against standard curves for each steroid
included in every assay batch. The average intraassay precision for all
steroids measured was less than 20% (n = 16 assays). In each assay batch,
water samples were included containing standard steroids and average
accuracy for all steroids varied from -4.4% to +5.5% (n = 16). Principal
urinary androgen metabolites were measured using the same method,
except that 5«-androstan-3a,17o'-diol was used as an internal standard.
Pathways of Cortisol and androgen metabolism leading to these metab¬
olites are illustrated in Fig. 1. The ratio between 5^-reduced and 5a-
reduced metabolites of Cortisol and androgens was closely correlated
(r = 0.80; P < 0.001).
Cortisol, estradiol, and progesterone were measured in plasma by
commercial RIAs.
Statistics
Results are presented as the mean ± sem for normally distributed
variables; groups were compared using unpaired Student's t tests or
repeated measures ANOVA. Many of the urinary Cortisol metabolites
had skewed distributions, necessitating nonparametric analyses; these
are presented as median (interquartile range). Data from men and
women in the menstrual phase were compared by Mann-Whitney U
tests; data from different phases of the menstrual cycle were compared
by Friedman ANOVA. Data for men and women in luteal and follicular
phases were not compared to avoid multiple statistical testing.
Results
Comparison between men and women
Men and women were well matched for age and body
mass index, but men were taller and heavier, with android
distribution of body fat (Table 1). Absolute excretion rates of
urinary Cortisol metabolites tended to be higher in men (Ta¬
ble 2). This was attributable principally to lower excretion of
5«-reduced and 5/3-reduced metabolites of Cortisol in
women. Excretions of Cortisol, cortisone, and tetrahydrocor¬
tisone were not different. Excretion of androgen metabolites
also tended to be higher in men, accounted for by a trend
toward lower excretion of 5<*-reduced metabolites inwomen.
Table 2 shows ratios of metabolites reflecting activities of
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Fasting baseline plasma Cortisol (nmol/L)a,/> 323 ± 74 268 ± 37 272 ± 43 270 ± 54 0.52 0.99
Peak plasma Cortisol (nmol/L)a 684 ± 53 733 ± 60 800 ± 62 792 ± 58 0.55 0.49
Time to peak (min) 75 ± 8 111 ± 9 99 ± 13 86 ± 7 0.01 0.27
Area under curvec 221 ± 162 343 ± 139 305 ± 157 352 ± 156 0.10 0.37
Data are the mean ± sem
a Subjects received 250 jug oral dexamethasone at 2300 h the previous evening and 25 mg oral cortisone acetate on the morning of the test.
h Baseline plasma Cortisol was calculated as the arithmetic mean of measurements at 5 and 0 minutes before cortisone administration.
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Fig. 2. Hepatic 11 pHSD 1 activity. Plasma Cortisol was measured
after overnight dexamethasone suppression (250 p.g, orally, at 2300 h)
and oral administration of25 mg cortisone acetate at 0900 h. Data are
the mean ± sem for males (n = 10), and females (n = 10) inmenstrual,
follicular, and luteal phases of the endogenous menstrual cycle. Com¬
parisons are given in Table 3.
different enzymes. 11/3HSD activities are conventionally in¬
ferred from relative excretion of metabolites of Cortisol and
cortisone [cortisol/cortisone ratio reflecting principally renal
110HSD2 activity (26, 27) and ratios of tetrahydrocortisols/
tetrahydrocortisone reflecting the balance between 11 jSHSDl
and 11/3HSD2 activities]; these ratios did not differ between
men and women, although there was a trend for a lower Cor¬
tisol/cortisone ratio in men. A-Ring 5a- and 5/3-reductase ac¬
tivities can be inferred relative to each other by the ratio of
5j3-tetrahydrocortisol/5a-tetrahydrocortisol and by 50-/5a-re-
duced androgen metabolites,which did not differ betweenmen
and women. Provided that urinary Cortisol and cortisone are
notdifferent (28), 50-reductase activity can also be inferred from
the ratios of 5/3-tetrahydrocortisol/cortisol, tetrahydrocorti¬
sone/cortisone (29), and 5({-reduced/5-oxidized androgen me¬
tabolites; in women this activity was less for Cortisol but not for
cortisone or androgens. 5a-Reductase activity can be inferred
from the ratio of 5«-tetrahydrocortisol/cortisol and 5a-re-
duced/5-oxidized androgens, which was lower in women.
Plasma Cortisol after overnight dexamethasone suppres¬
sion was not different between men and women (Table 3).
The rise in plasma Cortisol after oral cortisone administration
is shown in Fig. 2. The rate of rise, maximum plasma Cortisol,
and area under the curves did not differ between men and
women. However, the peak Cortisol occurred earlier in men
than women, apparently because Cortisol was cleared from
plasma more quickly in men.
Comparison between phases of menstrual cycle in women
Accuracy of timing of phases of the menstrual cycle was
confirmed by measurements of plasma estradiol and pro¬
gesterone (data not shown). For all women, estradiol was
higher in the follicular than in the menstrual phase, and
progesterone was only detectable in the luteal phase.
There were no differences in urinary Cortisol or androgen
metabolite excretion (Table 2) or conversion of oral cortisone
to plasma Cortisol (Fig. 2) in different phases of the menstrual
cycle.
Discussion
This study is consistent with previous observations that
urinary excretion of the A-ring reduced metabolites of Cor¬
tisol is lower in premenopausalwomen than in men (22), and
that this is out of proportion to the excretion of other me¬
tabolites of Cortisol in women. The disproportionality of
these differences excludes technical confounders, such as
incomplete urine collection. The absolute excretion rates for
some Cortisolmetabolites, particularly 5«-tetrahydrocortisol,
are somewhat higher in this group than those reported by
others in healthy volunteers (3, 27, 30, 31). This may reflect
differences between groups of subjects or methodological
differences, for example in the choice of internal standards.
In addition, this study confirms previous reports that urinary
androgen excretion is onlymarginally higher in men than in
women (30), reflecting the fact that most urinary androgen
metabolites are derived from adrenal androgens.
Previously, differences in Cortisol metabolite excretion be¬
tweenmen and women have been attributed to alterations in
11 (1-hydroxysteroid dehydrogenases. Whether this reflects
enhanced inactivation of Cortisol to cortisone by 110HSD2 or
impaired reactivation of cortisone to Cortisol by 11 (JHSD1 in
women had not been tested. However, it was assumed that
lesser 110HSD1 activity in women was responsible on the
basis of studies in rats suggesting that only 11J3HSD1 is
regulated by other hormones, including down-regulation by
estrogen (17, 20, 21).
In the present study, ratios of urinary cortisol/cortisone
(26, 27) suggest that conversion of Cortisol to cortisone by
renal 11/3HSD2 activity is lower, rather than higher, in
women than men. Therefore, differences in 11/3HSD2 could
not explain lower ratios of cortisol/cortisone metabolites;
this is consistent with the hypothesis that these differences
reflect sexual dimorphism in lljSHSDl activity. However,
we also made a more specific assessment of hepatic 11 /SHSD1
activity by measuring the conversion of cortisone adminis-
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tered orally into Cortisol in the peripheral circulation. The
rate of appearance of Cortisol is lower when 11/3HSD1 is
inhibited, e.g. by carbenoxolone (32), but is not influenced by
11/3HSD2 activity (33). The lack of sexual dimorphism in the
rate of appearance of Cortisol in the present study suggests
that llfiHSDl activity is not different in men and women.
Moreover, in marked contrast with dramatic changes over a
similar time course in rats (17,21), changes in estrogen levels
in women during the menstrual cycle were not associated
with alterations in any index of 11/fHSDl activity.
The present data suggest an alternative explanation for the
disproportionately low excretion of tetrahydrocortisols in
women. As previously described in postmenopausal (14) and
hypopituitary (23) women, the excretion of Cortisol and corti¬
sone is similar or even increased inwomen compared with that
inmen; the differences are observed only in the A-ring reduced
metabolites. Thus, the ratios of urinarymetabolites suggest that
rates of A-ring reduction of Cortisol are lower in women than
in men. This is substantiated by examining A-ring reduction of
androgen metabolites. Lower A-ring reduction could also ex¬
plainwhyCortisol is cleared less rapidly from plasma inwomen
than in men after an oral dose of cortisone. Unlike postmeno¬
pausal women (14), this difference does not affect the 5(1-re¬
duction of cortisone and could therefore account both for the
lower ratio of tetrahydrocortisols/tetrahydrocortisone ob¬
served in young women (22), but not postmenopausal women
(14), and for the trend toward higher urinary cortisol/cortisone
in women in this study.
It is no t clearwhy A-ring reduction of Cortisol should differ
between men and women. The principal enzymes involved
are 50-reductase (34) and 5«-reductase types 1 and 2 (35).
5/3-Reductase is expressed in liver and is involved in the
metabolism of bile acids. Although there is some evidence
that affinities for Cortisol and cortisone/androgens can be
separated by semipurification and subcellular fractionation
in vitro (36, 37), there is no evidence that there is more than
one 5(l-reductase active in vivo in man (38). 5(J-Reductase
activity is lower in female than in male rat livers (39), but it
is up-regulated by estrogen (40). 5a-Reductase type 1, the
principal isozyme in human liver and fat (41), is usually
thought to be constitutive and not regulated hormonally (42,
43), but there is some evidence that this isozyme is down-
regulated by androgens (44, 45) more so than by estrogen
(46), so that its activity is higher in female liver (47) and
adrenal (48). 5a-Reductase type 2 is expressed mainly in the
prostate and is up-regulated by androgens (35). These ob¬
servations from animals predict that activities of 5/1-reduc-
tase may be lower, and hepatic 5«-reductase may be higher,
rather than decreased, in women. Moreover, the lack of acute
effect of changes in gonadal steroids on urinary Cortisol me¬
tabolite excretion in the current study suggests that the ex¬
planation for sexual dimorphism in A-ring reductases does
not relate to acute gonadal steroid regulation in humans. An
alternative explanation relates to the relative mass of tissues
expressing A-ring reductases in men and women. It is not
clear whether the prostate contributes substantially to A-ring
reduction of Cortisol, but, interestingly, finasteride, a rela¬
tively specific inhibitor of 5«-reductase type 2, does alter the
relative excretion of Cortisol metabolites in men (49). The
quantity and distribution of body fat may also be important,
as 5a-reductase type 1 is expressed in adipocytes and is more
active in peripheral sc than central visceral fat in culture (41),
although the contribution of adipose 5a-reductase activity to
Cortisol clearancemaybe small. Previous studies suggest that
increased visceral fat in men maybe associated with greater
So-reductase activity (14). However, the current study is too
small, and subjects within it too similar, to explore whether
differences in body fat distribution might explain sexual
dimorphism in Cortisol metabolite excretion.
We have previously reported Cortisol metabolite profiles
in older subjects, in whom we found relationships between
greater central/visceral obesity and enhanced activity of 5a-
reductase, but not 5/3-reductase (14). The pattern of differ¬
ences between older men and women contrasts with the
results in young subjects studied here and previously (22).
Olderwomen had higher 5a-reductase, but not 5/3-reductase,
activity and higher ratios of metabolites of Cortisol to those
of cortisone in urine compared with men. Comparing values
in Table 2 with values in the older population measured by
the same method (14), it appears that there is little difference
between postmenopausal and premenopausal women, but
that the major differences are between younger and older
men. Thus, aging in men may be associated with falling
activities of 5a-reductase and 11/3HSD1.
Whatever the reason for sexual dimorphism of A-ring re¬
duction ofCortisol and its changewith age, this observation has
important implications for physiological glucocorticoid action
and for interpretation of apparent pathological disruption of
Cortisol metabolism. Lesser A-ring reduction of Cortisol in
women predicts a lower MCR of Cortisol, which, in turn, pre¬
dicts greater feedback suppression of the hypothalamic-pitu-
itary-adrenai axis. If A-ring reduction is increased, as in obesity
(14) and probably also in polycystic ovarian syndrome (50,51),
increased ACTH drive to the adrenal cortex may contribute to
excessive androgen secretion. Conversely, a decline in A-ring
reduction, as may occur with normal aging in men, may con¬
tribute to the fall in adrenal androgen excretion with age (52).
In addition, the extent of A-ring reduction in specific organs,
including adipose tissue and liver, will influence local concen¬
trations of Cortisol independently of circulating glucocorticoid
concentrations. It remains to be established whether this has a
potent influence on corticosteroid receptor activation, but it
may contribute to the sexual dimorphism of body fat
distribution.
Arguably the most important implications of this study are
that care should be exercised in extrapolating to humans from
studies of regulation of 11/3HSD1 in rodents, and that ratios of
tetrahydrometabolites of Cortisol and cortisone should be in¬
terpreted cautiously if they are not accompanied by measure¬
ments of Cortisol and cortisone (26, 27). The latter has not been
measured in some other studies comparing men and women
(22) or in studies of polycystic ovarian syndrome (50, 51) or
essential hypertension (53, 54). Arguably for this reason the
inferences concerning 11/1HSD activities may have been over¬
emphasized, and the potential importance of disturbances in
A-ring reduction of Cortisol may have been overlooked.
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